--
ISSN 2686 – 682Х (Online)    ISSN 1810 – 8830 (Print)     тел.: +7 (977) 469-24-40 /
  • Editorial board
  • Editorial ethics
  • The rules for reviewing
  • Manuscript preparation
  • Contacts

RJA for 2018

null
2018 № 1

Read

null
2018 № 3

Read

null
2018 № 2

Read

null
2018 № 4

Read

Rubrics

  • Editorial
  • Review
  • Lectures
  • Original articles
  • News of pharmaceutical market
    and medical technologies
  • Chronicles

Publishing company

  • Books for doctors and patients
  • Scientific editions
  • Periodical
  • Advertizing production
  • Our partners

Journals

  • Archive
  • RJA for 2018

Подписаться на журнал


Подписаться
© 2019 Российский Аллергологический Журнал

Член редакционной коллегии,

доктор медицинских наук, профессор

https://orcid.org/0000-0002-9001-1437

Индекс Хирша 10

Файзуллина Резеда Мансафовна, с «отличием» окончила Башкирский государственный медицинский институт в 1983г., интернатуру по специальности «Педиатрия» и после 3-х летней работы врачом педиатрического отделения ГКБ №18 поступила в клиническую ординатуру, а потом в очную аспирантуру по педиатрии в выше названном институте. В 1992г. защитила кандидатскую диссертацию в НИИ педиатрии РАМН на тему: «Аллергические болезни у детей, проживающих в регионе с развитой химической и биотехнологической промышленностью», а в 1999г.  –  докторскую диссертацию на тему «Особенности аллергических болезней у детей и возможности снижения их роста в республике Башкортостан» по специальностям «Педиатрия» и «Аллергология и иммунология». В 2001г. получила звание профессора. Преподавателем ФГБОУ ВО БГМУ Минздрава России работает с 1991 года в качестве ассистента, доцента и профессора на кафедре госпитальной педиатрии – 1991- 1994 гг., затем – пропедевтики детских болезней – 1994 – 2011гг., начальником методического отдела УМУ – 2011-2016гг., совмещая профессором кафедры факультетской педиатрии с курсами педиатрии, неонатологии и симуляционным центром ИДПО и продолжает работать на названной кафедре по настоящее время в должности профессора. Главный внештатный детский аллерголог Министерства здравоохранения республики Башкортостан РБ с 1996 года.

Победитель Российского конкурса «Лучший педиатр года» (2008г.) в номинации «За верность профессии», «Заслуженный врач республики Башкортостан», «Отличник здравоохранения Российской Федерации», «Отличник образования республики Башкортостан», лауреат Ежегодной премии в сфере медицинского и фармацевтического образования России 2018 года «Docendo discimus» в номинации «За лучшую практику учебно-методического сопровождения образовательных программ». Под руководством защищено 8 кандидатских диссертаций.

Публикаций – более 345; патенты на изобретение -2; свидетельство о государственной регистрации программы для ЭВМ – 1; монографии – 2. Соавтор 3 учебников по педиатрии для студентов медицинских вузов.

 Область научных интересов: аллергические заболевания у детей – атопический дерматит, аллергический ринит, бронхиальная астма и др. болезни дыхательных путей.

Файзуллина Р.М. выступает с докладами на Европейском Конгрессе респираторного общества и Европейской Ассоциации аллергологов и клинических иммунологов, Консенсусах по респираторной патологии, Российских и Межрегиональных научно-практических конференциях по педиатрии, респираторной патологии, аллергологии и иммунологии. Руководитель ряда многоцентровых Международных и Российских клинических исследований, руководитель ГосЗаказа по НИР, член оргкомитета педиатрических секций Российского Национального Конгресса по болезням органов дыхания (2009 -2018гг.), член правления Всероссийского педиатрического респираторного общества и председатель отделения в Республике Башкортостан, член Российской Ассоциации Аллергологов и Клинических Иммунологов – РААКИ, Европейской Академии Аллергологии и Клинической Иммунологии – EAACI, Европейского респираторного общества – ERS,  Российского респираторного общества – РРО, участник Школ по молекулярной аллергологии Международной платформы университетов по молекулярной аллергологии и иммунологии INUNIMAI, Вена, Австрия.

Файзуллина Р.М. -эксперт в области пульмонологии, аллергологии и иммунологии, участвовала в подготовке современной классификации болезней органов дыхания у детей в РФ, клинических рекомендаций и научно-практических программ по бронхиальной астме у детей, иммуномодулирующим препаратам, крупу, внебольничной пневмонии; является членом общественного Совета при уполномоченном по правам ребенка в РБ. Член редакционной коллегии Российского аллергологического журнала.

Member of the editorial Board,

Doctor of medical Sciences, Professor

https://orcid.org/0000-0002-9001-1437

Hirsch Index 10

Rezeda Fayzullina graduated with honors from the Bashkir state medical Institute specialty Pediatrics in 1983. After she worked as a pediatrician for 3 years in the pediatric department in children’s hospital No.18 in Ufa. R. Fayzullina completed clinical residency and postgraduate studies in the above-named Institute and in 1992 defended her dissertation “Allergic diseases in children living in the region with a developed chemical and biotechnology industry” at the research Institute of Pediatrics of the Russian Academy of Sciences. In 1999 defended the doctor’s dissertation “Features of allergic diseases in children and the possibility of reducing their growth in the Republic of Bashkortostan” in the specialty “Pediatrics” and “Allergy and immunology”. In 2001, she received the title of Professor. During 1991- 1994 she worked as an assistant, associate professor and professor at the Department of hospital pediatrics. In the period 1991-2011 R. Fayzullina worked at the Department of propaedeutic of children’s diseases. During 2011-2016 she head of the methodical Department of the Bashkir state medical University. At the same time, she led a teaching career as a professor of the Department of faculty pediatrics with courses of pediatrics, neonatology and simulation center of Institute of additional professional education of the Bashkir state medical University to the present time. Since 1996 chief freelance pediatric allergist of the Ministry of health of the Republic of Bashkortostan.

In 2008, R. Fayzullina awarded “the Best pediatrician of the year” for loyalty to the profession. In addition, she has awards “Honored doctor of the Republic of Bashkortostan”, “Great health of the Russian Federation”, ” Great education of the Republic of Bashkortostan». In 2018, laureate of the Annual prize “Docendo discimus” in the field of medical and pharmaceutical education of Russia in the nomination “For the best practice of educational support of educational programs”. R. Fayzullina is the head of 8 candidates dissertations.

She has more than 345 scientific publications; 2 patents for invention; 1 certificate of state registration of computer programs; 2 monographs and сoauthor of 3 textbooks on Pediatrics for medical students.

Research interests: allergic diseases in children – atopic dermatitis, allergic rhinitis, bronchial asthma and other respiratory diseases.

Rezeda Fayzullina makes presentations at the European Congress of the respiratory society and the European Association of Allergy and Clinical Immunology, Consensuses on Respiratory pathology, Russian and Interregional scientific conferences on Pediatrics, Respiratory pathology, Allergology and Immunology. Head of a number of multicenter International and Russian clinical studies, head of state Order for research work, member of the organizing Committee of pediatric sections of the Russian National Congress on respiratory diseases (2009-2018). Rezeda Fayzullina is a member of the Board of the all-Russian pediatric respiratory society and Chairman of the branch in the Republic of Bashkortostan; member of the Russian Association of Allergists and Clinical Immunologists (RAAСI), European Academy of Allergy and Clinical Immunology (EAACI), European respiratory society (ERS), Russian respiratory society (RRS), member of the schools of molecular allergy of the international platform of universities of molecular allergy and immunology (INUNIMAI, Vienna, Austria).

Rezeda Fayzullina – expert in the field of pulmonology, Allergy and immunology, participated in the preparation of modern classification of respiratory diseases in children in the Russian Federation, clinical recommendations and scientific and practical programs on bronchial asthma in children, immunomodulatory drugs, croup, and pneumonia in children. In addition, she is a member of the public Council under the Commissioner for children’s rights in Belarus. Member of the editorial Board of the Russian allergological journal.

ORCID ID: 0000-0003-3425-3463

Curriculum Vitae Mohamed H Shamji, PhD. CS. iFAAAAI
Current Positions
• Senior Lecturer in Immunology and Allergy at Imperial College London.
• Group leader (head), Immunomodulation and Tolerance Group, Allergy & Clinical Immunology, Imperial college London,
UK.
• Director, Immune Tolerance Network (ITN) Distributed Centre of Excellence for Allergy & Asthma at Imperial College
London.
International/National Positions & membership
• Chair, Scientific Programme Committee for the European Allergy and Clinical Immunology (EAACI) (2019-2021)
• Secretary, EAACI Immunotherapy Interest Group (2017-2019).
• Chair, EAACI Rhinallergy (RHINA) meeting (2019).
• Council member for the British Society of Allergy and Clinical Immunology (2016-2018)
• Member of the Collegium Internationale Allergologicum (CIA)
Qualifications
2010 PhD in Clinical Medicine Research/Allergy and Immunology, Imperial College London, UK
2005 Clinical Scientist fellowship training in Clinical Immunology, Chelsea & Westminster
Hospital NHS Foundation Trust in London, United Kingdom (UK)
2003 MSc Medical Immunology, St. George’s Hospital Medical School, University of London, UK
Teaching/Academic Experience
2016- NHLI- Basic and Clinical Allergy Course – Lead and Organiser
2015- Lecture, mark exam scripts and assess research projects on Molecular MSc course
2015- Lecture, mark exam scripts and assess research projects on Immunology MSc course
2011- Course leader and co-organiser, Respiratory Medicine BSc course, Allergy Module, Imperial College
London, UK
2011- Course co-organiser with Professor Stephen Durham, British Society of Allergy and Clinical Immunology Specialist Registrar
training day in Allergy. Imperial College London, UK
2013- Assess Early and Late Stage Reviews for NHLI PhD students
Selected Prizes and Fellowships
2018 PhARF Award 2018 (the most Prestigious Award in Allergy) in recognition to my contribution to allergen Immunotherapy
2018 Best postgraduate supervision Award 2018 at Imperial College London
2016 Travel grant – Alain de Weck Travel Grant, 31st Symposium of the Collegium International Allergologicum, Chalrstone, N
Carolina, USA, 2016 (March) $1250.
2015 Imperial College London President’s Award for Excellence in research at Imperial College London, UK.
2015 Outstanding abstract presentation at the European Academy, Allergology and Clinical Immunology (EAACI) congress 2015
(June), Barcelona, Spain
2012 Travel grant – Alain de Weck Travel Grant, 29th Symposium of the Collegium International Allergologicum, Jeju Island,
2012 (Oct) EURO 1,000.
2012 2 x Outstanding abstract presentations at the European Academy, Allergology and Clinical Immunology (EAACI) congress
2012 (June), Geneva, Switzerland
2011 Travel grant – World Allergy Congress in Cancun, Mexico, 2011 (Dec) $1000
2011 Outstanding World Allergy Organization (WAO) junior abstract at the World Allergy Congress, Cancun, Mexico, 2011
(Dec), best abstract award and oral presentation in the basic science category at the British Society of Allergy & Clinical
Immunology (BSACI) annual meeting (July) Nottingham, UK
2006-10 Best abstract presentation at the American Academy of Allergy, Asthma an Immunology (AAAAI) congress 2010 (Feb),
New Orleans, United States of America.
Best poster presentation at the European Academy, Allergology and Clinical Immunology (EAACI) congress 2009 (June),
Warsaw, Poland.
Best abstract award and oral presentation from Rhinitis, Sinusitis and Ocular Diseases (RSOD) interest section at the
annual American Academy of Allergy, Asthma and Immunology (AAAAI) congress 2007 (March), Philadelphia, United
States of America
2005-11 Awarded Postgraduate research (PhD) degree in allergy & clinical immunology funded by Biotechnology and Biological
Sciences Research Council (BBSRC) case studentships, a collaborative award in Science and Engineering in partnership
with Syngenta Ltd.
2000-5 Fellowship Award – 4year Clinical Scientist fellowship award funded by the Department of Health. Qualified as Clinical
Scientist in Clinical Immunology with certificate of attainment from the Association of Clinical Scientist (ACS).
* denotes equal contributions
Original Research Publications (2019)
1. Shamji, M.H.*, Thomsen, I.*, Layhadi, J.A., Kappen, J., Holtappels, G., Sahiner, U., Switzer, A., Kouser, L.,
Durham, S.R., Pabst, O., Bachert, C., Broad Immunglobulin G Repertoire in Chronic Rhinosinusitis with Nasal
Polyps regulates pro-inflammatory IgE responses. J Allergy Clin Immunol. 2019 Jun;143(6):2086-2094.e2. doi:
10.1016/j.jaci.2019.02.001. Epub 2019 Feb 11.
2. Shamji, M.H., Kappen J., Abubakar-Waziri, H., Zhang, J., Steveling, E., Watchman, S., Kouser, L., Eifan, A.,
Switzer, A., Varrichi, G., Marone, G., Couto-Francisco, N.C., Calderon, M., Durham, S.R. Nasal Allergen
Specific IgG4 antibodies with Neutralising Capacity to Block IgE-mediated Responses: A Novel biomarker of
Subcutaneous Grass Pollen Immunotherapy Evaluated in a Cross-Sectional Pilot Study. J Allergy Clin Immunol.
2019 Mar;143(3):1067-1076.
3. Sharif, H., Singh, I., Kouser, L., Mosges, R., Bonny, M., Karamani, A., Parkin, R.V., Bovy, N., Kishore, U., Robb,
A., Katotomichelakis, M., Holtappels, G., Derycke, L., Corazza, F., Von Frenckell, R., Wathelet, N., Duchateau,
J., Legon, T., Pirotton, S., Durham, S.R., Bachert, C., Shamji, M.H. Immunologic mechanisms of short-course
of Lolium Perenne Peptide Immunotherapy: A Randomized Double-Blind Placebo-Controlled Trial. J Allergy
Clin Immunol. 2019 Mar 5. pii: S0091-6749(19)30287-8. doi: 10.1016/j.jaci.2019.02.023.
4. Shamji MH, Layhadi JA, Achkova D, Kouser L, Perera-Webb A, Couto-Francisco NC, Parkin RV, Matsuoka T,
Scadding G, Ashton-Rickardt PG, Durham SR. Role of IL-35 in sublingual allergen immunotherapy. J Allergy
Clin Immunol. 2019 Mar;143(3):1131-1142.e4. doi: 10.1016/j.jaci.2018.06.041. Epub 2018 Jul 25.
5. Layhadi JA, Eguiluz-Gracia I, Shamji MH. Role of IL-35 in sublingual allergen immunotherapy. Curr Opin
Allergy Clin Immunol. 2019 Feb;19(1):12-17.
6. Skypala IJ, Cecchi L, Shamji MH, Scala E, Till S. Lipid Transfer Protein allergy in the United Kingdom:
Characterization and comparison with a matched Italian cohort. Allergy. 2019 Feb 14. doi: 10.1111/all.13747.
(In Press)
7. Rauber MM, Wu HK, Adams B, Pickert J, Bohle B, Shamji MH, Pfützner W, Möbs C. Birch pollen allergenspecific
immunotherapy with glutaraldehyde-modified allergoid induces IL-10 secretion and protective
antibody responses. Allergy. 2019 Aug;74(8):1575-1579. doi: 10.1111/all.13774. Epub 2019 Apr 11. No
abstract available.
Review Publications (2019)
8. Bousquet J, Pfaar O, Togias A, Schünemann HJ, Ansotegui I, Papadopoulos NG, Tsiligianni I, Agache I, Anto
JM, Bachert C, Bedbrook A, Bergmann KC, Bosnic-Anticevich S, Bosse I, Brozek J, Calderon M, Canonica
GW, Caraballo L, Cardona V, Casale T, Cecchi L, Chu DK, Costa E, Cruz AA, Czarlewski W, Durham SR, Du
Toit G, Dykewicz M, Ebisawa M, Fauquert JL, Fernandez-Rivas M, Fokkens WJ, Fonseca J, Fontaine JF, van
Wijk RG, Haahtela T, Halken S, Hellings PW, Ierodiakonou D, Iinuma T, Ivancevich JC, Jacobsen L, Jutel M,
Kaidashev I, Khaitov M, Kalayci O, Kleine Tebbe J, Klimek L, Kowalski ML, Kuna P, Kvedariene V, La Grutta
S, Larenas-Linemann D, Lau S, Laune D, Le L, Carlsen KL, Lourenço O, Malling HJ, Marien G, Menditto E,
Mercier G, Mullol J, Muraro A, O’Hehir R, Okamoto Y, Pajno GB, Park HS, Panzner P, Passalacqua G, Pham-
Thi N, Roberts G, Rolland C, Rosario N, Ryan D, Samolinski B, Sanchez-Borges M, Scadding G, Shamji MH,
Sheikh A, Sturm GJ, Todo Bom A, Toppila-Salmi S, Valentin-Rostan M, Valiulis A, Valovirta E, Ventura MT,
Wahn U, Walker S, Wallace D, Waserman S, Yorgancioglu A, Zuberbier T; ARIA Working Group. ARIA Care
pathways for allergen immunotherapy. Allergy. 2019 Apr 7. doi: 10.1111/all.13805.
9. Campo P, Eguiluz-Gracia I, Bogas G, Salas M, Plaza Serón C, Pérez N, Mayorga C, Torres MJ, Shamji MH,
Rondon C. Local allergic rhinitis: Implications for management. Clin Exp Allergy. 2019 Jan;49(1):6-16. doi:
10.1111/cea.13192. Epub 2018 Jul 5.
10. Eguiluz-Gracia I, Layhadi JA, Rondon C, Shamji MH. Mucosal IgE immune responses in respiratory diseases.
Curr Opin Pharmacol. 2019 Jun 17;46:100-107. doi: 10.1016/j.coph.2019.05.009. [Epub ahead of print]
11. Layhadi JA, Eguiluz-Gracia I, Shamji MH. Role of IL-35 in sublingual allergen immunotherapy. Curr
Opin Allergy Clin Immunol. 2019 Feb;19(1):12-17. doi: 10.1097/ACI.0000000000000499
12. Agache I, Annesi-Maesano I, Bonertz A, Branca F, Cant A, Fras Z, Ingenrieth F, Namazova-
Baranova L, Odemyr M, Spanevello A, Vieths S, Yorgancioglu A, Alvaro-Lozano M, Barber
Hernandez D, Chivato T, Del Giacco S, Diamant Z, Eguiluz-Gracia I, van Wijk RG, Gevaert P,
Graessel A, Hellings P, Hoffmann-Sommergruber K, Jutel M, Lau S, Lauerma A, Maria Olaguibel J,
O’Mahony L, Ozdemir C, Palomares O, Pfaar O, Sastre J, Scadding G, Schmidt-Weber C, Schmid-
Grendelmeier P, Shamji MH, Skypala I, Spinola M, Spranger O, Torres M, Vereda A, Bonini S.
Prioritizing research challenges and funding for allergy and asthma and the need for translational research-
The European Strategic Forum on Allergic Diseases. Allergy. 2019 May 9. doi: 10.1111/all.13856. [Epub ahead of
print]
Book Chapters
1. Shamji MH, Francis JN. Measurement of Allergen-Specific Inhibitory Antibody Activity. Methods Mol
Biol. 2019;2020:33-43. doi: 10.1007/978-1-4939-9591-2_3.
Original Research Publications (2018)
1. Rondón C, Eguíluz-Gracia I, Shamji MH, Layhadi JA, Salas M, Torres MJ, Campo P. IgE Test in Secretions of
Patients with Respiratory Allergy. Curr Allergy Asthma Rep. 2018 Oct 13;18(12):67.
2. Shamji, M.H., Layhadi, J.A., Achkova, D., Kouser, L., Perera-Webb, A., Couto-Francisco, N.C., Parkin, R.,
Matsuoka, T., Scadding, G., Ashton-Rickardt, P.G., Durham, S.R. Role of Interleukin-35 in sublingual allergen
immunotherapy. J Allergy Clin Immunol. 2018 Jul 25. (In press)
3. Renand, A*., Shamji, M.H*., Harris, K.M., Qin, T., Wambre, E., Scadding, G.W., Wurtzen, P.A., Till, S.J., Togias,
A., Nepom, G.T., Kwok, W.W., Durham, S.R. Synchronous immune alterations mirror clinical response during
allergen immunotherapy. J Allergy Clin Immunol. 2018 May;141(5):1750–1760.e1. (Editor’s Choice)
4. Shamji, M.H., Temblay, J.N., Cheng, W., Byrne, S.M., Macfarlane, E., Switzer, A.R., Francisco, N.D.C.,
Olexandra, F., Jacubczik, F., Durham, S.R., Ashton-Rickardt, P.G. Antiapoptotic serine protease inhibitors
contribute to survival of allergenic TH2 cells. J Allergy Clin Immunol. 2018 Aug;142(2):569-581.e5.
5. Mosges, R., Bachert, C., Panzner, P., Calderon, M.A., Haazen, L., Pirotton, S., Wathelet, N., Durham, S.R.,
Bonny, M.A., Legon, T., von Frenckell, R., Pfaar, O., Shamji, M.H. Short course of grass allergen peptides
immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A
randomized, multicenter, double-blind, placebo-controlled trial. Allergy. 2018;73(9):1842-50.
6. Mosges, R., Kasche, E.M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah-Hosseini, K., Pirotton,
S., Haazen, L., Durham, S.R., Legon, T., Zadoyan, G., Shamji, M.H. A randomized, double-blind, placebocontrolled,
dose-finding trial with Lolium perenne peptide immunotherapy. Allergy. 2018 Apr;73(4):896-904.
7. Mosges, R., Koch, A.F., Raskopf, E., Singh, J., Shah-Hosseini, K., Astvatsatourov, A., Hauswald, B., Yarin, Y.,
Corazza, F., Haazen, L., Pirotton, S., Allekotte, S., Zadoyan, G., Legon, T., Durham, S.R., Shamji, M.H. Lolium
perenne peptide immunotherapy is well tolerated and elicits a protective B-cell response in seasonal allergic
rhinitis patients. Allergy. 2018 Jun;73(6):1254-1262.
8. Shamji, M.H., Ceuppens, J., Bachert, C., Hellings, P., Placier, G., Thirion, G., Bovy, N., Durham, S.R.,
Duchateau, J., Legon, T., Pirotton, S. Lolium perenne peptides for treatment of grass pollen allergy: A
randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol. 2018 Jan;141(1):448-451.
9. Bahri, R., Custovic, A., Korosec, P., Tsoumani, M., Barron, M., Wu, J., Sayers, R., Weimann, A., Ruiz-Garcia,
M., Patel, N., Robb, A., Shamji, M.H., Fontanella, S., Silar, M., Mills, E.N.C., Simpson, A., Turner, P.J., Bulfone-
Paus, S. Mast cell activation test in the diagnosis of allergic disease and anaphylaxis. J Allergy Clin Immunol.
2018 Aug;142(2):485-496.e16.
10. Bulfone-Paus, S., Bahri, R., Shamji, M.H., Custovic, A., Turner, P.J. Reply. J Allergy Clin Immunol. 2018.
EAACI White Paper publication (2018)
11. Schmidt-Weber*, C.B., Shamji, M.H*. The innate Immune Response. EAACI White Paper on Research and
Innovation. 2018;B1:25-26.
Review Publications (2018)
12. Pfaar, O., Bonini, S., Cardona, V., Demoly, P., Jakob, T., Jutel, M., Kleine-Tebbe, J., Klimek, L., Klysner, S.,
Kopp, M. V, Kuna, P., Larche, M., Muraro, A., Schmidt-Weber, C.B., Shamji, M.H., Simonsen, K., Somoza, C.,
Valovirta, E., Zieglmayer, P., Zuberbier, T., Wahn, U. Perspectives in allergen immunotherapy: 2017 and
beyond. Allergy. 2018 Jan;73 Suppl 104:5-23.
13. Campo, P., Eguiluz-Gracia, I., Bogas, G., Salas, M., Plaza Seron, C., Perez, N., Mayorga, C., Torres, M.J.,
Shamji, M.H., Rondon, C., 2018. Local allergic rhinitis: Implications for management. Clin Exp Allergy. 2018.
(In press)
14. Kortekaas Krohn, I., Shikhagaie, M.M., Golebski, K., Bernink, J.H., Breynaert, C., Creyns, B., Diamant, Z.,
Fokkens, W.J., Gevaert, P., Hellings, P., Hendriks, R.W., Klimek, L., Mjosberg, J., Morita, H., Ogg, G.S.,
O’Mahony, L., Schwarze, J., Seys, S.F., Shamji, M.H., Bal, S.M. Emerging roles of innate lymphoid cells in
inflammatory diseases: Clinical implications. Allergy. 2018 Apr;73(4):837-850.
15. Rondon, C., Eguíluz-Gracia, I., Shamji, M.H., Layhadi, J.A., Salas, M., Torres, M.J., Campo, P. IgE test in
secretions of patients with respiratory allergy. Curr Allergy Asthma Rep. 2018;18(12):67.
Original Research Publications (2017)
16. Scadding, G.W*., Calderon, M.A*., Shamji, M.H*., Eifan, A.O., Penagos, M., Dumitru, F., Sever, M.L., Bahnson,
H.T., Lawson, K., Harris, K.M., Plough, A.G., Panza, J.L., Qin, T., Lim, N., Tchao, N.K., Togias, A., Durham,
S.R. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to
Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS
Randomized Clinical Trial. JAMA. 2017 Feb 14;317(6):615-625.
17. Qaseem, A.S., Singh, I., Pathan, A.A., Layhadi, J.A., Parkin, R., Alexandra, F., Durham, S.R., Kishore, U.,
Shamji, M.H. A Recombinant Fragment of Human Surfactant Protein D Suppresses Basophil Activation and THelper
Type 2 and B-Cell Responses in Grass Pollen-induced Allergic Inflammation. Am J Respir Crit Care
Med. 2017 Dec 15;196(12):1526-1534.
18. Slovick, A., Douiri, A., Muir, R., Guerra, A., Tsioulos, K., Hay, E., Lam, E.P.S., Kelly, J., Peacock, J.L., Ying, S.,
Shamji, M.H., Cousins, D.J., Durham, S.R., Till, S.J. Intradermal grass pollen immunotherapy increases TH2
and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol. 2017 Jun;139(6):1830-
1839.e13.
19. Korosec, P., Turner, P.J., Silar, M., Kopac, P., Kosnik, M., Gibbs, B.F., Shamji, M.H., Custovic, A., Rijavec, M.,
2017. Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis. J Allergy Clin Immunol. 2017
Sep;140(3):750-758.e15.
EAACI Positions Paper publication (2017)
20. Shamji, M.H., Kappen, J.H., Akdis, M., Jensen-Jarolim, E., Knol, E.F., Kleine-Tebbe, J., Bohle, B., Chaker,
A.M., Till, S.J., Valenta, R., Poulsen, L.K., Calderon, M.A., Demoly, P., Pfaar, O., Jacobsen, L., Durham, S.R.,
Schmidt-Weber, C.B. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic
rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy. 2017 Aug;72(8):1156-1173.
Review Publications (2017)
21. Kappen, J.H., Durham, S.R., Veen, H.I., Shamji, M.H. Applications and mechanisms of immunotherapy in
allergic rhinitis and asthma. Ther Adv Respir Dis. 2017 Jan;11(1):73-86.
22. Kouser, L., Kappen, J., Walton, R.P., Shamji, M.H. Update on Biomarkers to Monitor Clinical Efficacy Response
During and Post Treatment in Allergen Immunotherapy. Curr Treat Options Allergy. 2017;4(1):43-53.
23. Shamji, M.H., Durham, S.R. Mechanisms of allergen immunotherapy for inhaled allergens and predictive
biomarkers. J Allergy Clin Immunol. 2017 Dec;140(6):1485-1498.
Original Research Publications (2016)
24. Chaker, A.M., Shamji, M.H., Dumitru, F.A., Calderon, M.A., Scadding, G.W., Makatsori, M., Jones, I., He, Q.A.,
Subramanian, K.K., Arm, J.P., Durham, S.R., Schmidt-Weber, C.B. Short-term subcutaneous grass pollen
immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. J Allergy Clin Immunol. 2016
Feb;137(2):452-461.e9.
25. Gadermaier, E., James, L.K., Shamji, M.H., Blatt, K., Fauland, K., Zieglmayer, P., Garmatiuk, T., Focke-Tejkl,
M., Villalba, M., Beavil, R., Keller, W., Valent, P., Durham, S.R., Gould, H.J., Flicker, S., Valenta, R. Epitope
specificity determines cross-protection of a SIT-induced IgG4 antibody. Allergy. 2016 Jan;71(1):36-46.
26. Pednekar, L., Pathan, A.A., Paudyal, B., Tsolaki, A.G., Kaur, A., Abozaid, S.M., Kouser, L., Khan, H.A.,
Peerschke, E.I., Shamji, M.H., Stenbeck, G., Ghebrehiwet, B., Kishore, U. Analysis of the Interaction between
Globular Head Modules of Human C1q and Its Candidate Receptor gC1qR. Front Immunol. 2016 Dec 13;7:567.
27. Pondman, K.M., Tsolaki, A.G., Paudyal, B., Shamji, M.H., Switzer, A., Pathan, A.A., Abozaid, S.M., Ten Haken,
B., Stenbeck, G., Sim, R.B., Kishore, U. Complement Deposition on Nanoparticles Can Modulate Immune
Responses by Macrophage, B and T Cells. J Biomed Nanotechnol. 2016 Jan;12(1):197-216.
28. Slovick, A., Douiri, A., Muir, R., Guerra, A., Tsioulos, K., Haye, E., Lam, E.P.S., Kelly, J., Peacock, J.L., Ying,
S., Shamji, M.H., Cousins, D.J., Durham, S.R., Till, S.J. A randomised placebo-controlled trial investigating
efficacy and mechanisms of low-dose intradermal allergen immunotherapy in treatment of seasonal allergic
rhinitis. NIHR publications. Southampton (UK). 2016 Dec.
Review Publications (2016)
29. Varricchi, G., Harker, J., Borriello, F., Marone, G., Durham, S.R., Shamji, M.H. T follicular helper (Tfh) cells in
normal immune responses and in allergic disorders. Allergy. 2016 Aug;71(8):1086-94.
30. Calderon, M.A., Demoly, P., Casale, T., Akdis, C.A., Bachert, C., Bewick, M., Bilo, B.M., Bohle, B., Bonini, S.,
Bush, A., Caimmi, D.P., Canonica, G.W., Cardona, V., Chiriac, A.M., Cox, L., Custovic, A., De Blay, F., Devillier,
P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S.R., Eng, P., Fiocchi, A., Fox, A.T., van Wijk, R.G., Gomez,
R.M., Haathela, T., Halken, S., Hellings, P.W., Jacobsen, L., Just, J., Tanno, L.K., Kleine-Tebbe, J., Klimek, L.,
Knol, E.F., Kuna, P., Larenas-Linnemann, D.E., Linneberg, A., Matricardi, M., Malling, H.J., Moesges, R., Mullol,
J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Del Rio, P.R., Rueff, R.,
Samolinski, B., Scadding, G.K., Senti, G., Shamji, M.H., Sheikh, A., Sisul, J.C., Sole, D., Sturm, G.J., Tabar,
A., Van Ree, R., Ventura, M.T., Vidal, C., Varga, E.M., Worm, M., Zuberbier, T., Bousquet, J. Allergy
immunotherapy across the life cycle to promote active and healthy ageing: from research to policies: An
AIRWAYS Integrated Care Pathways (ICPs) programme item (Action Plan B3 of the European Innovation
Partnership on active and healthy ageing) and the Global Alliance against Chronic Respiratory Diseases
(GARD), a World Health Organization GARD research demonstration project. Clin Transl Allergy. 2016 Nov
23;6:41.
Original Research Publications (2015)
31. Shamji, M.H., Layhadi, J.A., Scadding, G.W., Cheung, D.K.M., Calderon, M.A., Turka, L.A., Phippard, D.,
Durham, S.R. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response.
J Allergy Clin Immunol. 2015 Apr;135(4):913-21.e9.
32. Shamji, M.H., Bellido, V., Scadding, G.W., Layhadi, J.A., Cheung, D.K.M., Calderon, M.A., Asare, A., Gao, Z.,
Turka, L.A., Tchao, N., Togias, A., Phippard, D., Durham, S.R. Effector cell signature in peripheral blood
following nasal allergen challenge in grass pollen allergic individuals. Allergy. 2015 Feb;70(2):171-9.
33. Scadding, G.W., Eifan, A., Penagos, M., Dumitru, A., Switzer, A., McMahon, O., Phippard, D., Togias, A.,
Durham, S.R., Shamji, M.H. Local and systemic effects of cat allergen nasal provocation. Clin Exp Allergy.
2015 Mar;45(3):613-23.
34. Scadding, G.W., Eifan, A.O., Lao-Araya, M., Penagos, M., Poon, S.Y., Steveling, E., Yan, R., Switzer, A.,
Phippard, D., Togias, A., Shamji, M.H., Durham, S.R. Effect of grass pollen immunotherapy on clinical and local
immune response to nasal allergen challenge. Allergy. 2015 Jun;70(6):689-96.
35. Shamji, M.H., Durham, S.R. Reply: To PMID 25457150. J Allergy Clin Immunol. 2015 Apr;135(4):1089-90.
36. Santos, A.F., James, L.K., Bahnson, H.T., Shamji, M.H., Couto-Francisco, N.C., Islam, S., Houghton, S., Clark,
A.T., Stephens, A., Turcanu, V., Durham, S.R., Gould, H.J., Lack, G. IgG4 inhibits peanut-induced basophil and
mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol.
2015 May;135(5):1249-56.
37. Steveling, E.H., Lao-Araya, M., Koulias, C., Scadding, G., Eifan, A., James, L.K., Dumitru, A., Penagos, M.,
Calderon, M., Andersen, P.S., Shamji, M., Durham, S.R. Protocol for a randomised, double-blind, placebocontrolled
study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal,
cutaneous and immunological outcomes. Clin Transl Allergy. 2015 Dec 17;5:43.
38. Dodev, T.S., Bowen, H., Shamji, M.H., Bax, H.J., Beavil, A.J., McDonnell, J.M., Durham, S.R., Sutton, B.J.,
Gould, H.J., James, L.K. Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but
different class. Allergy. 2015 Jun;70(6):720-4.
39. Pondman, K.M., Pednekar, L., Paudyal, B., Tsolaki, A.G., Kouser, L., Khan, H.A., Shamji, M.H., Ten Haken,
B., Stenbeck, G., Sim, R.B., Kishore, U. Innate immune humoral factors, C1q and factor H, with differential
pattern recognition properties, alter macrophage response to carbon nanotubes. Nanomedicine. 2015
Nov;11(8):2109-18.
Original Research Publications (2014)
40. Lao-Araya, M., Steveling, E., Scadding, G.W., Durham, S.R., Shamji, M.H. Seasonal increases in peripheral
innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol.
2014 Nov;134(5):1193-5.e4. (Editor’s Choice)
41. Wood, R.A., Togias, A., Wildfire, J., Visness, C.M., Matsui, E.C., Gruchalla, R., Hershey, G., Liu, A.H.,
O’Connor, G.T., Pongracic, J.A., Zoratti, E., Little, F., Granada, M., Kennedy, S., Durham, S.R., Shamji, M.H.,
Busse, W.W. Development of cockroach immunotherapy by the Inner-City Asthma Consortium. J Allergy Clin
Immunol. 2014 Mar;133(3):846-52.e6.
42. Vickery, B.P., Scurlock, A.M., Kulis, M., Steele, P.H., Kamilaris, J., Berglund, J.P., Burk, C., Hiegel, A., Carlisle,
S., Christie, L., Perry, T.T., Pesek, R.D., Sheikh, S., Virkud, Y., Smith, P.B., Shamji, M.H., Durham, S.R., Jones,
S.M., Burks, A.W. Sustained unresponsiveness to peanut in subjects who have completed peanut oral
immunotherapy. J Allergy Clin Immunol. 2014 Feb;133(2):468-75.
43. Turner, P.J., Mehr, S., Sayers, R., Wong, M., Shamji, M.H., Campbell, D.E., Mills, E.N. Loss of allergenic
proteins during boiling explains tolerance to boiled peanut in peanut allergy. J Allergy Clin Immunol. 2014
Sep;134(3):751-3.
44. Pillai, P., Fang, C., Chan, Y.-C., Shamji, M.H., Harper, C., Wu, S.-Y., Ohm-Laursen, L., Durham, S.R., Menzies-
Gow, A., Rajakulasingam, R.K., Ying, S., Corrigan, C.J., Gould, H.J. Allergen-specific IgE is not detectable in
the bronchial mucosa of nonatopic asthmatic patients. J Allergy Clin Immunol. 2014 Jun;133(6):1770-2.e11.
45. Jones, M., Jeal, H., Schofield, S., Harris, J.M., Shamji, M.H., Francis, J.N., Durham, S.R., Cullinan, P. Ratspecific
IgG and IgG(4) antibodies associated with inhibition of IgE-allergen complex binding in laboratory
animal workers. Occup Environ Med. 2014 Sep;71(9):619-23.
Review Publications (2014)
46. Shamji, M.H. Mechanisms of Allergen-Specific Sublingual Immunotherapy and the Use of Biological Markers
in Allergic Rhinitis. Curr Treat Options Allergy. 2014 Mar;1(1):1-13.
Original Research Publications (2013)
47. Shamji, M.H., Francis, J.N., Wurtzen, P.A., Lund, K., Durham, S.R., Till, S.J. Cell-free detection of allergen-IgE
cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J
Allergy Clin Immunol. 2013 Oct;132(4):1003-5.e1-4.
48. Shamji, M.H., Ljorring, C., Wurtzen, P.A. Predictive biomarkers of clinical efficacy of allergen-specific
immunotherapy: how to proceed. Immunotherapy. 2013 Mar;5(3):203-6.
49. Marth, K., Breyer, I., Focke-Tejkl, M., Blatt, K., Shamji, M.H., Layhadi, J., Gieras, A., Swoboda, I., Zafred, D.,
Keller, W., Valent, P., Durham, S.R., Valenta, R. A nonallergenic birch pollen allergy vaccine consisting of
hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses
to a tolerogenic and Th1 phenotype. J Immunol. 2013 Apr 1;190(7):3068-78.
50. Slovick, A., Douiri, A., Kelly, J., Guerra, A., Muir, R., Tsioulos, K., Murphy, C., Shamji, M.H., Ying, S., Durham,
S.R., Till, S.J. Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen
immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic
rhinitis (PollenLITE). Clin Transl Allergy. 2013 Aug 21;3(1):27.
51. Varga, E.-M., Kausar, F., Aberer, W., Zach, M., Eber, E., Durham, S.R., Shamji, M.H. Tolerant beekeepers
display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol. 2013
May;131(5):1419-21.
Review Publications (2013)
52. Durham, S.R., Scadding, G.W., Phippard, D., Wurtzen, P.A., Shamji, M.H. Biomarkers of tolerance in response
to allergen immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess.
2013;97:75-81.
53. Matsuoka, T., Shamji, M.H., Durham, S.R. Allergen immunotherapy and tolerance. Allergol Int. 2013
Dec;62(4):403-13.
54. Qaseem, A.S., Sonar, S., Mahajan, L., Madan, T., Sorensen, G.L., Shamji, M.H., Kishore, U. Linking surfactant
protein SP-D and IL-13: implications in asthma and allergy. Mol Immunol. 2013 May;54(1):98-107.
Original Research Publications (2012)
55. Shamji, M.H., Ljørring, C., Francis, J.N., A Calderon, M., Larché, M., Kimber, I., Frew, A.J., Ipsen, H., Lund, K.,
Würtzen, P.A., Durham, S.R. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical
response to grass pollen immunotherapy. Allergy. 2012 Feb;67(2):217-26.
56. Rotiroti, G., Shamji, M., Durham, S.R., Till, S.J. Repeated low-dose intradermal allergen injection suppresses
allergen-induced cutaneous late responses. J Allergy Clin Immunol. 2012 Oct;130(4):918-24.e1.
57. James, L.K., Bowen, H., Calvert, R.A., Dodev, T.S., Shamji, M.H., Beavil, A.J., McDonnell, J.M., Durham, S.R.,
Gould, H.J. Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol. 2012 Sep;130(3):663-670.e3.
58. Herranz, F., Schmidt-Weber, C.B., Shamji, M.H., Narkus, A., Ruiz-Cabello, J., Vilar, R. Superparamagnetic iron oxide nanoparticles conjugated to a grass pollen allergen and an optical probe. Contrast Media Mol Imaging. 2012 Jul-Aug;7(4):435-9. Original Research Publications (2011)
59. James, L.K*., Shamji, M.H*., Walker, S.M., Wilson, D.R., Wachholz, P.A., Francis, J.N., Jacobson, M.R., Kimber, I., Till, S.J., Durham, S.R. Long term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol. 2011 Feb;127(2):509-516.e1-5.
60. Dumitru, A.F., Shamji, M., Wagenmann, M., Hindersin, S., Scheckenbach, K., Greve, J., Klenzner, T., Hess, L., Nebel, S., Zimmermann, C., Zahner, C., Schmidt-Weber, C.B., Chaker, A.M. Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. J Allergy Clin Immunol. 2011 Jun;127(6):1515-21.e6. Review Publications (2011)
61. Shamji, M.H., Durham, S.R. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy. 2011 Sep;41(9):1235-46.
62. Shamji, M.H., James, L.K., Durham, S.R. Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am. 2011 May;31(2):311-23, x.
63. Eifan, A.O., Shamji, M.H., Durham, S.R. Long-term clinical and immunological effects of allergen
immunotherapy. Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):586-93. Original Research Publications (2010)
64. Pree, I*., Shamji, M.H*., Kimber, I., Valenta, R., Durham, S.R., Niederberger, V. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy. 2010 Sep;40(9):1346-52.
65. Scadding, G.W*., Shamji, M.H*., Jacobson, M.R., Lee, D.I., Wilson, D., Lima, M.T., Pitkin, L., Pilette, C., Nouri-Aria, K., Durham, S.R. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010 Apr;40(4):598-606. Original Research Publications (2008)
66. Steel, A., John, L., Shamji, M.H., Henderson, D.C., Gotch, F.M., Gazzard, B.G., Kelleher, P. CD38 expression on CD8 T cells has a weak association with CD4 T-cell recovery and is a poor marker of viral replication in HIV-1-infected patients on antiretroviral therapy. HIV Med. 2008 Feb;9(2):118-25. Original Research Publications (2007)
67. Steel, A., Cox, A.E., Shamji, M.H., John, L., Nelson, M., Henderson, D.C., Gotch, F.M., Gazzard, B.G., Kelleher, P. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ Tcell activation. Antivir Ther. 2007;12(6):971-5. Original Research Publications (2006)
68. Shamji, M.H., Wilcock, L.K., Wachholz, P.A., Dearman, R.J., Kimber, I., Wurtzen, P.A., Larche, M., Durham, S.R., Francis, J.N. The IgE facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods. 2006 Dec 20;317(1-2):71-9. Book Chapters
1. Sahiner, U.M., Kappen, J.H., Yildirim, O., Shamji, M.H. (2018). Chapter 12. Clinical Markers to AIT Response. Immunotherapies for Allergic Disease. (Accepted). Edited by L. Cox. Publisher: Elsevier
2. Shamji, M.H., Till, J.S., Durham, S.R. (Feb 2014). Immunological Responses to Subcutaneous Allergen Immunotherapy. Allergens and Allergen Immunotherapy. Publisher: CRC Press, Taylor and Francis Group
3. Shamji, M.H., Francis, J.N. Measurements of Allergen-Specific Inhibitory Antibody Activity by Facilitated Antigen Binding (FAB) and Enzyme Linked Facilitated Antigen Binding (ELIFAB) Assays. Methods in Molecular Medicine: Allergy Methods and Protocols. Edited by: M.G. Jones and P. Lympany. Publisher: Humana Press Inc., Totowa, NJ 1.
Conference proceedings
1. Shamji, M.H., Scadding, G.W., Calderon, M.A., Phippard, D., Durham, S.R. Effects of Grass Pollen Immunotherapy
on Peripheral Innate Lymphoid Type 2 cells (30th Symposium of the Collegium Internationale Allergologicum
Petersberg, Germany-2014).
2. Durham, S.R., Abubakar-Waziri, A., Steveling, E., Varricci, G., Parkin, R.V., Shamji, M.H. Allergen Immunotherapy
is associated with the induction of Nasal and Serum immunereactive and inhibitory IgG4 antibodies in grass-pollen
induced seasonal allergic rhinitis. (30th Symposium of the Collegium Internationale Allergologicum Petersberg,
Germany-2014)
3. Varricchi, G., Parkin, R.V., Steveling, E., Marone, G., Durham, S.R., Shamji, M.H. Interleukin-21 induced IgEsythesis
in memory B cells: A role for T follicular helper cells in Seasonal Allergic Rhinitis. (30th Symposium of the
Collegium Internationale Allergologicum Petersberg, Germany-2014).
4. Shamji, M.H., Durham, S.R. Non-IgE blocking antibodies: Surrogate biomarkers of clinical efficacy to grass pollen
immunotherapy (28th Symposium of the Collegium Internationale Allergologicum, Ischia, Italy-2010).
5. Shamji, M.H., Layhadi, J.A., Achkova, D., Scadding, G.W., Phippard, D., Durham, S.R. IL-35+CD4+CD25+Foxp3-
regulatory T cells suppress Th2 responses and are induced following grass pollen-specific sublingual
immunotherapy (29th Symposium of the Collegium Internationale Allergologicum Jeju island, South Korea-2012).
6. Durham, S.R., Bellido, V., Scadding, G.W., Layhadi, J.A., Calderon, M., Togias, A., Tchao, N., Turka, L., Phippard,
D., Shamji, M.H. Effects of nasal allergen challenge on T effector cell signature in peripheral blood in patients with
grass pollen-induced rhinitis. (29th Symposium of the Collegium Internationale Allergologicum Jeju island, South
Korea-2012).
7. Shamji, M.H., Scadding, G.W., Calderon, M., Phippard, D., Durham, S.R. Monitoring Basophil Responsiveness
Following Allergen Immunotherapy. 29th Symposium of the Collegium Internationale Allergologicum Jeju island,
South Korea-2010).
Conferences peer – reviewed abstracts
2018
1. Kirtland M, Tsitoura D, Durham SR, Shamji MH. An in vitro assay to screen Toll-like Receptor agonists as potential
adjuvants in allergen immunotherapy. BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual
Meeting; 2018.
2. Ntavli E, Sahiner U, Layhadi J, Robb AO, Ruiz-Garcia M, Skypala I, Mills C, Durham SR, Turner P, Shamji MH.
Group 2 Innate Lymphoid Cells (ILC2s) contribute to the pathophysiology of Peanut. BRITISH SOCIETY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2018.
3. Layhadi JA, Achkova D, Kouser L, Perera-Webb A, Couto Francisco N, Parkin R, Matsuoka T, Scadding G, Ashton-
Rickardt P, Durham SR, Shamji MH. Interleukin-35 regulates type II-mediated responses elicited by innate lymphoid
cells in allergic diseases. BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2018.
4. Singh I, Sharif H, Kouser L, Karamani A, Kishore U, Gabriele H, Derycke L, von Frenckell R, Wathelet N, Duchateau
J, Legon T, Pirotton S, Mösges R, Durham SR, Bachert C, Shamji MH. IL-35+ T regulatory cells (iTR35) induces
IL-10-producing B regulatory cells and blocking antibodies in short course of Lolium Perenne Peptide (LPP)
Immunotherapy. BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2018.
5. Hug O, Singh I, Robb A, Yildirim O, Durham S, Shamji MH. IL-35 induces IL-10 producing Regulatory B cells in
immunotherapy treated patients. BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual
Meeting; 2018.
6. Tang J, Singh I, Parkin R, Wang C, Kostic A, DurhamSR , Radin A, Shamji MH. Clinical and Immunologic Effects
of a Single Dose of Anti-Fel d 1-IgG4 monoclonal antibodies in Cat Allergic Individuals: A Double Blind Randomized
Placebo-Controlled Study. BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting;
2018.
7. Stranzl T, Lundegaard C, Ohashi-Doi K, Shamji MH, Andersen PS. A machine learning approach to evaluate IgE
and IgG4 responses as patient-specific measure of exposure to sublingual allergen immunotherapy. EUROPEAN
ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2018: John Wiley & Sons, Inc. Allergy
73, 336-337.
8. Layhadi JA, Matsuoka T, Scadding G, Ashton-Rickardt P, Durhma SR, Shamji MH. Interleukin (IL)-35 producing
T regulatory cells (iTR35) suppresses type II innate lymphoid cell (ILC2) and T helper 2 (Th2) cell function and are
induced following grass pollen immunotherapy. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2018: John Wiley & Sons, Inc. Allergy 73, 43.
9. Moesges R, Demoly P, Lehmacher W, Durham S, Shamji M, Pirotton S, Haazen L, Calderon M. Safety of a 3-
week allergen immunotherapy course with grass pollen peptides: A randomised double-blind placebo-controlled
trial. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2018: John Wiley
& Sons, Inc. Allergy 73, 471.
10. Mosges R, Bachert C, Creticos PS, Cox L, Durham SR, Pirotton S, Bonny, MA, Legon T, Haazen L, Shamji MH.
Quality of Life during the hay fever season after short-course subcutaneous immunotherapy with Lolium perenne
peptides (LPP) in grass pollen related rhinoconjunctivitis: A RDBPCT. AMERICAN ACADEMY OF ALLERGY,
ASTHMA AND IMMUNOLOGY Annual Meeting; 2018; J Allergy and Clinical Immunology 141(2):AB291.
11. Singh I, Sharif H, Kouser L, Karamani A, Kishore U, Holtappels G, Derycke L, Von Frenckell R, Wathelet N,
Duchateau J, Legon T, Pirotton S, Mosges R, Durham SR, Bachert C, Shamji MH. Short Course of Lolium Perenne
Peptides (LPP) Immunotherapy Induces IL-35+ T Regulatory Cells (iTr35) that Promote B Regulatory Cells (Bregs)
and Blocking Antibodies. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting;
2018; J Allergy and Clinical Immunology 141(2):AB122.
12. Sharif H, Karamani A, Parkin R, Kouser L, Singh I, Robb A, Holtappels G, Derycke L, Von Frenckell R, Wathelet
N, Duchateau J, Legon T, Pirotton S, Mosges R, Durham SR, Bachert C, Shamji MH. Short Course of Lolium
Perenne Peptides (LPP) Immunotherapy Deletes Circulating IL-4+ IL-21+ T follicular helper cells and Induces
FoxP3+ T follicular regulatory cells: A Randomized Controlled Trial. AMERICAN ACADEMY OF ALLERGY,
ASTHMA AND IMMUNOLOGY Annual Meeting; 2018; J Allergy and Clinical Immunology 141(2):AB197.
13. Eifan A, Scadding G, Calderon M, Shamji M, Penagos M, Alder-Wurtzen P, Sever M, Bahnson H, Lawson , Harris
K, Qin T, Lim N, Plough A, Tchao N, Togias A, Durham S. Relationship between response to grass pollen nasal
allergen challenge and seasonal symptoms and the effect of treatment compliance. BRITISH SOCIETY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2017: WILEY-BLACKWELL 111 RIVER ST,
HOBOKEN 07030-5774, NJ USA. Clinical and Experimental Allergy 47(12): 1686-1687.
14. Kim EH, Sicherer SH, Wood RA, Bidslev-Jensen C, Hamilton RG, Shamji MH, Van Twuijver E, Opstelten D, De
Kam PJ. Safety and tolerability of subcutaneous immunotherapy (SCIT) with a modified peanut extract in peanutallergic
adults, adolescents and children. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY
Annual Meeting; 2017: John Wiley & Sons, Inc. Allergy 72: 738-739.
15. Bahri R, Robb A, Shamji MH, Custovic A, Turner PJ, Bulfone-Paus S. Mast cell activation test distinguishes between
sensitisation and clinical reactivity with improved diagnostic characteristics compared to other diagnostic techniques
including basophil activation. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual
Meeting; 2017: John Wiley & Sons, Inc. Allergy 72: 139-140.
16. Skypala IJ, Cecchi L, Shamji MH, Scala E, Till S. Lipid transfer protein allergy in UK adults-characterisation and
comparison to adults with pollen-food syndrome. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2017: John Wiley & Sons, Inc. Allergy 72: 29.
17. Durham S, Schwabe C, Robson R, Emanuelsson C, Shamji M, Singh D, Man T, Clarke G, Zhong S, Kamal M,
Newell D, Stahl N, Yancopoulos GD, Kostic A. A randomized clinical trial of passive immunotherapy with singledose
anti-Fel d1 monoclonal antibodies REGN 1908-1909 in cat-induced rhinoconjunctivitis: exploratory efficacy
endpoints, safety. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2017:
John Wiley & Sons, Inc. Allergy 72: 64-65.
18. Turner PJ, Robb A, Gibbs BF, Shamji MH, Silar M, Custovic A, Korosec P. Peripheral basopenia during
peanutinduced allergic reactions-a protective response? EUROPEAN ACADEMY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2017: John Wiley & Sons, Inc. Allergy 72: 131-131.
19. Shamji MH, Mosges R, Bonny M, Bovy N, Karamani A, Parkin R, Katotomichelakis M, Holtappels G, Derycke L,
Corazza F, Von Frenckell R, Duchateau J, Legon T, Pirotton S, Durham SR, Bachert C. Short course treatment of
subcutaneous peptide hydrolysate from lolium perenne (LPP) suppresses basophil responses and induces iggassociated
blocking antibodies: a RDPCT. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY
Annual Meeting; 2017: John Wiley & Sons, Inc. Allergy 72: 143-143.
20. Moesges R, Panzner P, Pfaar O, Thomson M, Haazen L, Bonny M, Von Frenckell R, Pirotton S, Legon T, Durham
SR, Shamji MH, Bachert C. Efficacy of a 3-week subcutaneous immunotherapy course in patients with grass polleninduced
rhinoconjunctivitis: Results of a phase-3 study. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2017: John Wiley & Sons, Inc. Allergy 72: 374-374.
21. Scadding GW, Eifan AO, Calderon MA, Shamji MH, Penagos M, Wurtzen PA, Sever ML, Bahnson HT, Lawson K,
Harris KM, Qin T, Lim N, Plough A, Tchao NK, Togias A, Durham SR. Response to Nasal Challenge Correlates
with Seasonal Outcomes during Grass Pollen Immunotherapy with Either Subcutaneous or Sublingual
Immunotherapy. . AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2017; J
Allergy and Clinical Immunology 139(2):AB385.
22. Singh I, Qaseem A, Pathan A, Parkin R, Kishore U, Durham SR, Shamji MH. Surfactant Protein-D (SP-D): a
Potential Therapeutic Target for Seasonal Allergic Rhinitis. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND
IMMUNOLOGY Annual Meeting; 2017; J Allergy and Clinical Immunology 139(2):AB84.
23. Froese van Dijck A, Kousar L, Layhadi J, Fedina O, Calvosa S, Scadding GW, Durham SR, Shamji MH. SATB1 is
repressed in FoxP3+ Tregs following Grass Pollen Subcutaneous and Sublingual Immunotherapy and Correlates
with Clinical efficacy. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting;
2017; J Allergy and Clinical Immunology 139(2):AB192.
2016
24. Scadding G, Calderon M, Shamji M, Penagos M, Eifan A, Wurtzen PA, Sever M, Bahnson H, Lawson K, Harris K,
Qin T, Lim N, Plough A, Tchao N, Togias A, Durham SR. Grass pollen subcutaneous and sublingual immunotherapy
inhibit allergen-induced nasal and skin responses: a randomised controlled trial. BRITISH SOCIETY OF ALLERGY
AND CLINICAL IMMUNOLOGY Annual Meeting; 2016: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-
5774, NJ USA. Clinical and Experimental Allergy 46 (12), 1639-1640.
25. Singh I, Qaseem AS, Pathan AA., Durham SR, Kishore U, Shamji MH. Surfactant protein D (SP-D): a novel
therapeutic target for suppressing grass pollen-induced Th2 and B responses in seasonal allergic rhinitis. BRITISH
SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2016: WILEY-BLACKWELL 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA. Clinical and Experimental Allergy 46, 1630.
26. Zadoyan G, Allekotte S, Shamji MH, Kasche EM, Singh J, Astvatsatourov A, Shah-Hosseini K, Pirotton S, Legon
T, Caplanusi A, Durham SR, Mosges R. Immunological biomarker predict clinical effects in subcutaneous peptide
allergen immunotherapy. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting;
2016: John Wiley & Sons, Inc. Allergy 71: 319-320.
27. Scadding G, Calderon M, Shamji MH, Penagos M, Eifan A, Phippard D, Harris KM, Chani E, Qin T, Tchao N, Togias
A, Sever ML, Lawson K, Wurtzen PA, Durham SR. Grass pollen subcutaneous and sublingual immunotherapy
inhibit allergen-induced nasal responses and local Th2 cytokines: a randomised controlled trial. EUROPEAN
ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2016: John Wiley & Sons, Inc. Allergy
71: 3-3.
28. Scadding G, Calderon M, Shamji MH, Penagos M, Eifan A, Phippard D, Harris KM, Tchao N, Lim N, Togias A,
Bahnson HT, Sever ML, Lawson K, Durham SR. Grass pollen subcutaneous immunotherapy results in faster and
greater suppression of allergen-induced skin responses compared to sublingual immunotherapy: a randomised
controlled trial. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2016: John
Wiley & Sons, Inc. Allergy 71: 172-172.
29. Kappen J, Schmidt-Weber C, Akdis M, Jensen-Jarolim E, Knol E, Klein-Tebbe J, Scadding G, Chaker A, Bohle B,
Valenta R, Poulsen L, Jacobsen L, Calderon M, Demoly P, Durham SR, Shamji MH. Evaluation of novel and current
biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic
asthma. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2016: John Wiley
& Sons, Inc. Allergy 71: 455-455.
30. Steveling-Klein EH, Lao-Araya M, Koulias C, Chowdhury M, Scadding G, Eifan A, Dumitru A, Penagos M, Calderon
M, Shamji M, Durham SR. A randomised placebo-controlled trial of sublingual immunotherapy tablet for seasonal
rhinitis to grass allergen: clinical outcomes, local symptoms and early time course of immunologic changes.
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2016: John Wiley & Sons,
Inc. Allergy 71: 616-616.
31. Slovick AD, Douiri A, Muir R, Guerra A, Tsioulos K, Haye E, Lam E, Kelly J, Peacock J, Ying S, Shamji MH. A
Randomized Placebo-Controlled Trial of Intradermal Grass Pollen Immunotherapy for Seasonal Allergic Rhinitis.
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2016; J Allergy and
Clinical Immunology 137(2): AB94.
32. Sharif HHA, Parkin R, Ito C, Scadding G, Durham SR, Shamji HM. Immune Tolerance Induction Following AIT Is
Associated with Induction of Circulating CD4+CXCR5+PD-1+FoxP3+ T Follicular Regulatory Cells. AMERICAN
ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2016; J Allergy and Clinical
Immunology 137(2): AB97.
33. Ntavli E, Turner PJ, Boyle RJ, Clark A, Robb AO, Durham SR, Shamji MH. Group 2 Innate Lymphoid Cells: New
Players in Peanut Allergy. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting;
2016; J Allergy and Clinical Immunology 137(2): AB74.
34. Steveling EH, Lao-Araya M, Koulias C, Chowdhury M, Scadding G, Eifan A, Dumitru A, Paniagua MJP, Shamji
MH, Durham SR. Randomised Placebo-Controlled Trial of Grass Pollen Allergen Tablet Immunotherapy for
Seasonal Rhinitis: Clinical and Surrogate Outcomes and Early Time Course of Immunologic Changes. AMERICAN
ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2016; J Allergy and Clinical
Immunology 137(2): AB197.
35. Mohseni YR, Turner PJ, Boyle RJ, Clark A, Robb AO, Durham SR, Shamji MH. Intracellular Expression of
Fluorochrome Labelled-Diamine Oxidase in Basophils: A Novel Diagnostic Tool for Peanut Allergy. AMERICAN
ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2016; J Allergy and Clinical
Immunology 137(2): AB137.
36. Allekotte S, Shamji MH, Zadoyan GV, Kasche EM, Shah-Hosseini K, Astvatsatourov A, Pirotton S, Caplanusi A,
Durham SR, Mosges R. Facilitated Allergen Binding (FAB) Is a Meaningful Immunological Biomarker for
Monitoring Immediate Clinical Efficacy in Short-Term Peptide Allergen Immunotherapy. AMERICAN ACADEMY
OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2016; J Allergy and Clinical Immunology 137(2):
AB403.
2015
37. 松岡伴和, 増山敬祐, Durham SR, Shamji MH. 抗原特異的 Th2 反応に対する IL-27 の免疫調節効果. 耳鼻咽喉科免
疫アレルギー. 2015;33(1):15-6.
38. Turner PJ, McMahon O, Switzer A, Clark A, Boyle RJ, Durham SR, Shamji MH. Marked Increase in Basophil
Activation during Non-Anaphylactic Allergic Reactions to Peanut in Man. AMERICAN ACADEMY OF ALLERGY,
ASTHMA AND IMMUNOLOGY Annual Meeting; 2015; J Allergy and Clinical Immunology 135(2):AB33.
39. Turner P, Mehr S, Sayers R, Wong M, Shamji M, Campbell D, Mills E, editors. Tolerance to boiled peanut in peanutallergic
children: are boiled peanuts an option for oral immunotherapy? BRITISH SOCIETY OF ALLERGY AND
CLINICAL IMMUNOLOGY Annual Meeting; 2015: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774,
NJ USA. Clinical and Experimental Allergy 45(2): 530.
40. Steveling E, Layhadi J, Scadding G, Calderon M, Durham S, Shamji M, editors. Diamine oxidase: a novel biomarker
for monitoring ex-vivo allergen-induced basophil reactivity following grass pollen immunotherapy. BRITISH
SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2015: WILEY-BLACKWELL 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA. Clinical and Experimental Allergy 45(2): 539.
41. Shamji MH, Durham SR. Measuring histamine content and release at single-cell level during venom allergy
immunotherapy Reply. MOSBY-ELSEVIER 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA; 2015.
p. 1089-90.
42. Shamji MH, Ceuppens JL, Hellings PW, Durham S, Duchateau J, Parkin R, Legon T, Pirotton S, editors.
Immunogenicity Evaluation of Subcutaneous Administration of Peptide Hydrolysate from Lolium Perenne (gpASIT
plus (TM)) in Combination with Bacterial HSP70 (DnaK) in Patients with Seasonal Allergic Rhinitis: A Double Blind
Placebo Controlled Trial. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting;
2015; J Allergy and Clinical Immunology 135(2):AB159.
43. Shamji MH, Ceuppens JL, Hellings PW, Durham S, Duchateau J, Parkin R, Legon T, Pirotton S. Immunogenicity
Evaluation of Subcutaneous Administration of Peptide Hydrolysate from Lolium Perenne (gpASIT+ (TM)) in
Combination with Bacterial HSP70 (DnaK) in Patients with Seasonal Allergic Rhinitis: A Double Blind Placebo
Controlled Trial. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2015; J
Allergy and Clinical Immunology 135(2):AB159.
44. Scadding G, Eifan A, Penagos M, Dumitru A, Switzer A, McMahon O, Phippard D, Togias A, Durham S, Shamji M.
Local and systemic effects of cat allergen nasal provocation. BRITISH SOCIETY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2015; Clinical and Experimental Allergy 45(2): 501.
45. Parkin R, Varricchi G, Steveling E, Marone G, Durham S, Shamji M, editors. Interleukin-21 induced IgE-synthesis
in memory B cells: a role for T follicular helper cells in seasonal allergic rhinitis. BRITISH SOCIETY OF ALLERGY
AND CLINICAL IMMUNOLOGY Annual Meeting; 2015: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-
5774, NJ USA. Clinical and Experimental Allergy 45(2): 539.
46. Lao-Araya M, Abubakar-Waziri H, Steveling E, Parkin R, Switzer A, Scadding G, Durham S, Shamji M, editors.
Grass pollen immunotherapy suppresses seasonal increases in type 2 innate lymphoid cells (ILC2s). BRITISH
SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2015: WILEY-BLACKWELL 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA. Clinical and Experimental Allergy 45(2): 538-39.
47. Abubakar-Waziri H, Parkin R, Switzer A, Steveling E, Scadding G, Durham S, Shamji M, editors. Local nasal
protective IgG4 antibodies: novel biomarker for monitoring allergen immunotherapy. BRITISH SOCIETY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2015: WILEY-BLACKWELL 111 RIVER ST,
HOBOKEN 07030-5774, NJ USA. Clinical and Experimental Allergy 45(2): 539-40.
2014
48. Zhang J, Steveling E, Yan R, Eifan A, Parkin R, Scadding GW, Shamji MH, Durham SR. Local’Protective’IgG4
Antibodies In Nasal Fluid Are Elevated Following Grass Pollen Immunotherapy. AMERICAN ACADEMY OF
ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2014; J Allergy and Clinical Immunology 133(2):AB157.
49. Zadoyan G, Hauswald B, Yarin Y, Shah-Hosseini K, Shamji M, Durham S, Pirotton S, Moesges R, Legon T, editors.
Safety, clinical tolerability and immunogenicity of increasing doses of gpASIT plus (TM) administered
subcutaneously to hay fever patients-a phase IIa dose-escalation study. EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY Annual Meeting; 2014: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-
5774, NJ USA. Allergy 69: 154.
50. Turner P, Mehr S, Sayers R, Wong M, Shamji M, Campbell D, Mills E, editors. Tolerance to boiled peanut in peanutallergic
children: potential for oral immunotherapy? EUROPEAN ACADEMY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2014: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
Allergy 69: 382.
51. Shamji MH. Mechanisms of Allergen-Specific Sublingual Immunotherapy and the Use of Biological Markers in
Allergic Rhinitis. Current Treatment Options in Allergy. 2014;1(1):1-13.
52. Shamji M, Ceuppens J, Hellings P, Durham S, Duchateau J, Legon T, Pirotton S, editors. Immunogenicity
evaluation of subcutaneous administration of peptide hydrolysate from Lolium perenne (gpASIT plus TM) in
combination with bacterial HSP70 (DnaK) in patients with seasonal allergic rhinitis. EUROPEAN ACADEMY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2014: John Wiley & Sons, Inc. Allergy 69: 31.
53. Shamji MH, Layhadi J, Perera-web A, Yan R, Durham SR. IL-35-Producing T Cells (iTR35) Inhibit Th2 Effector
Function, Induce Infectious Tolerance and Are Elevated Following Grass Pollen Sublingual Immunotherapy.
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2014. J Allergy and Clinical
Immunology 133(2):AB51
54. Scadding GW, Eifan A, Lao-Araya M, Paniagua MJP, Poon SY, Steveling E, Goldstone A, Yan R, Switzer A,
Phippard D, Shamji MH, Durham SR. Grass Pollen Immunotherapy: Impaired Allergen-Induced Nasal and
Cutaneous Responses Correlate With Overall Seasonal Symptom Scores and Are Associated With Suppressed
Local Th2 Cytokines In Nasal Fluid. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual
Meeting; 2014; J Allergy and Clinical Immunology 133(2):AB158.
55. Mehr S, Turner PJ, Campbell DE, Sayers R, Shamji MH, Mills E, Wong M, editors. TOLERANCE TO BOILED
PEANUT IN PEANUT-ALLERGIC CHILDREN. INTERNAL MEDICINE JOURNAL; 2014: WILEY-BLACKWELL 111
RIVER ST, HOBOKEN 07030-5774, NJ USA. 44: 17.
56. Matsuoka T, Yan R, Scadding GW, Durham SR, Shamji MH. Interleukin IL-27+ Dendritic Cells Modulate Ex-Vivo
Th2 Responses In a Pdl-1-Dependent Manner and Increase In-Vivo Following Grass Pollen Immunotherapy.
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2014; J Allergy and Clinical
Immunology 133(2):AB157.
57. Gadermaier E, James LK, Shamji MH, Blatt K, Garmatiuk T, Beavil R, Flicker S, Valent P, Durham SR, Gould HJ.
A Phl p 7-specific IgG4 antibody inhibits allergic patients IgE cross-reactivity to allergens from the EF-hand family:
importance of affinity and degree of cross-reactivity. Clinical and Translational Allergy. 2014;4(2):1-2.
58. Couto-Francisco NC, Matsuoka T, Yan R, Durham SR, Shamji MH. Interleukin 35 Modulates TSLP, IL-25 and IL-
33 Primed Dendritic Cells and Inhibits Naive T Cell Differentiation and Grass Pollen-Specific T Cell Proliferation.
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; J Allergy and Clinical
Immunology 2014; 133(2):AB149.
59. Charlesworth JE, Scadding GW, Eifan A, Yan R, Goldstone A, Calderon MA, Durham SR, Shamji MH. IL-10-
Producing B Cells Are Increased After Grass Pollen Immunotherapy Compared To Untreated Grass Pollen Allergic
Controls: A Blinded Cross-Sectional Study. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY
Annual Meeting; 2014; J Allergy and Clinical Immunology 133(2):AB53.
2013
60. Shamji M, Saleem N, Nicholson J, Schmidt-Weber C, Chaker A, Durham S, editors. Local nasal antiinflammatory
IgG4 responses are induced following grass pollen sublingual and subcutaneous immunotherapy. EUROPEAN
ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2013: WILEY-BLACKWELL 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA. Allergy 68: 21-22.
61. Shamji M, Matsuoka T, Durham S, editors. IL-27 supresses allergen-driven TH2 responses and IL-27+ dendritic
cells are significantly reduced in grass pollen allergic individuals compared to non-atopic controls. EUROPEAN
ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2013: WILEY-BLACKWELL 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA. Allergy 68: 23.
62. Shamji M, Layhadi J, Scadding G, Durham S, editors. A novel subset of regulatory T cells: interleukin-35 producing
T regs (iTR35) are induced after grass pollen sublingual immunotherapy. EUROPEAN ACADEMY OF ALLERGY
AND CLINICAL IMMUNOLOGY Annual Meeting; 2013: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-
5774, NJ USA. Allergy 68: 67.
63. Shamji M, Layhadi J, Perera-Web A, Scadding G, Durham SR. IL-35+ Regulatory T Cells Suppress Grass Pollen-
Driven Th2 Responses and Are Induced Following Grass Pollen-Specific Sublingual Immunotherapy. AMERICAN
ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2013; J Allergy and Clinical Immunology
131(2):AB146.
64. Scadding G, Eifan A, Penagos M, Koed GK, Wurtzen PA, Shamji M, Durham S. Grass pollen nasal challenge is
associated with increases in Th2 cytokines, Eotaxin, MDC and IL-6 in nasal fluid. BRITISH SOCIETY OF ALLERGY
AND CLINICAL IMMUNOLOGY Annual Meeting; 2013; Clinical and Experimental Allergy 3(2): P29
65. Saleem N, Chaker A, Zissler U, Schmidt-Weber CB, Durham SR, Shamji MH. Local
Nasal’Protective’Immunoglobulin G4 (IgG4) Responses in Nasal Fluid Following Grass Pollen Sublingual
Immunotherapy. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2013; J
Allergy and Clinical Immunology 131(2):AB202.
66. Qaseem A, Pathan A, Layhadi J, Chinea Y, Durham S, Kishore U, Shamji M. Recombinant human pulmonary
surfactant protein-D (rhSP-D) modulates Th2 responses and suppresses IgE-facilitated allergen binding to B cells.
European Respiratory Journal. 2013; 42 (Suppl 57):P898.
67. Pillai PC, Fang C, Chan Y-C, Shamji MH, Harper C, Ohm-Laursen L, Durham SR, Menzies-Gow A, Rajakulasingam
R, Sun Y. Detection and Quantitation of Total and Allergen-Specific IgE in the Bronchial Mucosa of Atopic and Non-
Atopic Asthmatics. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2013;
J Allergy and Clinical Immunology 131(2):AB331.
68. Matsuoka T, Stott B, Durham SR, Shamji MH. Immunomodulatory Effects of IL-27 on Allergen-induced Th2
responses. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2013; J Allergy
and Clinical Immunology 131(2):AB203.
69. Matsuoka T, Shamji MH, Durham SR. Review Series: Immunotherapy and Tolerance—Cutting Edge. Allergology
International. 2013;62: 403-13.
70. Matsuoka T, Durham S, Shamji M. Interleukin 27-primed dendritic cells suppress grass pollen-specific Th2
responses in patients with seasonal allergic rhinitis. BRITISH SOCIETY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2013: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
71. Marri E, Nayak A, Qaseem A, Pednekar L, Shamji M, Mitchell D, Kishore U, editors. Modulation of DC-SIGNallergen
interaction by surfactant protein SP-D. BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY
Annual Meeting; 2013: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
72. Cifuentes L, Ploetz S, Chaker A, Pennino D, Durham S, Shamji M, Ollert M, Ring J, Schmidt-Weber C, Darsow U,
editors. In vitro immunomonitoring of birch pollen-allergic patients during allergen-specific immunotherapy.
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2013: WILEYBLACKWELL
111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
73. Charlesworth JE, Goldstone A, Calderon MA, Cousins D, Durham SR, Shamji MH. Grass Pollen Allergics Have
Fewer IL-10-Producing B Cells Than Non-Atopic Controls. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND
IMMUNOLOGY Annual Meeting; 2013;2(131):AB204.
74. Charlesworth J, Goldstone A, Yan R, Calderon M, Cousins D, Durham S, Shamji M, editors. Regulatory B cells are
reduced amongst grass-pollen allergic patients compared with non-allergic controls. BRITISH SOCIETY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2013: WILEY-BLACKWELL 111 RIVER ST,
HOBOKEN 07030-5774, NJ USA.
2012
75. Shamji M, Patel V, Till S, Phippard D, Turcanu V, Durham S, editors. Functional but not quantitative peanut-specific
IgE antibodies as diagnostic biomarker for peanut allergy. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2012: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
76. Shamji M, Layhadi J, Cheung D, Khan S, Phippard D, Durham S. 97 Grass Pollen Allergen-induced Surface
Expression of CD203C, CD63 and CD107A on CRTH2+ Basophils: Novel Biomarkers for Monitoring Efficacy of
Allergen-specific Immunotherapy. The World Allergy Organization Journal. 2012;5(Suppl 2):S49-S.
77. Shamji M, Kent A, Baron-Bodo V, Rodriguez P, Robert Z, Moingeon P, Durham S, editors. Pre-coseasonal
treatment with five-grass sublingual tablets induces inhibitory antibodies that correlate with clinical efficacy.
EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2012: WILEYBLACKWELL
111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
78. Shamji M, Bellido V, Scadding G, Leyhadi J, Calderon M, Togias A, Tchao N, Plaut M, Turka L, Phippard D. Effects
of Nasal Allergen Challenge on T cell signature in Peripheral Blood in Patients with Severe Seasonal Allergic
Rhinitis. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting;
2012;129(2):AB196.
79. Shamji M, Achkova D, Layhadi J, Perera-Webb A, Scadding G, Khan S, Durham S, editors. IL-35 producing
regulatory T cells modulate grass pollen-specific Th2 responses and are induced following sublingual grass pollen
immunotherapy. BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2012: WILEYBLACKWELL
111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
80. Shamji M, Achkova D, Chung W, Janice L, Scadding G, Phippard D, Durham S, editors. Inducible IL-35+ T regs
attenuate allergen-specific Th2 and Th17 responses in patients with seasonal allergic rhinitis. EUROPEAN
ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2012: WILEY-BLACKWELL 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA.
81. Rotiroti G, Shamji M, Durham SR, Till SJ. Repeated low-dose intradermal allergen injection suppresses allergeninduced
cutaneous late responses. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual
Meeting; 2012;130(4):918-24. e1.
82. Qaseem A, Pathan A, Layhadi J, Chianea Y, Durham S, Kishore U, Shamji M, editors. Recombinant human
pulmonary surfactant protein-D (rhSP-D) suppresses IgE-facilitated allergen binding to B cells. BRITISH SOCIETY
OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2012: WILEY-BLACKWELL 111 RIVER ST,
HOBOKEN 07030-5774, NJ USA.
83. Charlesworth J, Khan S, Scadding G, Cousins D, Durham S, Shamji M, editors. IL-10-producing regulatory B cells
suppress allergen-specific T cell proliferation and are elevated ex vivo following specific immunotherapy. BRITISH
SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2012: WILEY-BLACKWELL 111 RIVER
ST, HOBOKEN 07030-5774, NJ USA.
84. Achkova D, Chung F, Layhadi J, Scadding G, Charlesworth J, Phippard D, Durham S, Shamji M. Interleukin-35
Suppresses Allergen-specific Th2 Response in Patients with Grass pollen induced Seasonal Allergic Rhinitis.
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2012;129(2):AB208.
2011
85. Varga E, Kausar F, Sturm G, Aberer W, Zach M, Durham S, Shamji M, editors. Repeated exposure to bee venom
during the beekeeping season induces high levels of venom-specific IgG4 serum antibodies with serum inhibitory
activity for IgE-facilitated antigen binding in non-allergic beekeepers. EUROPEAN ACADEMY OF ALLERGY AND
CLINICAL IMMUNOLOGY Annual Meeting; 2011: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774,
NJ USA.
86. Shamji M, Layhadi J, Cheung D, Khan S, Durham S, editors. Allergen-induced expression of CD203c, CD63 and
CD107a on CRTH2+ basophils: Biomarkers for monitoring efficacy of grass pollen immunotherapy. BRITISH
SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2011: WILEY-BLACKWELL
COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.
87. Shamji M, Hamilton A, Harris J, Jeal H, Cullinan P, Durham S, Jones M, editors. Is’ natural tolerance’at high allergen
exposure associated with inhibitory IgG4 antibodies? BRITISH SOCIETY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2011: WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN
02148, MA USA.
88. Shamji M, Chaker A, Cheung D, Poon M, Schmidt-Weber C, Durham S. Frequency Of Grass Pollen-specific Il-4,
Il-10 And Dual Il-4 And Il10 Positive Cells In Atopic And Non-atopic Individuals In And Out Of The Pollen Season
AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2011;127(2):AB128.
89. Patel R, Shamji M, Flohr C, Brown A, Pritchard D, Till S, editors. Necatoramericanus (hookworm) excretorysecretory
product modulates in vitro recall responses to grass pollen in allergic subjects. BRITISH SOCIETY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2011: WILEY-BLACKWELL COMMERCE PLACE, 350
MAIN ST, MALDEN 02148, MA USA.
90. Nicholson J, Ratnayake A, Poon M, Togias A, Durham S, Shamji M. Ige-facilitated Binding Of Cockroach Allergenige
Complexes To B Cells: An Assay To Monitor Efficacy During Immunotherapy? AMERICAN ACADEMY OF
ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2011;127(2):AB225.
91. Dumitru F, Schmidt-Weber C, Shamji M, Durham S, Hindersin S, Scheckenbach K, Wagenmann M, Klenzner T,
Greve J, Zimmermann C, editors. Petasites hybridus extract (Ze 339) as an alternative, innovative treatment of
seasonal allergic rhinitis. EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting;
2011: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774, NJ USA.
92. Dumitru AF, Shamji M, Wagenmann M, Hindersin S, Scheckenbach K, Greve J, Klenzner T, Hess L, Nebel S,
Zimmermann C. Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more
effectively than desloratadine. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual
Meeting; 2011; 127(6):1515-21. e6.
2010
93. Shamji MH. Grass pollen immunotherapy: Immunoreactive and functional antibody responses and their relationship
to clinical response: Imperial College London; 2010.
94. Shamji M, Ljørring C, Francis J, Kimber I, Frew A, Lund K, Würtzen P, Durham S. Blocking antibodies: relationship
between IgG4-associated inhibitory activity and clinical response to grass-pollen immunotherapy. AMERICAN
ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2010;125(2):AB131.
2009
95. Shamji M, Ljorring C, Francis J, Kimber I, Frew A, Lund K, Wurtzen P, Durham S, editors. Functional antibodies: a
time-dependent and dose-related response following grass pollen immunotherapy. BRITISH SOCIETY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2009: WILEY-BLACKWELL PUBLISHING, INC
COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.
96. Shamji M, James L, Francis J, Kimber I, Till S, Durham S, editors. Long-term remission after withdrawal of
subcutaneous immunotherapy is associated with persistent elevated serum IgG4-dependent inhibitory activity that
is not detectable by measuring serum immunoreactive allergen-specific IgG4 antibody levels. EUROPEAN
ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2009: WILEY-BLACKWELL
PUBLISHING, INC COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.
97. Scadding G, Shamji M, Jacobson M, Schmidt-Weber C, Nouri-Aria K, Durham S, editors. Foxp3 is increased in the
sublingual mucosa after grass pollen sublingual immunotherapy and is accompanied by increases in serum IgG4
and serum inhibitory activity for allergen-IgE binding to B cells. EUROPEAN ACADEMY OF ALLERGY AND
CLINICAL IMMUNOLOGY Annual Meeting; 2009: WILEY-BLACKWELL PUBLISHING, INC COMMERCE PLACE,
350 MAIN ST, MALDEN 02148, MA USA.
98. Scadding G, Shamji M, Jacobson M, Lee D, Kimber I, Schmidt-Weber C, Nouri-Aria K, Durham S, editors. Local
mucosal and systemic regulatory effects of grass pollen sublingual immunotherapy. BRITISH SOCIETY OF
ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2009: WILEY-BLACKWELL PUBLISHING, INC
COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.
99. Ljørring C, Shamji M, Würtzen P, Lund K, Frew A, Durham S, Ipsen H. IgE-blocking Antibodies may account for a
large Proportion of the observed Treatment Effect Induced by Specific Immunotherapy (SIT). AMERICAN
ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2009; 123(2):S154.
2008
100. Shamji M, Barkans J, Francis J, Kimber I, Durham S. Confocal Imaging of Low Affinity IgE Receptor Distribution
on B cells: Effects of Grass Pollen Immunotherapy. AMERICAN ACADEMY OF ALLERGY, ASTHMA AND
IMMUNOLOGY Annual Meeting; 2008; 121(2):S141.
2007
101. Shamji MH, Barkans J, Kimber I, Francis JN, Durham SR, editors. Visualising the inhibitory effect of blocking
antibodies in grass pollen immunotherapy using confocal microscopy. BRITISH SOCIETY OF ALLERGY AND
CLINICAL IMMUNOLOGY Annual Meeting; 2007: BLACKWELL PUBLISHING 9600 GARSINGTON RD, OXFORD
OX4 2DQ, OXON, ENGLAND.
2006
102. Shamji M, Wilcock L, Larche M, Francis J, Durham S. Validation of a functional assay of IgE-facilitated CD23-
dependent allergen binding to B cells to monitor clinical efficacy of immunotherapy. AMERICAN ACADEMY OF
ALLERGY, ASTHMA AND IMMUNOLOGY Annual Meeting; 2006; 117(2):S330.
103. Steel A, Cox A, Shamji M, Henderson D, Gotch F, Gazzard B, Kelleher P, editors. CD38 expression on CD8+
T cells is a marker of residual viral replication in HIV-1 infected patients on successful anti-retroviral therapy.
BRITISH SOCIETY OF IMMUNOLOGY; 2005: BLACKWELL PUBLISHING 9600 GARSINGTON RD, OXFORD
OX4 2DQ, OXON, ENGLAND.
104. Shamji M, Wilcock L, Larche M, Durham S, Francis J, editors. Analytical validation of a novel flow cytometricbased
Facilitated Allergen Presentation (FAP) assay as a tool for monitoring allergen-specific immunotherapy.
BRITISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 2005: BLACKWELL
PUBLISHING 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND.
105. Shamji M. Mechanisms and Biomarkers Related to Sublingual and Subcutaneous Immunotherapy. BRITISH
SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY Annual Meeting; 1998; 102:558-62.
106. Shamji M, Henderson D. 52P Medical Research Society.
107. Prathap Chellappan Pillai M, Fang C, Shamji MH, Ohm-Laursen L, Menzies-Gow A, Rajakulasingam R, Sun
Y. L14 Antibiotic Exposure and the Risk of Food Allergy in Young Children Bryan L. Love, PharmD, BCPS1, Joshua
Mann, MD, MPH2, James W. Hardin, PhD3, David Amrol, MD2; 1South Carolina College of Pharmacy, Columbia,
SC, 2University of South Carolina School of Medicine, Colum. J BRITISH SOCIETY OF ALLERGY AND CLINICAL
IMMUNOLOGY Annual Meeting; 2006; 131(2).

Мешкова Раиса Яковлевна,
доктор медицинских наук, профессор

Индекс Хирша 13

Мешкова Раиса Яковлевна, окончила Смоленский государственный медицинский институт (СГМИ) в 1973 году, а затем клиническую ординатуру по детской инфекции. После поступила и закончила аспирантуру по иммунологии. В 1984 году защитила кандидатскую диссертацию «РТПХ в условиях репаративной регенерации селезенки». С 1988 года возглавляет кафедру клинической иммунологии и аллергологии СГМИ. В 1996 году защитила докторскую диссертацию на тему «Скрининг больных с нарушениями иммунной системы и оказание специализированной лечебно-диагностической помощи» и была избрана на должность проффесора кафедры клинической иммунологии и аллергологии Смоленской государственной медицинской академии.

С 1993 года – заведующая отделением аллергологии и иммунологии Городской клинической больницы №1 г.Смоленска, а с 2006 по 2012 год – руководитель областного центра аллергологии и иммунологии.

Является членом комиссии по преподаванию аллергологии и иммунологии при МЗ РФ, председатель Смоленского научного общества аллергологов-иммунологов, главный внештатный аллерголог-иммунолог Департамента Смоленской области по здравоохранению, член EAACI (The European Academy of Allergy and Clinical Immunology) и РААКИ (Российской ассоциации аллергологов и клинических иммунологов). Руководитель первого в России центра GA2LEN UCARE.

Автор более 200 научных работ, 3 монографий, 13 изобретений. Соавтор учебника «Клиническая иммунология и аллергология с основами общей иммунологии», рекомендованного для студентов учреждений высшего профессионального образования. Под руководством Мешковой Р.Я. защищено 5 кандидатских диссертаций, являлась научным консультантом 12 кандидатских работ. Заслуженный врач РФ.

Raisa Y. Meshkova, Professor, MD, DSc

Hirsch Index: 13

Meshkova Raisa Yakovlevna, graduated from Smolensk State Medical Institute (SSMI) in 1973, and then clinical residency in childhood infection. After she entered in postgraduate school in immunology. In 1984 she defended her Phd study «GVHR under conditions of reparative regeneration of the spleen». Since 1988, heads of the Department of Clinical Immunology and Allergology of the SSMI. In 1996 she defended her MD on the topic “Screening of patients with impaired immune systems and the provision of specialized diagnostic and treatment assistance” and was elected to the post of professor at the Department of Clinical Immunology and Allergology of the Smolensk State Medical Academy.

From 1993 – head of the department of allergology and immunology of the Smolensk City Clinical Hospital No. 1, and from 2006 to 2012 – the head of the regional center of allergology and immunology.

She is a member of the commission for teaching allergology and immunology at the Ministry of Health of the Russian Federation, chairman of the Smolensk Scientific Society of Allergists-Immunologists, chief allergist-immunologist of the Department of Health (Smolensk region), member of EAACI (The European Academy of Allergy and Clinical Immunology) and RAACI (The Russian Association of Allergologists and Immunologists). Head of  first GA2LEN UCARE center in Russia.

The author of more than 200 scientific papers, 3 monographs, 13 inventions. Co-author of the textbook “Clinical Immunology and Allergology with the Basics of General Immunology”, which recommended for students of higher education institutions. Under the leadership of Meshkova R.Ya. defended 5 Phd, she was a scientific consultant for 12 Phd studies.

Председатель редакционного совета

Хаитов Рахим Мусаевич

доктор медицинских наук, профессор, академик РАН

http://orcid.org/0000-0003-1829-0424

h=45

Р.М. Хаитов является ведущим специалистом в области медицины, в частности, иммунологии и аллергологии. Работы академика Р.М. Хаитова оказали значительное влияние на развитие отечественной и мировой науки, он во многом способствовал становлению современной иммунологии в наиболее важных её областях – фундаментальной, прикладной и общеобразовательной. В 1967 Р.М.Хаитов с отличием окончил Самаркандский государственный медицинский институт, в 1968 году защитил кандидатскую диссертацию, а в 1973 году – докторскую. В 1980 г. Р.М.Хаитову было присвоено ученое звание профессора, в 1991 г. он был избран членом-корреспондентом РАМН, в 1997 г. – действительным членом РАМН, в 2006 г. – действительным членом РАН. Р.М.Хаитов стоял у истоков создания Института иммунологии – ведущего научного учреждения России в этой области. С 1988 по 2015 гг. он был директором института, в настоящее время является его научным руководителем.

Труды Р.М.Хаитова внесли огромный вклад в развитие фундаментальных представлений об иммунной системе, в том числе о механизмах миграции и регуляции дифференцировки кроветворных стволовых клеток, описаны механизмы регуляции со стороны тимуса и гипофиз-адреналовой системы. Р.М. Хаитовым открыты пептидные медиаторы костного мозга, обнаружены и изучены неизвестные ранее субпопуляции иммуноцитов. На протеомном и молекулярно-генетическом уровнях исследована часть генома человека, осуществляющая регуляцию иммунного ответа. С разработкой этой проблемы связаны перспективы генодиагностики и персонифицированной медицины, лечения онкологических, аутоиммунных, инфекционных и аллергических заболеваний. К числу основных областей научных интересов Р.М.Хаитова относятся иммуногенетика, иммунорегуляция, вакцинология, патогенез и иммунотерапия аллергических заболеваний, иммунология и иммунотерапия рака, молекулярная иммунология.

Р.М. Хаитовым созданы новые принципы конструирования вакцинирующих препаратов с повышенными защитными свойствами – вакцин нового поколения. Эти препараты широко используются в клинической практике в России и за рубежом (вакцины против гриппа, брюшного тифа, дизентерии). Подготовлены к производству принципиально новые вакцины для лечения аллергий. Для терапии нарушений иммунитета Р.М. Хаитовым и его сотрудниками создан ряд новых эффективных лекарств (полиоксидоний, тактивин, миелопид, иммуномакс и др.), широко используемых в практической медицине. Также разработаны инновационные иммуномодулирующие лекарственные препараты для терапии рака. Р.М. Хаитовым и его сотрудниками создан  широкий спектр систем диагностики инфекций, аллергий, иммунопатологий, разработаны инновационные методы типирования генов иммунного ответа и оценки их функций. В настоящее время эти реагенты и приборы применяются в Российской Федерации и за рубежом.

Р.М. Хаитов опубликовал более 1000 научных работ, в том числе 20 монографий и национальных руководств, 10 учебников по иммунологии, многие из них переведены на иностранные языки. Он автор 27 патентов и авторских свидетельств, 3-х международных патентов. Р.М. Хаитовым создана крупная научная школа. Им подготовлено 38 докторов и 69 кандидатов наук.

Р.М.Хаитов является президентом Российской ассоциации аллергологов и клинических иммунологов (РААКИ), представляет Россию в ведущих международных научных организациях – EAACI и WAO (член советов национальных обществ).

В 2004 г. при непосредственном участии Р.М.Хаитова был основан «Российский аллергологический журнал». С момента основания и по настоящее время он является председателем редакционного совета журнала.

Chairman of the Editorial council

Khaitov Rakhim Musaevich

Doctor of medical sciences (MD), Professor, Academician of RAS

http://orcid.org/0000-0003-1829-0424

h=45

R.M. Khaitov is a leading specialist in the field of medicine, in particular, immunology and allergology. The works of academician R. M. Khaitov made a significant impact on the development of Russian and world science, he made a great contribution to the formation of modern immunology in its most important areas – fundamental, applied and educational. In 1967 R.M. Khaitov excellently graduated the Samarkand state medical Institute, in 1968 received PhD degree, in 1973 – doctoral degree (MD). In 1980, R. M. Khaitov became a professor, in 1991 he was elected as corresponding member of the RAMS, in 1997 – became a full member of the RAMS, in 2006 – a full member (fellow) of the RAS. R.M. Khaitov was one of the founders of the Institute of immunology – the leading scientific institution in Russia in this field. From 1988 to 2015 he was the director of the Institute, now he is its scientific advisor.

The works of R. M. Khaitov made a great contribution to the development of basic concepts of immune system, including the mechanisms of migration and regulation of differentiation of hematopoietic stem cells, described the mechanisms of regulation by the thymus and pituitary-adrenal system. R.M. Khaitov discovered peptide mediators of bone marrow, discovered and investigated previously unknown subpopulations of immunocytes. The immune response regulating part of the human genome has been studied at the proteomic and molecular genetic levels. The development of this problem is closely associated with prospects in gene diagnostics and personalized medicine, treatment of oncological, autoimmune, infectious and allergic diseases. The main areas of scientific interests of R.M. Khaitov include immunogenetics, immunoregulation, vaccinology, pathogenesis and immunotherapy of allergic diseases, cancer immunology and immunotherapy, molecular immunology.

R.M. Khaitov created new principles of design of vaccinating preparations with increased protective properties – vaccines of new generation. These vaccines are widely used in clinical practice in Russia and abroad (vaccines against influenza, typhoid, dysentery). Basically new vaccines for the treatment of allergies prepared for the production. A number of new effective drugs widely used in practical medicine have been developed by R. M. Khaitov and his colleagues for the treatment of immune disorders (polyoxidonium, tactivin, myelopid, immunomax, etc.). Innovative immunomodulatory drugs for cancer therapy have also been developed. R. M. Khaitov and his colleagues created a wide range of innovative systems for diagnostics of infections, allergies, immunopathologies, developed and innovative methods of gene typing of the immune response and evaluation of their functions. Currently, these reagents and devices are used in Russian Federation and abroad.

R.M. Khaitov has published more than 1000 scientific works, including 20 monographs and national guides, 10 textbooks on immunology, many of them have been translated into foreign languages. He is the author of 27 patents and copyright certificates, 3 international patents. R.M. Khaitov created a big scientific school. He was scientific advisor of 38 doctors and 69 candidates of sciences.

R.M. Khaitov is the President of the Russian Association of Allergology and Clinical Immunology (RAACI), represents Russia in the leading international scientific organizations – EAACI and WAO (R.M.Khaitov is a member of the Councils of National societies).

In 2004, with the direct participation of R.M. Khaitov was founded “Russian journal of allergy”, and until the present time he is the Chairman of the editorial council of the journal.

Biography:

Rudolf Valenta studied Medicine at the University of Vienna and obtained his MD degree in 1987 with distinction. He then started to work on the molecular characterization of allergens, became Associate Professor at the University of Vienna and founded his research group “Molecular Immunopathology” in 1993. He currently is full Professor for Allergology at the Medical University of Vienna and Foreign Adjunct Professor for Allergy at the Karolinska Institutet, Stockholm, Sweden. He co-ordinated two allergy research programs at the Medical University of Vienna, served as chairman of the standardization committee of the International Union of Immunological Societies (IUIS), as vice-president of the European Academy for Allergy and Clinical Immunology, as president of the Austrian Society for Allergology and Immunology and is member of the Austrian Academy of Sciences. He has been working in the field of allergy research for 31 years. Starting with the molecular characterization of allergens he systematically developed recombinant allergen-based diagnostic tests as well as therapeutic allergy vaccines based on recombinant allergens and genetically engineered hypoallergens and advanced them into clinical application. He has been awarded several prestigious national and international awards, among them the START Award of the Austrian Science Fund (FWF), the International Pharmacia Award and the Sarstedt Award which he received in 2000 for his work on the genetic analysis of allergy-eliciting substances and their recombinant production and a Megagrant of the Russian Federation. Rudolf Valentas work is highly cited (Total number of citations: 30693; h-index: 91 according to Scopus, September 2019). He has published more than 640 original scientific publications, reviews and book chapters, more than 200 patents/patent applications and gave more than 400 invited lectures. He is currently working on the development of molecular tests which allow predicting the development of allergy early in childhood and on prophylactic allergy vaccines for eradicating allergic diseases.

Personal Data            Rudolf VALENTA

                                        Date of Birth          February 25, 1963

                                          Place of Birth         Vienna

                                          Nationality              Austria

                                          Spoken Languages  German native speaker, English

                                          Acad. Degree          M.D.

                                          Current Position      Professor for Allergology, Medical University of Vienna

                                Work Address         Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology

                                         Division of Immunopathology

                                         Medical University of Vienna

                                         Vienna General Hospital

                                         Währinger Gürtel 18-20, 1090 Vienna, Austria

                                          T:         +43 (0) 1 40400-51080

                                          F:         +43 (0) 1 40400-51300

                                         M:        +43 699 12570519

                                         E-mail: rudolf.valenta@meduniwien.ac.at

        Web:                       www.allergy-research-program.at/

                                        www.phd-mcca.at/

                                        https://www.ncbi.nlm.nih.gov/pubmed/?term=valenta+r

Main areas of research: Molecular and cellular allergology

Scientific Education and Career History

1981 High school degree with distinction
1981-1987 Study of Medicine, parts I to III with distinction
1987 M.D. degree at the University of Vienna, Vienna, Austria
1988 Training in molecular biological techniques in Salzburg at the Institute of Molecular Biology of the Austrian Academy of Sciences (Dr. M. Susani) and at the Institute of Microbiology and Genetics (Prof. M. Breitenbach)
1988-1993 Postdoctoral fellow at the Institute of General and Experimental Pathology, Division of Immunopathology (Prof. D. Kraft), University of Vienna
1993 General and special training on care and handling of radioactive substances, Seibersdorf, Austria
1993 Habilitation in General and Experimental Pathology, University of Vienna Medical School, Associate Professor (a. o. Univ. Prof. 1996)
1993-now Head of the group “Molecular Immunopathology” in the Division of Immunopathology (Prof. D. Kraft), Dept. of General and Experimental Pathology, Vienna General Hospital, University of Vienna, now Center for Pathophysiology, Infectiology and Immunology, MedUniVienna, Austria
1994-1995 Training in hematology, internal medicine and design of clinical studies at the University clinics, Vienna, General Hospital (Dept. of Hematology, Dept. of Clinical Pharmacology), Austria
1996 Board certified specialist in Pathophysiology
1998 Board certified specialist in Immunology
1998 a.o.Prof. for Pathophysiology
2000-2015 Chairman of the standardization committee of the International Union of Immunological Societies IUIS, www.iuisonline.org/pages/standard.htm
2001-now Head of the Division of Immunpathology, Dept. of Pathophysiology, Vienna General Hospital, University of Vienna, Austria, now within the Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna
2002-2012 Speaker and co-ordinator of the FWF-funded special research program F18 “Molecular and immunological strategies for prevention, diagnosis and treatment of Type I allergies” at the Medical University of Vienna, Austria
2004 Professor for Allergology, Medical University of Vienna
2005-2007 Vice president of the European Academy of Allergology and Clinical Immunology
2006 Member of the Austrian Academy of Sciences
2006-2012 Head of the “Christian Doppler Laboratory for Allergy Research” at the Dept. of Pathophysiology, Medical University of Vienna
2006-2008 President elect of the Austrian Society for Allergology and Immunology
2008-2010 President of the Austrian Society for Allergology and Immunology

http://www.oegai.org/html/

2012-now Speaker and co-ordinator of the FWF-funded special research program F46 “Towards prevention and therapy of allergy” at the Medical University of Vienna, Austria. http://www.allergy-research-program.at/cms/
2013-now Deputy Speaker of the FWF-funded PhD program “Molecular, cellular and clinical allergology” at the Medical University of Vienna.  http://www.phd-mcca.at/

 

Major scientific contributions

  1. Elucidation of the primary structure of allergens through molecular cloning: (Valenta et al., Science 253: 557-560, 1991; Valenta et al., J. Exp. Med. 175: 377-385, 1992; Vrtala et al. J. Immunol. 151: 4773-4781, 1993; Seiberler et al., EMBO J. 13: 3481-3486, 1994)
  2. Profilin as actin-binding protein in plants: (Valenta et al., J. Biol. Chem. 268: 22777-22781, 1993; Staiger et al., Curr. Biol. 4: 215-219, 1994; Drobak et al., Plant J. 6: 389-400, 1994; Giehl et al., Eur. J. Biochem. 226: 681-689, 1994)
  3. Use of recombinant allergens for in vitro and in vivo allergy diagnosis: (Valenta et al., J. Allergy Clin. Immunol. 88: 889-894, 1991; Valenta et al., J. Allergy Clin. Immunol. 91: 88-97, 1993; Menz et al., Clin. Exp. Allergy 26: 50-60, 1996; Hiller et al., FASEB J. 16: 414-416, 2002; Hauswirth et al., J. Allergy Clin. Immunol. 110: 102-109, 2002)
  4. Discovery of IgE autoreactivity in allergy: (Valenta et al., Science 253: 557-560, 1991; Valenta et al., J. Invest. 107: 203-208, 1996; Natter et al., FASEB J. 12: 1559-1569, 1998; Bünder et al., J. Allergy Clin. Immunol. 114; 422-428, 2004)
  5. Animal models for allergy based on recombinant allergens: (Ferreira et al., J. Allergy Clin. 97: 95-103, 1996; Vrtala et al., J Allergy Clin Immunol 98: 913-921, 1996; Vrtala et al., J. Immunol. 160: 6137-6144, 1998)
  6. Molecular characterization of human allergen-specific IgE antibodies by combinatorial cloning and their interaction with the corresponding allergens and cellular receptors as well as therapeutic intervention strategies targeting the IgE-Fcepsilon RI interaction: (Steinberger et al., J. Biol. 271: 10967-10972, 1996; Vangelista et al., J. Clin. Invest. 103: 1571-1578, 1999; Flicker et al., J. Immunol. 165: 3849-3859, 2000; Laffer et al., J. Allergy Clin. Immunol. 108: 409-416, 2001; Lupinek et al., J. Immunol. 182: 4817-4829, 2009)
  7. Solution of the three-dimensional structures of allergens and the corresponding IgE antibodies: (Fedorov et al., Structure 5: 33-45, 1997; De Marino et al., Structure 7: 943-952, 1999; Verdino et al., EMBO J. 21: 5007-5016, 2002; Padavattan et al., J. Immunol. 182: 2141-2151, 2009)
  8. Development of allergen-specific antibodies for therapy of allergy: (Visco et al., J. Immunol. 157: 956-962, 1996; Denepoux et al., FEBS Lett. 465: 39-46, 2000; Flicker et al., Eur. J. Immunol. 32: 2156-2162, 2002)
  9. Engineering of recombinant hypoallergenic allergen derivatives for safe immunotherapy of allergy: (Ball et al., J. Biol. 269: 28323-28328, 1994; Vrtala et al., J. Clin. Invest. 99: 1673-1681: 1997; Vrtala et al., FASEB J. 15: 2042-2044, 2001; Focke et al., FASEB J. 15: 2042-2044, 2001).
  10. Recombinant hypoallergenic allergen derivatives for allergy treatment in man: (Niederberger et al., Proc. Natl. Acad. Sci. USA 101: 14677-14682, 2004; Reisinger et al., 116: 347-354, 2005; Pauli et al., J. Allergy Clin. 122: 951-960, 2008)
  11. Mechanisms of allergen-induced IgE-cross linking, basophil and mast cell activation and termination of the immediate reaction (Gieras et al., J. Allergy Clin. 119: 384-390, 2007; Rauter et al., FASEB J 20: 967-969, 2006; Rauter et al., J. Allergy Clin. Immunol. 121: 197-202, 2008; Gieras et al., J. Allergy Clin. Immunol. 137: 1557-1565, 2016)
  12. Non-IgE-mediated allergic inflammation induced by allergens (Campana et al., J. Allergy Clin. Immunol. 121: 528-530; 2008)
  13. Suppression of allergy through tolerization with allergen-expressing hematopoetic stem cells (Baranyi et al., J. Immunol. 180: 8168-8175; 2008)
  14. Molecular and immunological characterization of rhinovirus antigens, development of serological tests and vaccines for rhinovirus infections as asthma triggers (Edlmayr et a al., J. Immunol. 182: 6298-6306, 2009; Edlmayr et al., Eur. Resp. J. 37: 2140-2148; 2011; Niespodziana et al., FASEB J. 26: 1001-1008, 2012; Niespodziana et al., EBioMedicine 2: 64-70, 2014)
  15. Molecular and immunological characterization of celiac disease-specific wheat antigens (Srinivasan et al., J. Allergy Clin. Immunol. 2015 DOI: 10.1016/j.jaci.2015.04.040)
  16. Micro-arrayed HIV peptides and antigens for diagnosis of HIV infections (Gallerano et al., PLos One 10: 2015. e0117204; DOI: 10.1371/journal.pone.0117204; Gallerano et al., Lab Chip 15: 1574-1589, 2015
  17. Development of an IgE-adsorber registered in Europe for the therapeutic depletion of IgE antibodies from allergic patients (Lupinek et al., EBioMedicine. 2017 Mar;17:119-133. doi: 10.1016/j.ebiom.2017.02.007).
  18. Development and successful clinical evaluation of a new generation of recombinant B cell epitope-based vaccines for allergy treatment (Focke-Tejkl et al., J Allergy Clin Immunol. 2015 May; 135(5):1207-7.e1-11. doi: 10.1016/j.jaci.2014.09.012; Zieglmayer et al., EBioMedicine. 2016 Sep;11:43-57. doi: 10.1016/j.ebiom.2016.08.022; Niederberger  et al., J Allergy Clin Immunol. 2018 Jan 11. pii: S0091-6749(17)31884-5. doi: 10.1016/j.jaci.2017.09.052).

 

Current research activities

  1. Investigation of the evolution of allergen-specific immune responses in childhood
  2. Development and clinical evaluation of therapeutic allergy vaccines
  3. Development of allergen-specific strategies for preventive vaccination and tolerance induction for allergy
  4. Development of IgE-targeting strategies for allergy therapy
  5. Investigation of virus-induced exacerbations of asthma, COPD and ACOS
  6. Development of diagnostic tests and immunotherapy strategies for celiac disease
  7. Development of a rhinovirus vaccine for asthma prevention
  8. Development of a therapeutic HIV vaccine
  9. Development of preventive and therapeutic vaccines for hepatitis B infections

 

Professional Awards and Honours

1991 Clemens von Pirquet Preis of the Austrian Society for Allergology and Immunology
1992 Gold Medal of the Foundation of Allergy Research of Europe (F.A.R.E.)
1992 Karl Landsteiner Award of the Austrian Society for Allergology and Immunology
1992 Theodor Billroth Preis Vienna Medical Society
1993 Scientific Award of Niederösterreich
1994 Sandoz Award for Biology-Austria
1996 International Award of the Pharmacia Allergy Research Foundation
1998 START Award of the Austrian Science Fund (FWF)
2000

 

6th Sarstedt Award for the genetic analysis of allergy-eliciting substances and their recombinant production (after: J. Klose and P. H. O’Farrell 1986 Two-dimensional electrophoresis, H. Towbin, T. Staehelin and J. Gordon, Western blot 1988, M. Wilchek and E. A. Bayer Biotin-Avidin system 1990, F. S. Collins, J. R. Riordan, L.-C. Tsui Cystic fibrosis gene 1993, B. Vogelstein and D. Sidransky Molecular biology of malignant tumors 1997)
2001 Alois Sonnleitner Award for Immunology of the Austrian Academy of

Sciences

2006 Corresponding member of the Austrian Academy of Sciences
2006 President elect of the Austrian Society for Allergology and Immunology
2008 President of the Austrian Society for Allergology and Immunology
2009

 

Paul Ehrlich Award for Experimental Research of the European Academy of Allergy and Clinical Immunology (EAACI)
2011 Forschungspreis ”Atopische Dermatitis” der Stiftung Pro Derma, Hamburg
2012 “Inventor of the year 2012” of the Medical University of Vienna
2013 “Würdigungspreis Wissenschaft 2013 des Landes Niederösterreich“
2013 Shortlisted for Else Kröner Fresenius Award
2014 Selected among best five scientists of the Medical University of Vienna
2016 Foreign Adjunct Professor, Department of Medicine Solna, Karolinska   Institutet, Stockholm, Sweden
2016 International Distinguished Fellow (IDF) Award of the American College of Allergy, Asthma & Immunology (ACAAI)
2016 Medal ‘Labour Glory’ II for significant contribution to the development of Allergology & Immunology, Ukraine, International Academy of the rating technologies and sociology “Golden Fortune’
2017 Megagrant recipient of the Ministry of Education and Science of the Russian Federation
2018 Global Allergology and Immunology Award of the Center for Pathophysiology, Infectiology and Immunology of MedUni Vienna
2017 Director of the new WAO Center of Excellence at MedUni Vienna, which comprises the SFB F46 allergy research program, the international MCCA PhD program and coordinates the international post-graduate teaching network INUNIMAI
1991 – 2019 58 awards to group members (52 female/6 male)
until 2018 11 Associate Professors
since 1990 more than 40 Theses supervised

 

Patents

Author or co-author on more than 330 international patents/patent applications according to EPO (Espacenet): https://worldwide.espacenet.com/searchResults?submitted=true&locale=en_EP&DB=EPODOC&ST=advanced&TI=&AB=&PN=&AP=&PR=&PD=&PA=&IN=valenta+rudolf&CPC=&IC=&Submit=Search

 

Publications                total number of scientific publications: >650

total impact factor: 3791,8 (per 8.7.2019). (ISI web of knowledge, JCR Science Edition)

total number of citations: 30.693 (Scopus, 28/09/2019)                   

h-index: 91 (Scopus, 28/09/2019)

10 most important academic publications in the career to date

1.                  Lupinek, C., H. Hochwallner, C. Johansson, A. Mie, E. Rigler, A. Scheynius, J. Alm, and R. Valenta. 2019. Maternal allergen-specific IgG might protect the child against allergic sensitization. J Allergy Clin Immunol. Doi: 10.1016/j.jaci.2018.11.051. [Epub ahead of print]

2.                  Niespodziana, K., K. Stenberg-Hammar, S. Megremis, C.R. Cabauatan, K. Napora-Wijata, P.C. Vacal, D. Gallerano, C. Lupinek, D. Ebner, T. Schlederer, C. Harwanegg, C. Söderhäll, M. van Hage, G. Hedlin, N.G. Papadopoulos, and R. Valenta. 2018. PreDicta chip-based high resolution diagnosis of rhinovirus-induced wheeze. Nat Commun. 18: 2382. Doi: 10.1038/s41467-018-04591-0.

3.                  Wickman, M., C. Lupinek, N. Andersson, D. Belgrave, A. Asarnoj, M. Benet, M. Pinart, S. Wieser, J. Garcia-Aymerich, A. Baar, G. Pershagen, A. Simpson, I. Kull, A. Bergström, E. Melén, C. Hamsten, J.M. Antó, J. Bousquet, A. Custovic, R. Valenta R, and van Hage M. 2017. Detection of IgE reactivity to a handful of allergen molecules in early childhood predicts respiratory allergy in adolescence. EBioMedicine 26: 91. Doi: 10.1016/j.ebiom.2017.11.009.

4.                  Niederberger, V., A. Neubauer, P. Gevaert, M. Zidarn, M. Worm, W. Aberer, H.J. Malling, O. Pfaar, L. Klimek, W. Pfützner, J. Ring, U. Darsow, N. Novak, R. Gerth van Wijk, J. Eckl-Dorna, M. Focke-Tejkl, M. Weber, H.H. Müller, J. Klinger, F. Stolz, N. Breit, R. Henning, and R. Valenta. 2018. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. J Allergy Clin Immunol. 142: 497. Doi: 10.1016/j.jaci.2017.09.052.

5.                  Cornelius, C., K. Schöneweis, F. Georgi, M. Weber, V. Niederberger, P. Zieglmayer, K. Niespodziana, M. Trauner, H. Hofer, S. Urban, and R. Valenta. 2016. Immunotherapy with the PreS-based grass pollen allergy vaccine BM32 induces antibody responses protecting against Hepatitis B infection. EBioMedicine 11: 58, Doi: 10.1016/j.ebiom.2016.07.023.

6.                  Niederberger, V., F. Horak, S. Vrtala, S. Spitzauer, M.T. Krauth, P. Valent, J. Reisinger, M. Pelzmann, B. Hayek, M. Kronqvist, G. Gafvelin, H. Grönlund, A. Purohit, R. Suck, H. Fiebig, O. Cromwell, G. Pauli, M. van Hage-Hamsten, and R. Valenta. 2004. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A. 101 Suppl 2: 14677-82.

7.                  Hiller, R., S. Laffer, C. Harwanegg, M. Huber, W.M. Schmidt, A. Twardosz, B. Barletta, W.M. Becker, K. Blaser, H. Breiteneder, M. Chapman, R. Crameri, M. Duchêne, F. Ferreira, H. Fiebig, K. Hoffmann-Sommergruber, T.P. King, T. Kleber-Janke, V.P. Kurup, S. B. Lehrer, J. Lidholm, U. Müller, C. Pini, G. Reese, O. Scheiner, A. Scheynius, H.D. Shen, S. Spitzauer, R. Suck, I. Swoboda, W. Thomas, R. Tinghino, M. Van Hage-Hamsten, T. Virtanen, D. Kraft, M.W. Müller, and R. Valenta. 2002. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J. 16: 414.

8.                  Vangelista, L., S. Laffer, R. Turek, H. Grönlund, W. R. Sperr, P. Valent, A. Pastore, and R. Valenta. The immunoglobulin-like modules Cepsilon3 and alpha2 are the minimal units necessary for human IgE-FcepsilonRI interaction. 1999. J Clin Invest. 103: 1571-8.

9.                  Vrtala, S., K. Hirtenlehner, L. Vangelista, A. Pastore, H.G. Eichler, W.R. Sperr, P. Valent, C. Ebner, D. Kraft, and R. Valenta. 1997. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest. 99: 1673.

10.              Valenta, R., M. Duchêne, K. Pettenburger, C. Sillaber, P. Valent, P. Bettelheim, M. Breitenbach, H. Rumpold, D. Kraft, and O. Scheiner. 1991. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 253: 557-60.

 

10 most important scientific/scholarly research achievements

1.                  2017: Megagrant of the Government of the Russian Federation

2.                  2016: Foreign Adjunct Professor, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

3.                  2016: International Distinguished Fellow (IDF) Award of the American College of Allergy, Asthma & Immunology (ACAAI)

4.                  2013: Appreciation Award of Science of the Federal State Government Lower Austria

5.                  2009: Paul Ehrlich Award for Experimental Research of the European Academy for Allergy and Clinical Immunology (EAACI)

6.                  2006: Member of the Austrian Academy of Sciences

7.                  2001: Alois Sonnleitner Award for Immunology of the Austrian Academy of Sciences

8.                  2000: International Sarstedt Award

9.                  1998: START Award of the Austrian Science Fund (FWF)

10.              1996: International Award of the Pharmacia Allergy Research Foundation

ORCHID ID: 0000-0001-6837-0532

Scopus author ID: 56431270700

H-index 29

Dr Edwards is a molecular immunologist who received his PhD in 2001 from the University of New South Wales, Sydney, Australia regarding IgE antibody expression in allergic diseases and then joined Professor Sebastian Johnston’s group at the National Heart Lung Institute, Imperial College London as a postdoctoral Research Associate. In 2007, Dr Edwards obtained a Fellowship from Asthma UK, was promoted to Lecturer in Respiratory Medicine & Infections within the NHLI at Imperial and began his career as an independent researcher. His research interests focus on lung innate immunity and how innate immune processes can contribute to virus-induced asthma exacerbations. He has since been promoted to Senior Lecturer at Imperial and has published over 80 manuscripts in journals including Nature Medicine, Nature Microbiology Reviews, PLoS Pathogens, JBC, JI and JACI. He has attracted research funding from Asthma UK, British Lung Foundation, GlaxoSmithKline, Pfizer, Chiesi and the MRC. Currently he is an Associate Editor for the journals Pharmacology & Therapeutics and BMC Pulmonary Medicine.

 

Research: Publications-Original Research Articles

  1. Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A, Porter JD, Toussaint M, Walton RP, Finney LJ, Aniscenko J, Zhu J, Trujillo-Torralbo MB, Calderazzo MA, Grainge C, Loo SL, Veerati PC, Pathinayake PS, Nichol KS, Reid AT, James PL, Solari R, Wark PAB, Knight DA, Moffatt MF, Cookson WO, Edwards MR, Mallia P, Bartlett NW, Johnston SL. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018 Jun 8;9(1):2229.
  2. Zhu J, Message SD, Mallia P, Kebadze T, Contoli M, Ward CK, Barnathan ES, Mascelli MA, Kon OM, Papi A, Stanciu LA, Edwards MR, Jeffery PK, Johnston SL. Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations. J Allergy Clin Immunol. 2018 Apr 24.
  3. Custovic A, Belgrave D, Lin L, Bakhsoliani E, Telcian AG, Solari R, Murray CS, Walton RP, Curtin J, Edwards MR, Simpson A, Rattray M, Johnston SL. Cytokine Responses to Rhinovirus and Development of Asthma, Allergic Sensitization and Respiratory Infections during Childhood. Am J Respir Crit Care Med. 2018 Feb 21. doi: 10.1164/rccm.201708-1762OC. [Epub ahead of print].
  4. Moskwa S, Piotrowski W, Marczak J, Pawełczyk M, Lewandowska-Polak A, Jarzębska M, Brauncajs M, Głobińska A, Górski P, Papadopoulos NG, Edwards MR, Johnston SL, Kowalski ML. Innate Immune Response to Viral Infections in Primary Bronchial Epithelial Cells is Modified by the Atopic Status of Asthmatic Patients. Allergy Asthma Immunol Res. 2018 Mar;10(2):144-154.
  5. Ritchie AI, Singanayagam A, Wiater E, Edwards MR, Montminy M, Johnston SL. β2-Agonists Enhance Asthma-Relevant Inflammatory Mediators in Human Airway Epithelial Cells. Am J Respir Cell Mol Biol. 2018 Jan;58(1):128-132. doi: 10.1165/rcmb.2017-0315LE.
  6. Reuschl AK, Edwards MR, Parker R, Connell DW, Hoang L, Halliday A, Jarvis H, Siddiqui N, Wright C, Bremang S, Newton SM, Beverley P, Shattock RJ, Kon OM, Lalvani A. Innate activation of human primary epithelial cells broadens the host response to Mycobacterium tuberculosis in the airways. PLoS Pathog. 2017 Sep 1;13(9):e1006577. doi: 10.1371/journal.ppat.1006577. [Epub ahead of print].
  7. Upton N, Jackson DJ, Nikonova AA, Hingley-Wilson S, Khaitov M, Del Rosario A, Traub S, Trujillo-Torralbo MB, Habibi M, Elkin SL, Kon OM, Edwards MR, Mallia P,  Footitt J, Macintyre J, Stanciu LA, Johnston SL, Sykes A. Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma. PLoS One. 2017 Aug 31;12(8):e0183864.
  8. Mucosal Type 2 Innate Lymphoid Cells are a Key Component of the Allergic Response to Aeroallergen. Dhariwal J, Cameron A, Trujillo-Torralbo MB, Del Rosario A, Bakhsoliani E, Paulsen M, Jackson DJ, Edwards MR, Rana BM, Cousins DJ, Hansel TT, Johnston SL, Walton RP; MRC-GSK strategic alliance consortium. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1586-1596. doi: 10.1164/rccm.201609-1846OC.
  9. Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Telcian AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, Mallia P, Johnston SL, Stanciu LA. Antiviral Res. 2017 Jan;137:93-101. doi: 10.1016/j.antiviral.2016.11.004.
  10. Raised interferon-β, type 3 interferon and interferon-stimulated genes – evidence of innate immune activation in neutrophilic asthma. da Silva J, Hilzendeger C, Moermans C, Schleich F, Henket M, Kebadze T, Mallia P, Edwards MR, Johnston SL, Louis R. Clin Exp Allergy. 2016 Sep 13. doi: 10.1111/cea.12809. [Epub ahead of print].
  11. Toussaint M, Jackson DJ, Swieboda D, Guedán A, Tsourouktsoglou TD, Ching YM, Radermecker C, Makrinioti H, Aniscenko J, Edwards MR, Solari R, Farnir F, Papayannopoulos V, Bureau F, Marichal T, Johnston SL. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med. 2017 Jun;23(6):681-691.
  12. Petrova NV, Emelyanova AG, Gorbunov EA, Edwards MR, Walton RP, Bartlett NW, Aniscenko J, Gogsadze L, Bakhsoliani E, Khaitov MR, Johnston SL, Tarasov SA, Epstein OI. Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results. Antiviral Res. 2017 Jun;142:185-192.
  13. Hansel TT, Tunstall T, Trujillo-Torralbo MB, Shamji B, Del-Rosario A, Dhariwal J, Kirk PDW, Stumpf MPH, Koopmann J, Telcian A, Aniscenko J, Gogsadze L, Bakhsoliani E, Stanciu L, Bartlett N, Edwards M, Walton R, Mallia P, Hunt TM, Hunt TL, Hunt DG, Westwick J, Edwards M, Kon OM, Jackson DJ, Johnston SL. A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-γ and IFN-λ) and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine. 2017 May;19:128-138.
  14. McFarlane AJ, McSorley HJ, Davidson DJ, Fitch PM, Errington C, Mackenzie KJ, Gollwitzer ES, Johnston CJ, MacDonald AS, Edwards MR, Harris NL, Marsland BJ, Maizels RM, Schwarze J. Enteric helminth-induced type I interferon signalling protects against pulmonary virus infection through interaction with the microbiota. J Allergy Clin Immunol. 2017 Feb 11. pii: S0091-6749(17)30229-4.
  15. Porter JD, Watson J, Roberts LR, Gill SK, Groves H, Dhariwal J, Almond MH, Wong E, Walton RP, Jones LH, Tregoning J, Kilty I, Johnston SL, Edwards MR. Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium. J Antimicrob Chemother. 2016 Jul 25. pii: dkw222. [Epub ahead of print]
  16. Hilzendeger C, da Silva J, Henket M, Schleich F, Corhay JL, Kebadze T, Edwards MR, Mallia P, Johnston SL, Louis R. Reduced sputum expression of interferon-stimulated genes in severe COPD. Int J Chron Obstruct Pulmon Dis. 2016 Jun 30;11:1485-94. doi: 10.2147/COPD.S105948. eCollection 2016.
  17. Aab A, Wirz O, van de Veen W, Söllner S, Stanic B, Rückert B, Aniscenko J, Edwards MR, Johnston SL, Papadopoulos NG, Rebane A, Akdis CA, Akdis M. Human Rhinoviruses Enter and Induce Proliferation of B Lymphocytes. 2016 May 11. doi: 10.1111/all.12931. [Epub ahead of print]
  18. Edwards MR, Facchinetti F, Civelli M, Villetti G, Johnston SL. Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokines. Pharmacol Res Perspect. 2016 Jan 15;4(1):e00202. doi: 10.1002/prp2.202. eCollection 2016 Feb.
  19. Stokes CA, Kaur R, Edwards MR, Mondhe M, Robinson D, Prestwich EC, Hume RD, Marshall CA, Perrie Y, O’Donnell VB, Harwood JL, Sabroe I, Parker LC. Human rhinovirus-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes. Mucosal Immunol. 2016 Feb 24. doi: 10.1038/mi.2015.137. [Epub ahead of print]
  20. Schögler A, Stokes AB, Casaulta C, Regamey N, Edwards MR, Johnston SL, Jung A, Moeller A, Geiser T, Alves MP. Interferon response of the cystic fibrosis bronchial epithelium to major and minor group rhinovirus infection. J Cyst Fibros. 2015 Nov 21. pii: S1569-1993(15)00257-X. doi: 10.1016/j.jcf.2015.10.013.
  21. Contoli M, Ito K, Padovani A, Poletti D, Marku B, Edwards MR, Stanciu LA, Gnesini G, Pastore A, Spanevello A, Morelli P, Johnston SL, Caramori G, Papi A. Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy. 2015 Aug;70(8):910-20. doi: 10.1111/all.12627. Epub 2015 Apr 24.
  22. Jackson DJ, Trujillo-Torralbo MB, del-Rosario J, Bartlett NW, Edwards MR, Mallia P, Walton RP, Johnston SL. The influence of asthma control on the severity of virus-induced asthma exacerbations. J Allergy Clin Immunol. 2015 Aug;136(2):497-500.e3. doi: 10.1016/j.jaci.2015.01.028.
  23. Jackson DJ, Glanville N, Trujillo-Torralbo MB, Shamji BW, Del-Rosario J, Mallia P, Edwards MJ, Walton RP, Edwards MR, Johnston SL. Interleukin-18 is associated with protection against rhinovirus-induced colds and asthma exacerbations. Clin Infect Dis. 2015 May 15;60(10):1528-31. doi: 10.1093/cid/civ062. Epub 2015 Feb 2.
  24. Gielen V, Sykes A, Zhu J, Chan B, Macintyre J, Regamey N, Kieninger E, Gupta A, Shoemark A, Bossley C, Davies J, Saglani S, Walker P, Nicholson SE, Dalpke AH, Kon OM, Bush A, Johnston SL, Edwards MR. Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons. J Allergy Clin Immunol. 2015 Jul;136(1):177-188.e11. doi: 10.1016/j.jaci.2014.11.039. Epub 2015 Jan 25.
  25. Schögler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, Kieninger E, Jung A, Moeller A, Geiser T, Regamey N, Alves MP. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. 2015 Feb;45(2):428-39. doi: 10.1183/09031936.00102014. Epub 2014 Oct 30.
  26. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, Jerico Del-Rosario, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL. IL-33-dependent type  2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82.
  27. Beale J, Jayaraman A, Jackson DJ, Macintyre JD, Edwards MR, Walton RP, Zhu J, Ching YM, Shamji B, Edwards M, Westwick J, Cousins DJ, Hwang YY, McKenzie A, Johnston SL, Bartlett NW. Rhinovirus-induced IL-25 in asthma exacerbation drives  type 2 immunity and allergic pulmonary inflammation. Sci Transl Med. 2014 Oct 1;6(256):256ra134. doi: 10.1126/scitranslmed.3009124.
  28. Reed DM, Foldes G, Gatheral T, Paschalaki KE, Lendvai Z, Bagyura Z, Nemeth T, Skopal J, Merkely B, Telcian AG, Gogsadze L, Edwards MR, Gough PJ, Bertin J, Johnston SL, Harding SE, Mitchell JA. Pathogen sensing pathways in human embryonic stem cell derived-endothelial cells: role of NOD1 receptors. PLoS One. 2014 Apr 1;9(4).
  29. Rohde G, Message SD, Haas JJ, Kebadze T, Parker H, Laza-Stanca V, Khaitov MR, Kon OM, Stanciu LA, Mallia P, Edwards MR, Johnston SL. Cxc-Chemokines And Antimicrobial Peptides In Rhinovirus-Induced Experimental Asthma Exacerbations. Clin Exp Allergy. 2014 Mar 26.
  30. Sykes A, Macintyre J, Edwards MR, Del Rosario A, Haas J, Gielen V, Kon OM, McHale M, Johnston SL. Rhinovirus-induced interferon production is not deficient in well controlled asthma. 2014 Mar;69(3):240-6.
  31. Sykes A, Edwards MR, Macintyre J, Del Rosario A, Gielen V, Haas J, Kon OM, McHale M, Johnston SL. TLR3, TLR4 and TLRs7-9 Induced Interferons Are Not Impaired in Airway and Blood Cells in Well Controlled Asthma. PLoS One. 2013 Jun 18;8(6):e65921.
  32. Edwards, N. Regamey, E. Kieninger, M. Vareille A. Gupta, A. Shoemark A. Sykes J. MacIntyre C. Bossley, J. Davies, J. MacIntyre, A. Bush, SL. Johnston Impaired interferon expression in bronchial epithelial cells from severe asthmatic children. Muc Immunol 2013 Jul;6(4):797-806.
  33. Bartlett, L. Slater, N. Glanville, JJ. Haas, G. Caramori, P. Casolari, DL. Clarke, SD. Message, J. Anisenko, T. Kebadze, P. Mallia, Joseph P. Mizgerd, M. Belvisi, A. Papi, SV. Kotenko, SL. Johnston and MR. Edwards. Critical distinct roles for NF-kB p65 and Type I interferon signalling in the innate immune response to rhinovirus infection. EMBO Mol Med 2012 Dec;4(12):1244-60.
  34. George PM, Badiger R, Shao D, Edwards MR, Wort SJ, Paul-Clark MJ, Mitchell JA Viral Toll Like Receptor activation of pulmonary vascular smooth muscle cells results in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial hypertension. Biochem Biophys Res Commun. 2012 Oct 5;426(4):486-91.
  35. Sykes A, Edwards MR, Macintyre J, Del Rosario A, Bakhsoliani E, Trujillo-Torralbo MB, Kon OM, Mallia P, McHale M, Johnston SL. Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012 Jun;129(6):1506-1514.e6.
  36. Zdrenghea MT, Telcian AG, Laza-Stanca V, Bellettato CM, Edwards MR, Nikonova A, Khaitov MR, Azimi N, Groh V, Mallia P, Johnston SL, Stanciu LA. RSV infection modulates IL-15 production and MICA levels in respiratory epithelial cells. Eur Respir J. 2011 Aug 18. [Epub ahead of print]
  37. Kieninger E, Vareille M, Kopf BS, Blank F, Alves MP, Gisler FM, Latzin P, Casaulta C, Geiser T, Johnston SL, Edwards MR, Regamey N. Lack of an exaggerated inflammatory response upon virus infection in cystic fibrosis. Eur Respir J. 2011 Jun 30.
  38. Vareille, E. Kieninger, MP. Alves, BS. Kopf, A. Möller, T. Geiser, SL. Johnston, MR. Edwards and N. Regamey. Impaired type I and III interferon induction and rhinovirus control in human cystic fibrosis airway epithelial cells. Thorax 2012 Jun;67(6):517-25.
  39. Laza-Stanca V, Message SD, Edwards MR, Parker HL, Zdrenghea MT, et al. The Role of IL-15 Deficiency in the Pathogenesis of Virus-Induced Asthma Exacerbations. PLoS Pathog (2011) 7(7): e1002114. doi:10.1371/1002114.
  40. Ouda R, Onomoto K, Takahasi K, Edwards MR, Kato H, Yoneyama M, Fujita T. RIG-I-inducible miR-23b inhibits infections by minor group rhinoviruses through down-regulation of the receptor VLDLR. J Biol Chem. 2011 Jun 3. [Epub ahead of print].
  41. Stokes CA, Ismail S, Dick EP, Bennett JA, Johnston SL, Edwards MR, Sabroe I, Parker LC. J The role of IL-1 and MyD88-dependent signaling in rhinoviral infection. J Virol. 2011 May 18. [Epub ahead of print].
  42. Telcian AG, Stanca, VL Edwards MR, Harker, JA Wang H, Bartlett, NW, Mallia, P, Zdrenghea, MT, Kebadze, T, Coyle, AJ, Openshaw, PJM, Stanciu, LA,  Johnston, SL. RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell non-specific anti-viral activity. J Infect Dis. 2010 203(1):85-94.
  43. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, Papi A, Stanciu LA, Kon OM, Johnson M, Johnston SL. Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbation. Am J Respir Crit Care Med. 2011 Mar 15;183(6):734-42.
  44. Slater, L, Bartlett, NW,  Haas, JJ, Zhu, J Message, SD Walton, RP,  Sykes, A, Dahdaleh, S, Clarke,  DL, Belvisi, M, Kon, OM, Fujita, T,  Jeffery, PK, Johnston SL and Edwards, MR. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathogens 2010 4;6(11):e1001178.
  45. Hewson CA, Haas JJ, Bartlett NW, Message SD, Laza-Stanca V, Kebadze T, Caramori G, Zhu J, Edbrooke MR, Stanciu LA, Kon OM, Papi A, Jeffery PK, Edwards MR, Johnston SL. Rhinovirus induces MUC5AC in a human infection model, & in vitro via NF-{kappa}B & EGFR pathways. Eur Respir J. 2010 36(6):1425-35.
  46. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3): 646-654.
  1. Khaitov, MR., Laza-Stanca, V., Edwards, MR., Walton, RP., Rohde, G, Contoli, M, Papi, A, Stanciu, LA, Kotenko, SV., and Johnston, SL. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 2009; 64(3): 375-386.
  2. Papi A, Contoli M, Gasparini P, Bristot L, Edwards MR, Chicca M, Leis M, Ciaccia A, Caramori G, Johnston SL, Pinamonti S. Role of xanthine-oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells. J Biol Chem. 2008; 283(42):28595-606.
  3. NW. Bartlett, RP. Walton, MR. Edwards, J. Aniscenko, G. Caramori, J. Zhu, N. Glanville, KJ. Choy, P. Jourdan, J. Burnet, TJ. Tuthill, MS. Pedrick, MJ. Hurle, C. Plumpton, NA. Sharp, JN. Bussell, DM. Swallow, J. Schwarze, , B. Guy, JW. Almond, PK. Jeffery, CM. Lloyd A. Papi, RA. Killington,  DJ. Rowlands, ED. Blair, NJ. Clarke, and SL. Johnston. Mechanisms of rhinovirus-induced disease & exacerbation of allergic airway inflammation in novel mouse models of rhinovirus infection, Nat Med 2008; 14(2):199-204.
  1. Edwards MR Hewson CA Laza-Stanca V, Lau HH, Mukaida N,. Hershenson MB, and Johnston SL. Protein kinase R, IkB kinase-b and NF-kB are required for human rhinovirus induced pro-inflammatory cytokine production in bronchial epithelial cells. Mol Immunol. 2007; 44(7):1587-97.
  2. Edwards MR, Haas, J, Panettieri RA, Johnson M, Johnston SL. Corticosteroids and beta 2 agonists differentially regulate rhinovirus induced IL-6 via distinct cis-acting elements. J Biol Chem 2007:282(21) 15366-15375.
  1. Contoli, M, Message, SD, Laza-Stanca, V, Edwards, MR, Wark, PA, Bartlett, NW .Kebadze, T, Mallia, P, Stanciu, LA, Parker, HL, Slater, L, Lewis-Antes, A, Kon, OM, Holgate, ST, Davies, DE, .Kotenko, SV, Papi, A, Johnston, SL. Role of deficient type III interferon-l production in asthma exacerbations. Nat Med. 2006; 12 1023-26.
  2. Laza-Stanca V, Stanciu LA, Message SD, Edwards MR, Gern JE, Johnston SL. Rhinovirus replication in human macrophages induces NF-kappaB-dependent tumor necrosis factor alpha production. J Virol. 2006; 80(16):8248-58.
  1. Edwards MR, Johnson MW, and Johnston SL. Combination therapy: Synergistic suppression of virus induced chemokines. Am J Res Mol Cell Biol. 2006; 34(5):616-24.
  1. Hewson CA, Jardine A, Edwards MR, Laza-Stanca V, Johnston SL. Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. J Virol. 2005; 79(19):12273-9.
  1. Edwards MR, Mukaida N, Johnson MW, Johnston S.L. IL-1beta induces IL-8 in bronchial cells via NF-kappaB and NF-IL6 transcription factors and can be suppressed by glucocorticoids. Pulm Pharmacol Ther. 2005;18(5):337-45.
  1. Yip YL, Novotny J, Edwards M, Ward RL. Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling. Int J Cancer. 2003;104(3):303-9.
  1. Edwards MR, Brouwer W, Choi, CH, Ruhno J, Ward RL, Collins AM. Analysis of IgE antibodies from a patient with atopic dermatitis: biased V gene usage and evidence for polyreactive IgE heavy chain complementarity-determining region 3. J Immunol. 2002:168(12):6305-13.
  1. Philips JR, Brouwer W, Edwards M, Mahler S, Ruhno J, Collins AM. The effectiveness of different rat IgG subclasses as IgE-blocking antibodies in the rat basophil leukaemia cell model. Immunol Cell Biol. 1999; 77(2):121-6.

Research: Publications-Reviews & Editorials

  1. Edwards MR, Strong K, Cameron A, Walton RP, Jackson DJ, Johnston SL. Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. J Allergy Clin Immunol. 2017 Oct;140(4):909-920.
  2. Edwards MR, Saglani S, Schwarze J, Skevaki C, Smith JA, Ainsworth B, Almond M, Andreakos E, Belvisi MG, Chung KF, Cookson W, Cullinan P, Hawrylowicz C, Lommatzsch M, Jackson D, Lutter R, Marsland B, Moffatt M, Thomas M, Virchow JC, Xanthou G, Edwards J, Walker S, Johnston SL; members of the EARIP WP2 working group. Addressing unmet needs in understanding asthma mechanisms: From the European Asthma Research and Innovation Partnership (EARIP) Work Package (WP)2 collaborators. Eur Respir J. 2017 May 1;49(5).
  3. Edwards MR, Walton RP, Jackson DJ, Feleszko W, Skevaki C, Jartti T, Makrinoti H, Nikonova A, Shilovskiy IP, Schwarze J, Johnston SL, Khaitov MR; EAACI Anti-infectives in Asthma and Asthma Exacerbations Task Force. The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations. Allergy. 2017 Jul 19. doi: 10.1111/all.13257. [Epub ahead of print].
  4. Ritchie AI, Jackson DJ, Edwards MR, Johnston SL. Airway Epithelial Orchestration of Innate Immune Function in Response to Virus Infection. A Focus on Asthma. Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S55-63. doi: 10.1513/AnnalsATS.201507-421MG.
  5. Wong EHC, Porter JD, Edwards MR, Johnston SL. The role of macrolides in asthma: current evidence and future directions. Lancet Respiratory Medicine. 2014. Accepted for publication.
  6. Dhariwal J, Edwards MR, Johnston SL. Anti-viral agents: potential utility in exacerbations of asthma. Curr Opin Pharmacol. 2013 Jun;13(3):331-6. doi: 10.1016/j.coph.2013.04.010.
  7. Almond MH, Edwards MR, Barclay WS, Johnston SL. Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax. 2013 Jul;68(7):684-6. doi: 10.1136/thoraxjnl-2012-203009.
  8. Edwards, NW. Bartlett, T. Hussell, P. Openshaw and SL Johnston. The Microbiology of Asthma. Nat Reviews Microbiol 2012 10(7):459-71.
  9. Edwards MR, Johnston SL. Interferon-lambda as a new approach for treatment of allergic asthma? EMBO Mol Med. 2011 Jun;3(6):306-8.
  10. Varielle, M, Kieninger, E, Edwards MR and Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. Clin Micr Rev 2010 24(1):210-29.
  11. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, & Johnston SL. Targetting the NF-kB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther. 2009, 121:1-13.
  12. Johnston SL, Edwards MR. Mechanisms of adverse effects of b2-agonists in asthma. Editorial Thorax 2009: 739-41.
  13. Edwards MR & Johnston SL Deficient interferon in virus-induced asthma exacerbations. Editorial Clin Exp Allergy. 2008; 38(9):1416-8.
  14. Edwards MR, Slater L and Johnston SL. Signalling pathways mediating type I interferon gene expression Microbes Infect. 2007 9(11):1245-51.
  15. Edwards MR, Kebadze T, Johnson MW, Johnston S.L. New treatment regimes for virus-induced exacerbations of asthma. Pulm Pharmacol Ther. 2005; 19: 320-334.
  16. Collins AM, Sewell WA, Edwards MR. Immunoglobulin gene rearrangement, repertoire diversity, and the allergic response. Pharmacol Ther. 2003; 100(2):157-70.
  17. Edwards MR, Collins AM and Ward RL. The application of phage display in allergy research: characterization of IgE, identification of allergens and development of novel therapeutics. Curr Pharm Biotechnol. 2001; 2(3):225-40.
  18. Mitchell AJ, Edwards MR, Collins AM. Valency or wahlency: is the epitope diversity of the B-cell response regulated or chemically determined? Immunol Cell Biol. 2001; 79(5):507-11.

PERSONAL INFORMATION
Dr. Daniel Munblit
Sex Male | Date of birth 18/09/1980 | Nationalities Russia , Romania , Israel , United Kingdom
Tel. + 0 7898257151 | email daniel munblit08@imperi al.ac.uk

QUALIFICATIONS

06.2019                       European Diploma in Paediatric Allergy
European Academy of Allergy and Clinical Immunology (EAACI)
01.2016-05.2016        Specialist Certificate in Allergy and Immunology
I. M. Sechenov First Moscow State Medical University, Russia
12.2010-03.2016        Doctor of Philosophy PhD in Pa e diatrics                                       EQF level 8
Faculty of Medicine, Imperial College London, UK
10.2008-09.2010       Master of Science (MSc in Allergy (with merit),                            EQF level 7
Faculty of Medicine, Imperial College London, UK
09.1997-08.2003       Medical Doctor (MD) (UK MBBS equi v alent)
Faculty of Paediatrics, Russian State Medical University, Moscow, Russia

 

CURRENT APPOINTMENTS

10.2017-present       Associate Professor
Department of Paediatrics & Infectious Diseases , Faculty of Paediatrics , Sechenov University, Russia
▪ Teaching, marking, research and clinical activities
04.2018 present      Honorary Lecturer
Section of Paediatrics, Department of Medicine, Imperial College London, UK
▪ Teaching , marking and research

EXPERT GROUPS AND COMMITTEEMEMBERSHIPS

2019-present                EAACI P a ediatrics Section Board
2019-present                EAACI Education & Training Committee – Paediatric Allergy
2018-present                World Allergy Organization ( WAO Education & Training Committee
2018-present                ILSI Europe: Immune Competence Across Lifespan: Impact of Nutrition on Immune Competence and its Consequences Later in Life expert group member

ONGOING GRANT ACTIVITIES

2019-2023                   EU COST Action grant 2019-2023
Approx. 520.000 Euro ( 130.000 Euro per annum for 4 years)
“The Core Outcome M easures for Food Allergy (COMFA)”
2018-2019                  Sechenov University grant 2019
Approx. 50.000 US dollars
“Clinical importance of T and B lymphocyte detection in Primary immunodeficiency diagnosis”

 

EDITORIAL ROLES & PEER REVIEW

Frontiers in Immunology[I F 5.5]
Guest Edit or “Impact of Early Life Nutrition on Immune System Development and Related Health Outcomes in Later Life”
Nutrients [I F 4.19]
Guest Edit “Nutrition, Diet, and Allergic Diseases”
Peer review activities https://publons.com/author/1186713/daniel munblit#profile
Served as a reviewer for 12 international journals, including Clinical Experimental Allergy, Frontiers in Immunology, International Journal of Obesity and Nutrients.

RESEARCH FOCUS

Main research focus            Investigation of human breast milk immune modulatory factors in relation to maternal health, nutrition and genotype and subsequent infant outcomes in relation to susceptibility to allergy.
Other research interests     Systematic reviews and meta ana lysis Food p roteins in human milk in r elation to tolerance development. Bre ast feeding association with non communicable diseases development. Assessment of quality of life in p aediatric allergy E a r l y p redic t i o n o f asthma development.

PUBLICATIONS

Total number of publ ications        19 peer-review publications indexed at Pubmed (6 in journals with IF > 5.0)
Key recent publications                    1. A Boix-Amorós, MC Collado, B Van’t Land….D Munblit. Looking into breast milk composition and immunological outcomes: Reviewing the evidence. ((Nutrition Reviews. 2019 May 21. pii: nuz019. doi: 10.1093/nutrit/nuz019. [Epub ahead of print]) [IF: 5.79]
2. Khaleva E, Gridneva Z….Munblit D. Transforming growth factor beta in human milk and allergic outcomes in children: a systematic review. (Clinical Experimental Allergy. 2019 May 6. doi: 10.1111/cea.13409. [Epub ahead of print]) [IF: 5.16]
3. D Peshko, E Titova…..D Munblit. Health-Related Quality of Life in Children and Adults with Primary Immunodeficiencies: A Systematic Review and Meta-analysis (JACI: In Practice, 2019 Feb 20. pii: S2213-2198(19)30179-5.) [IF: 6.97]
4. S Colicino* and D Munblit*, et al. Validation of childhood asthma predictive tools: a systematic review. (Clin Exp Allergy. 2019 Jan 18. doi: 10.1111/cea.13336) [IF: 5.16]
5. Munblit, D., Peroni, D.G., Boix-Amorós, A., et al. Human Milk and Allergic Diseases: An Unsolved Puzzle. (Nutrients 2017, 9, 894.) [IF: 4.19]

ORGANISATIONAL ACTIVITIES & TEACHING

Organisational activities
– Co lead and coordi nator of COST Action (COMFA – The Core Outcome Measures for Food Allergy), approved by the EU c ommissioners in 2019
– Co-lead and c oordinated EU Ho rizon 2020 applic ation (BIRTH p r oject Human breast milk research: from knowledge towards health promotion and disease prevention ) – 2014
– Co-lead and coordinated COST Action applications (BreM iR project Breast milk research collaboration: towards o ptimizing the health promoting effects of human breast milk – 2013

Teaching activities Undergraduate medical education
– Supervis or for BSc project dissertations at Imperial College London since 2012 six students (all successfully completed a BSc Five with 1 st class honours and one with 2:1) One student won an abstract prize at a conference.
– Lecturer and marker at BSc in Reproductive & Developmental Sciences course since 2012.
– Supervis or for medical student research projects at Sechenov University – since 2016 (7 students were rewarded at National level)
– Lecturing at Pa ediatrics course for medical students at Sechenov Univers ity since 20 16

Postgraduate medical education
– Supervisor for two MSc pro ject dissertation at Imperial College London since 2014 (Dr Gaby Fe ke tea awarded M s Ellen Ni Cleirigh in preparation)
– Lecturing at MSc in Allergy sin ce 2010 and MSc in Paediatrics since 2015 , at Imperial College London
– Member of MSc in Allergy Course Committee and Examinati on Board , at Imperial College
– Lecturing at Paediatrics certificate training course in Paediarics at Sechenov University since 2016
– Supervisor for PhD project dissertation at Sechenov University (Dr Yulia Petrova).
“Development of a sthma predictive models in children” in preparation due for viva September 2020.

Member of the Editorial Board

Prosekova Elena Viktorovna, Doctor of Medical Sciences, Professor

http://orcid.org/0000-0001-6632-9800

Scopus author ID: 6507148681

ResearcherID: www.researcherid.com/rid/A-5843-2016

H-index 8

Prosekova Elena Viktorovna in 1983 graduated summa cum laude from the Vladivostok State Medical Institute with a degree in general medicine and started internship as a pediatrician with a subsequent primary specialization in clinical immunology and allergology.

In 1987–1990 completed postgraduate studies in the specialty 14.00.36 – Immunology-Allergology. In 1990 defended her thesis on “The immune status of children with bronchopulmonary allergoses in conditions of coastal monsoons”. In 2000 defended her doctoral dissertation on the topic “Immunotropic therapy of bronchial asthma in children and its pharmacoeconomic assessment”. In 2011 she received the title of professor of medicine.

In 2002 – 2008 was the head of the Far Eastern branch of the Research Institute of Clinical Immunology SB RAMS, and a leading researcher in the laboratory of hematopoiesis regulation in the Research Institute of CI SB RAMS.

Since 1999 has been the head of «Vladivostok Children’s Asthma-Center» and the chief freelance allergist and immunologist at the Department of Health of the Primorsky Territory.

Since 2009 has been the head of the Clinical Laboratory Diagnostics, General and Clinical Immunology Department at the Federal State Budgetary Educational Institution of Higher Education  «Pacific State Medical University» of the Russian Ministry of Health.

Prosekova E.V. has the certificate of Merit and the honorary title “Excellent Worker of Public Health” of the Russian Ministry of Health.

Prosekova E.V. is the author of more than 150 scientific papers, published in Russian periodicals and authoritative scientific journals such as Bratislava Medical Journal and teaching aids, including 4 monographs on various aspects of clinical immunology and allergology. She has 2 copyright certificates for the inventions (co-authored) of “A method of the treatment of patients with bronchopulmonary pathology”, “A method of the treatment of atopic dermatitis in children”. Research interests: genetic predictors, mechanisms of impaired immune homeostasis and therapy personification of allergic and immuno-mediated diseases (allergic rhinitis, bronchial asthma, angioedema and others).

Since 2011 Prosekova E.V. has been a Scientific Secretary of the Dissertation Board D.208.007.03 with the specialty of clinical pharmacology, pharmacology, and allergology. Since 2015 Prosekova E.V. has been a member of the Dissertation Board D. 999.195.03 with the specialty of clinical immunology. Prosekova E.V. is a member of Russian Association of Allergologists and Immunologists (RAACI) and European Academy Allergy and Clinical Immunology (EAACI) and regularly participates in the organization of congresses, scientific conferences, symposia on allergology and immunology both as a lecturer and an expert on the problem of allergic and immuno-mediated diseases in the Far East and Russia.

Under the leadership of Prosekova E.V. 5 PhD theses were defended in the 14.03.09 – clinical immunology, allergology specialty.

Since 2017 has been a member of the Editorial Board of the Russian Allergological Journal.

Editorial Board Member

Tatyana G. Fedoskova, MD, PhD

https://orcid.org/0000-0003-1456-3923

Reseacher ID WoS:  Р–1278-2015

Scopus author ID: 12765658700

Author ID RSI (Russian science index):   190990

H-index 10

Fedoskova T.G. is the graduate of the 2nd Moscow State Medical Institute named after N.I. Pirogov. She worked at the Scientific Advisory Department of the Institute of Immunology as a leading researcher between 1996 and 2016, and since 2016 leads the Laboratory of Molecular Allergy Mechanisms.

In 2008, Fedoskova T.G. successfully defended her PhD dissertation entitled “Allergy to “non-stinging” insects (prevalence, clinical characteristics, diagnosis and allergen-specific immunotherapy).”

Fedoskova T.G.  was awarded the badge of honor “Veteran of the nuclear industry” and the Certificate of Merit of Federal Biomedical Agency (FMBA). She is the author of more than 150 scientific papers, including 11 monographs and 6 manuals for clinicians (co-authored) on various aspects of clinical allergology and immunology published both in Russia and abroad.  Fedoskova T.G. has 3 copyright patents for inventions (co-authored) (“Allergoid from bee venom for allergen-specific immunotherapy of patients with allergic reactions to bee sting and a method for its production”, “Method for determination of specific IgE to staphylococcus in the blood serum of patients with allergic diseases, hypersensitive to staphylococcus allergens, using a test system for determination of specific IgE for staphylococcus and active allergenic substance isolated from staphylococcus”, “Method for the differential diagnosis of hypersensitivity to bee venom Apis mellifera») and 1 individual patent (“Mean and method of specific immunotherapy in patients with allergic diseases and sensitization to mosquito bites”). Fedoskova T.G.  successfully combines scientific, clinical and advisory work as well as teaching activities as a professor of the Department of Immunology of the Russian National Research Medical University named after N.I. Pirogov and the Department of Clinical Immunology and Allergology of the Federal State Educational Institution “Advanced Training Institute of FMBA of Russia”.

Her research interests include mechanisms of development, clinical features of the course and diagnosis of insect, bacterial and drug allergies, elaboration of new methods for treating insect allergy, immunotherapy, pharmacotherapy of immuno-mediated conditions, allergen-specific immunotherapy, the combined effect of climatic and production factors on human organism and others.

Fedoskova T.G. is a frequent lecturer on the problem of allergic diseases and other immuno-mediated conditions at scientific conferences, congresses, conventions on allergology and immunology both in Russia and abroad. She is a member of the Expert Council of the Russian Academy of Sciences, two dissertation councils and the Corresponding Member of the Russian Academy of Natural Sciences.

Fedoskova T.G.  is an Editorial Board member of the Russian Allergy Journal, where she acted as an Executive Secretary from its foundation until 2011.

Editorial Council

Sergey Tsarev, MD, PhD

https://orcid.org/0000-0003-2235-243X

Scopus Author ID: 42462654000

H-index 7

Sergey Tsarev graduated from the Moscow State University of Medicine and Dentistry in 1985, completed his clinical scientist fellowship training in allergology and immunology at the Main department of biomedical and extremal problems, in 1992. S. Tsarev completed his PhD study “The role of micromycetes in allergopathology. Modern areas of diagnosis and therapy” in 2010. S. Tsarev has worked at the Institute of immunology since 1992. Since 2010 up to now S. Tsarev is a leading researcher at the National Research Center “Institute of Immunology” Federal Medical Biological Agency in Moscow, Russia.

  1. Tsarev has a specific interest in allergic diseases, particularly in atopic dermatitis, urticaria, bronchial asthma, allergic rhinitis, mycoallergoses and fungal-associated immunopathology. He is an author over a hundred scientific studies in varied aspects of clinical allergology and immunology. In 2008 S. Tsarev obtained a patent for the invention of the “Rhinosinusitis polyposa treatment method”
  2. Tsarev regularly takes part as a lecturer and expert in scientific conferences on allergology and immunology.

Член редколлегии

Просекова Елена Викторовна, доктор медицинских наук, профессор

http://orcid.org/0000-0001-6632-9800

Scopus author ID: 6507148681

ResearcherID: www.researcherid.com/rid/A-5843-2016

Индекс Хирша 8

Просекова Елена Викторовна в 1983 году с отличием окончила Владивостокский государственный медицинский институт по специальности лечебное дело и поступила в интернатуру по специальности педиатрия с последующей первичной специализацией по клинической иммунологии и аллергологии. В 1987–1990г.г. прошла обучение в аспирантуре по специальности 14.00.36- иммунология-аллергология и в 1990 году защитила кандидатскую диссертацию на тему «Иммунный статус детей с бронхолегочными аллергозами в условиях береговых муссонов». В 2000 году защитила докторскую диссертацию на тему «Иммунотропная терапия бронхиальной астмы у детей и ее фармакоэкономическая оценка», в 2011 году получила звание профессора. В 2002 – 2008 годах являлась руководителем Дальневосточного филиала ГУ НИИ клинической иммунологии СО РАМН, ведущим научным сотрудником лаборатории регуляции гемопоэза ГУ НИИ КИ СО РАМН. С 1999 года является руководителем ООО «Владивостокский детский Астма – центр» и главным внештатным аллергологом иммунологом Департамента здравоохранения Приморского края. С 2009 года по настоящее время заведующая кафедрой КЛД, общей и клинической иммунологии в ФГБОУ ВО «Тихоокеанский государственный медицинский университет» Министерства Здравоохранения Российской Федерации. Имеет почетную грамоту и почетное звание «Отличник здравоохранения» Министерства Здравоохранения Российской Федерации. Является автором более 150 научных трудов и учебных пособий, по различным аспектам клинической иммунологии и аллергологии, опубликованных в России и за рубежом, в том числе 4 монографии, имеет 2 авторских свидетельства на изобретения (в соавторстве) «Способ лечения больных бронхолегочной патологией», «Способ лечения атопического дерматита у детей».

Область научных интересов: генетические предикторы, механизмы нарушения иммунного гомеостаза и персонификация терапии при аллергических и иммуноопосредованных заболеваниях (аллергический ринит, бронхиальная астма, ангионевротический отек и другие).

Просекова Е.В. с 2011 года ученый секретарь диссертационного совета Д.208.007.03 по специальности  клинической фармакологии, фармакологии и с 2015г. член диссертационного совета Д. 999.195.03 по специальности клиническая иммунология, аллергология.

Просекова Е.В. член РААКИ и EAACI, регулярно принимает участие в организации конгрессов, научных конференций, симпозиумов по аллергологии и иммунологии и как лектор и эксперт по проблеме аллергических и иммуноопосредованных заболеваний в Дальневосточном регионе и России. Под руководством Просековой Е.В. защищено 5 кандидатских диссертаций по специальности 14.03.09 клиническая иммунология, аллергология.

С 2017 года является членом Редколегии Российского аллергологического журнала.

Член редколлегии

Гущин Игорь Сергеевич,

Член-корреспондент РАН, доктор медицинских наук, профессор

https://orcid.org/0000-0002-4465-6509

Scopus author ID: 7005173833

Индекс Хирша 19

Гущин Игорь Сергеевич, окончил  2-й Московский медицинский институт им. Н.И.Пирогова в 1961г. C 1961 по 1979г. работал в Научно-исследовательской аллергологической лаборатории АМН СССР. В 1963г. защитил кандидатскую диссертацию на тему «К участию центральной нервной системы в развитии анафилактоидного шока у белых крыс», а в 1970г. – докторскую диссертацию на тему «Экспериментальный анализ механизма анафилаксии гладкой и сердечной мускулатуры». В 1974г. работал на кафедре фармакологии Каролинского медицинского института (Стокгольм, Швеция), где выполнил две оригинальные экспериментальные работы, по материалам которых были опубликованы статьи в центральных зарубежных научных журналах. В 1979г. организовал и возглавил лабораторию клинической иммунологии 4-го Главного управления при Минздраве СССР, а в 1980 г. получил приглашение в Институт иммунологии (ФГБУ «ГНЦ Институт иммунологии» ФМБА России), где и работает по настоящее время заведующим отделом аллергологии и клинической иммунологии.

И.С.Гущин – автор 460 печатных научных работ, опубликованных в отечественной и зарубежной научной печати, в том числе шести  монографий, посвященных актуальным проблемам аллергологии, разделов в различных руководствах и учебниках, методических рекомендаций и пособий для врачей, имеет 14 патентов и авторских свидетельств на изобретения. Он является вице-президентом Российской ассоциации аллергологов и клинических иммунологов, членом Европейской академии аллергологии и клинической иммунологии, Европейского общества по исследованию гистамина, членом диссертационного совета, экспертом научно-технической сферы ФГБНУ НИИ РИНКЦЭ, заместителем главного редактора журнала «Патологическая физиология и экспериментальная терапия», членом редколлегий журналов «Иммунология»,  «Пульмонология», «Russian Journal of Immunology», «Химико-фармацевтический журнал» и др. С момента основания Российского аллергологического журнала является членом его редколлегии и научным редактором.

И.С.Гущин читал курсы лекций по аллергологии и общей патологии для студентов, врачей, аспирантов и ординаторов. В качестве члена оргкомитетов и докладчика принимал участие в работе научных конференций, конгрессов, съездов по аллергологии и иммунологии, как в России, так и за рубежом. Под руководством И.С.Гущина подготовлено и защищено 28 кандидатских и 4 докторских диссертаций.

И.С.Гущин награжден медалью «Ветеран труда», медалью «В память 850-летия Москвы», золотой медалью имени А.Д.Сперанского «За выдающийся вклад в общую патологию, патофизиологию и клиническую аллергологию», знаком отличия в труде «Ветеран атомной энергетики и промышленности», нагрудным знаком «А.И.Бурназян», памятной медалью «110 лет со дня рождения А.И.Бурназяна», серебряной медалью Российской Академии Естественных Наук «За развитие медицины и здравоохранения», памятной серебряной медалью Университета Палермо.

 

Member of Editorial board

Gushchin Igor S., MD, PhD, professor, corresponding  member of the RAS

 

https://orcid.org/0000-0002-4465-6509

Scopus author ID: 7005173833

H-index 19

Gushchin Igor Sergeevich, graduated from the 2nd Moscow Medical Institute named after N.I.Pirogov in 1961. From1961 to 1979 worked in the Allergological Research Laboratory of the Academy of Medical Sciences of the USSR. He completed his PhD study “Experimental analysis of the mechanism of smooth and cardiac muscle anaphylaxis” in 1970 and in 1982 has become professor of medicine. In 1998 he was elected Corresponding Member of the Russian Academy of Medical Sciences, since 2012 – Corresponding Member of the Russian Academy of Sciences.

From 1980 to the present, I.S.Gushchin works at the National Research Center “Institute of Immunology” Federal Medical Biological Agency in Moscow, Russia. He is the Head of the Department of Allergology and Clinical Immunology at the Center. Professor I.Gushchin has special interests in fundamental allergology, including immunology, pathophysiology, pharmacology of the allergic process and their clinical applications.  Igor Gushchin  was a guest keynote speaker at various Russian and international scientific conferences, symposia, congresses.

He is the author of  more than 240 scientific articles published in Russian and international journals, six monographs on current problems of allergology, sections in various manuals and textbooks, guidelines and manuals for doctors, has 14 patents and copyright certificates for inventions.

He is a vice-editor-in chief of the journal “Pathological Physiology and Experimental Therapy” (Russia); Member of editorial boards of the journals “Immunology” (Russia), “Pulmonology” (in Russia), “Russian Journal of Immunology”, “Pharmaceutical Chemistry Journal” (Russia).

Since 2004, he is a member of the editorial board and scientific editor of the Russian Journal of Allergy.

Астафьева Наталья Григорьевна,

доктор медицинских наук, профессор

https://orcid.org/0000-0002-7691-4584    

Scopus author ID:  6506637441

Индекс Хирша 16

Астафьева Наталья Григорьевна  после окончания  с золотой медалью школы в 1960 году поступила в Саратовский медицинский институт , закончив его с отличием в 1966г, поступила в  аспирантуру при кафедре патологической физиологии Саратовского медицинского института, в 1970 г.  защитила диссертацию на соискание ученой степени кандидата медицинских наук на тему « Роль гипоталамо-гипофизарно-надпочечниковой системы в развитии демиелинизирующих заболеваний  нервной системы (на модели экспериментального аллергического энцефаломиелита и постдифтерийного полиневрита),  в 1989 г.  диссертацию на соискание ученой степени доктора медицинских наук на тему «Роль тромбоцитов в развитии аллергических заболеваний». С 1991 г. имеет ученое звание профессора. С 1969 года руководитель аллергологического центра, и одновременно с 1972 года Н.Г.Астафьева главный внештатный специалист  аллерголог- иммунолог  Министерства здравоохранения Саратовской области. С  2004 года по настоящее время заведует кафедрой клинической иммунологии и аллергологии Саратовского государственного медицинского университета им. В.И.Разумовского.

Автор более 470 научных работ, опубликованных в Росси и за рубежом; имеются 3 авторских свидетельства на  изобретения (в соавторстве – № 967970 и 1070854 –  на  технологию  изготовления многоканальных медицинских капилляров, которые широко используются   в иммунологических тестах  торможения миграции лейкоцитов и № 1527588 –  оригинальный метод определения аллергических реакций на лекарственные препараты из группы нестероидных противовоспалительных средств  );  14  монографий из них «Растения и аллергия» получила серебряную медаль ВДНХ. Монография  «Современные тенденции в фармакотерапии атопической астмы» получила  диплом 27 Международной Московской книжной выставки – ярмарки  и золотую медаль Парижского книжного салона – награду Европейского научного и промышленного консорциума, Книга «Гетерогенная бронхиальная астма: как лечить, чему учить» (написанная Астафьевой  Н.Г. с сотрудниками кафедры ) была  представлена на выставке в Москве, Франкфурте на Майне и вошла в каталоги  Франкфуртской книжной выставки (19-23 октября 2016, Франкфурт–на-Майне) и книжной выставки-ярмарки в Лондоне. При участии Н.Г.Астафьевой подготовлено  около 20  учебных пособий, руководств, одобренных российскими    научными    обществами, (например, «Основы общей иммунологии»- М.:ПедиатрЪ,2014.-124 с., «Аллерген-специфическая  иммунотерапия» Союз педиатров России. РААКИ.- М.2014.-22с. и др. ) а также клинических национальный рекомендаций и программ : «Бронхиальная астма у детей. Стратегия лечения и профилактика»(2016) ; Федеральные клинические рекомендации «Аллергология» (2013); «РАДАР»(аллергический ринит)(2015); программа «ПРИМА» по иммуномодулирующей терапии (2016); Национальных согласительных документов по крапивнице (2008) и др.

Под руководством Н. Г. Астафьевой выполнено и защищено 28 диссертаций, в том числе 2 докторских.

Награды и почетные звания : «Отличнику здравоохранения», «Заслуженный врач Российской Федерации»(2003); Медаль ордена «За заслуги перед Отечеством» II степени (2010); Медаль им.В.И.Разумовского СГМУ (2013); Лауреат профессионального конкурса для преподавателей, доцентов, профессоров вузов «Высота»  (2017); Почетная грамота Президента России (2018); Почетный профессор Саратовского государственного медицинского университета (2019).

Astafieva Natalia ,

MD, PhD, professor

https://orcid.org/0000-0002-7691-4584    

Scopus author ID:  6506637441

H-index 16

Natalia Astafieva graduated with distinction from Saratov Medical University in 1966 and completed her PhD programme in 1970; she also completed a higher level Doctor of Medical Sciences research “The role of platelets in the development of allergic diseases” in 1989 and became Professor of Medicine in 1991. She was the Head of Saratov Allergology Centre since 1969 and became the Leading Specialist in allergology and immunology at Saratov Region Department of Health in 1972. Since 2004 till present time Professor Astafieva is the Chair of Clinical Immunology and Allergology Department at Saratov State Medical University.

Professor Astafieva is the author of more than 470 publications, published internationally and in Russia, 3 patents and 14 books. Many of them received prestigious awards, like “Allergy and Plants” – Silver Medal of The Exhibition of Achievements of National Economy, “Modern Trends in the Pharmacotherapy of Atopic Asthma” – an Award of International Book Fair (Moscow, 2014) and Golden Medal of 35th International Paris Book Fair (Salon Du Livre) / ESIC, European Scientific and Industrial Consortium (Paris, 2015), etc.

Professor Astafieva was leading the development of more than 20 methodology and clinical recommendations, endorsed by professional associations and government bodies, and supervised 28 PhD and 2 Doctor of Medical Science research programmes to successful completions.

She  has been invited to speak at plenary, keynote, symposia and expert discussion sessions, workshops and industry sponsored meetings at the Russian Association of Allergologists and Immunologists (RAACI),  thematic sessions European Academy Allergy and Clinical Immunology ( EAACI) , European Respiratory Society (ERS) .

Major Honours & Awards: “Excellence in Health Care”, “Honoured Doctor of Russian Federation” (2003); Medal of the Order “For the Merit to the Fatherland” (2010); Medal of V.I.Rasumovsky (2013) , The Laureate of the Professional Completion for Lecturers, Readers and Professors (2017), The Certificate of Honour of the President of Russia (2018)

Curriculum Vitae: Michael Robert Edwards

 

Date of birth                                    28th November, 1972

Current Address                            Department of Respiratory Medicine

National Heart & Lung Institute and

Wright Fleming Institute of Infection & Immunity

Imperial College London

Norfolk Place, London W2 1PG

Tel +44 020 7594 3775

Fax +44 020 7262 8913

Email                                                             michael.edwards@imperial.ac.uk

Nationality                                       Dual Australian & British

Professional Qualifications

  • 1996-2001: PhD University of New South Wales (UNSW) Sydney, NSW Australia
  • 1992-1996 Bachelor of Science Degree (BSc) with Honours (first class) UNSW

Current Post

  • Non-Clinical Senior Lecturer in Respiratory Medicine & Infections (2012-present), Airway Disease Infection Section, National Heart Lung Institute & Wright Fleming Institute of Infection Diseases, St Mary’s Campus, Imperial College London.
  • Chief Scientific Director & Founder Member, Therapeutic Frontiers a Respiratory CRO (2014-present) http://therapeuticfrontiers.com/

 

Previous Posts

  • Non-Clinical Lecturer in Respiratory Medicine & Infections (2007-2012)
  • Postdoctoral Research Associate (2001-2007). National Heart Lung Institute & Wright Fleming Institute of Infection Diseases, St Mary’s Campus, Imperial College London.

 

Research Interests & Goals

  • To understand the molecular and cellular basis of virus-induced asthma exacerbations, with a particular focus on the innate host response involved in inflammation and host defence to respiratory viral infections. To use this knowledge in the identification of improved therapeutic targets for virus-induced asthma exacerbations.

 

Academic Affiliations

  • MRC & Asthma UK Centre in Allergic Mechanisms of Asthma
  • European Academy of Allergy & Clinical Immunology (EAACI) Allergy & Infection Interest Group member (2012-present)
  • National Medical Research Council (NMRC-Singapore) International Expert Panel Member (2014-present)
  • European Respiratory Society (ERS) Advanced Fellowship Panel Member (2014-present)

 

Collaborations with Industry

  • Research collaborations with and funding and/or consultancy from GlaxoSmithKline (2001-2010, 2012-2017), Pfizer (2010-2014), Merck (2012-2015), Chiesi (2012-2016), Materia Medica Holdings (MMH, Russia) 2015-2016.

Scientific Director Experience

 

  • As Chief Scientific Director of Therapeutic Frontiers, I have been involved with establishing a laboratory at White City Campus, Imperial College London and have managed Phase II Clinical Trials and Clinical Studies with Industry. Duties include patient recruitment, Clinical Protocol & Laboratory Manual writing, study design, writing statement of work(s), contracts, clinical and non-clinical staff supervision & management, study budget management; report writing, data analysis, liaisons with NHS administration, medical monitors and clients (pharmaceutical companies and small biotechs).

Research: Awarded Funding

  • Awarded a British Research Council Confidence in Concepts grant for 1 year October 2013-2014 to the value of £63,000 titled Uncoupling harmful pro-inflammatory cytokine responses from beneficial anti-viral immunity in virus induced exacerbations of asthma and COPD Dr Michael R Edwards Principle Investigator.

 

  • Awarded a MRC Project Grant for 3 years October 2014-2017 titled Phenotyping immune responses in asthma and respiratory infections – A systems approach to understanding changes from childhood to adulthood (MR/L012693/1) to the value of £2,000,000 Dr Michael R Edwards Co-Investigator.

 

  • Awarded a Industry Grant for Merck Sharp & Dome titled Mechanisms of House Dust Mite Sublingual Immunotherapy (SLIT): Studied through a Nasal Allergen Challenge (NAC) and Network Biology Approach to the value of  £900,000  Dr Michael R Edwards Co-Investigator.

 

  • Awarded an Asthma UK Fellowship (RF07_04), start date October 2007-October 2010, to the value of £180,000, titled Molecular regulation of deficient rhinovirus induced interferon-l in asthmatic bronchial epithelial cells.

 

  • Awarded MRC G110023 MRC-GSK Alliance: Mechanisms of interplay between allergy and viruses in asthma October, 2011-2015 £3,960,000 Dr Michael R Edwards Co-Investigator.

 

  • Awarded BBSRC CASE PhD Studentship Anti-viral properties of novel macrolide antibiotics. October 2010-2014 £80,000 Dr Michael R Edwards Principle Investigator.

  • Awarded a British Lung Foundation (BLF) Project Grant to the sum of £119,979 over three years February 2007-February 2010 (BLF Grant P06/3 Dr Michael R. Edwards Principle Investigator). Regulation of rhinovirus induced interferon-b and pro-inflammatory cytokine production in bronchial epithelial cells from asthmatic and normal individuals.

  • Awarded a NHLI PhD studentship to the value £42,000 over three years (2007-2010) titled Novel Anti-viral activities of macrolide antibiotics.

 

  • Co-Investigator with Prof S.L. Johnston on MRC Project Grant (MRC G0601236) to the value of £1,219,733 for three years (2007-2010), titled Mechanisms of deficient innate immune response in asthma.

 

  • Awarded a BBSRC CASE PhD Studentship (2010-2013) to the value of approx £80,000 over 4 years titled Anti-viral properties of novel macrolide antibiotics.

 

  • With Prof. S.L. Johnston as co-investigator, awarded funds to the sum of £388,575 (2005-2011) renewed yearly from GlaxoSmithKline for research projects focusing on affects of new glucocorticoids and b2 agonists in the control of virus and bacterial induced inflammatory mediators and interferons.

Research: Publications-Original Research Articles

  1. Custovic A, Belgrave D, Lin L, Bakhsoliani E, Telcian AG, Solari R, Murray CS, Walton RP, Curtin J, Edwards MR, Simpson A, Rattray M, Johnston SL. Cytokine Responses to Rhinovirus and Development of Asthma, Allergic Sensitization and Respiratory Infections during Childhood. Am J Respir Crit Care Med. 2018 Feb 21. doi: 10.1164/rccm.201708-1762OC. [Epub ahead of print].
  2. Moskwa S, Piotrowski W, Marczak J, Pawełczyk M, Lewandowska-Polak A, Jarzębska M, Brauncajs M, Głobińska A, Górski P, Papadopoulos NG, Edwards MR, Johnston SL, Kowalski ML. Innate Immune Response to Viral Infections in Primary Bronchial Epithelial Cells is Modified by the Atopic Status of Asthmatic Patients. Allergy Asthma Immunol Res. 2018 Mar;10(2):144-154. doi: 10.4168/aair.2018.10.2.144.
  3. Ritchie AI, Singanayagam A, Wiater E, Edwards MR, Montminy M, Johnston SL. β2-Agonists Enhance Asthma-Relevant Inflammatory Mediators in Human Airway Epithelial Cells. Am J Respir Cell Mol Biol. 2018 Jan;58(1):128-132. doi: 10.1165/rcmb.2017-0315LE.
  4. Reuschl AK, Edwards MR, Parker R, Connell DW, Hoang L, Halliday A, Jarvis H, Siddiqui N, Wright C, Bremang S, Newton SM, Beverley P, Shattock RJ, Kon OM, Lalvani A. Innate activation of human primary epithelial cells broadens the host response to Mycobacterium tuberculosis in the airways. PLoS Pathog. 2017 Sep 1;13(9):e1006577. doi: 10.1371/journal.ppat.1006577. [Epub ahead of print].
  5. Upton N, Jackson DJ, Nikonova AA, Hingley-Wilson S, Khaitov M, Del Rosario A, Traub S, Trujillo-Torralbo MB, Habibi M, Elkin SL, Kon OM, Edwards MR, Mallia P,  Footitt J, Macintyre J, Stanciu LA, Johnston SL, Sykes A. Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma. PLoS One. 2017 Aug 31;12(8):e0183864.
  6. Mucosal Type 2 Innate Lymphoid Cells are a Key Component of the Allergic Response to Aeroallergen. Dhariwal J, Cameron A, Trujillo-Torralbo MB, Del Rosario A, Bakhsoliani E, Paulsen M, Jackson DJ, Edwards MR, Rana BM, Cousins DJ, Hansel TT, Johnston SL, Walton RP; MRC-GSK strategic alliance consortium. Am J Respir Crit Care Med. 2017 Jun 15;195(12):1586-1596. doi: 10.1164/rccm.201609-1846OC.
  7. Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro. Telcian AG, Zdrenghea MT, Edwards MR, Laza-Stanca V, Mallia P, Johnston SL, Stanciu LA. Antiviral Res. 2017 Jan;137:93-101. doi: 10.1016/j.antiviral.2016.11.004.
  8. Raised interferon-β, type 3 interferon and interferon-stimulated genes – evidence of innate immune activation in neutrophilic asthma. da Silva J, Hilzendeger C, Moermans C, Schleich F, Henket M, Kebadze T, Mallia P, Edwards MR, Johnston SL, Louis R. Clin Exp Allergy. 2016 Sep 13. doi: 10.1111/cea.12809. [Epub ahead of print].
  9. Toussaint M, Jackson DJ, Swieboda D, Guedán A, Tsourouktsoglou TD, Ching YM, Radermecker C, Makrinioti H, Aniscenko J, Edwards MR, Solari R, Farnir F, Papayannopoulos V, Bureau F, Marichal T, Johnston SL. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med. 2017 Jun;23(6):681-691.
  10. Petrova NV, Emelyanova AG, Gorbunov EA, Edwards MR, Walton RP, Bartlett NW, Aniscenko J, Gogsadze L, Bakhsoliani E, Khaitov MR, Johnston SL, Tarasov SA, Epstein OI. Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results. Antiviral Res. 2017 Jun;142:185-192.
  11. Hansel TT, Tunstall T, Trujillo-Torralbo MB, Shamji B, Del-Rosario A, Dhariwal J, Kirk PDW, Stumpf MPH, Koopmann J, Telcian A, Aniscenko J, Gogsadze L, Bakhsoliani E, Stanciu L, Bartlett N, Edwards M, Walton R, Mallia P, Hunt TM, Hunt TL, Hunt DG, Westwick J, Edwards M, Kon OM, Jackson DJ, Johnston SL. A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-γ and IFN-λ) and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine. 2017 May;19:128-138.
  12. McFarlane AJ, McSorley HJ, Davidson DJ, Fitch PM, Errington C, Mackenzie KJ, Gollwitzer ES, Johnston CJ, MacDonald AS, Edwards MR, Harris NL, Marsland BJ, Maizels RM, Schwarze J. Enteric helminth-induced type I interferon signalling protects against pulmonary virus infection through interaction with the microbiota. J Allergy Clin Immunol. 2017 Feb 11. pii: S0091-6749(17)30229-4.
  13. Porter JD, Watson J, Roberts LR, Gill SK, Groves H, Dhariwal J, Almond MH, Wong E, Walton RP, Jones LH, Tregoning J, Kilty I, Johnston SL, Edwards MR. Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN-augmenting activity in airway epithelium. J Antimicrob Chemother. 2016 Jul 25. pii: dkw222. [Epub ahead of print]
  14. Hilzendeger C, da Silva J, Henket M, Schleich F, Corhay JL, Kebadze T, Edwards MR, Mallia P, Johnston SL, Louis R. Reduced sputum expression of interferon-stimulated genes in severe COPD. Int J Chron Obstruct Pulmon Dis. 2016 Jun 30;11:1485-94. doi: 10.2147/COPD.S105948. eCollection 2016.
  15. Aab A, Wirz O, van de Veen W, Söllner S, Stanic B, Rückert B, Aniscenko J, Edwards MR, Johnston SL, Papadopoulos NG, Rebane A, Akdis CA, Akdis M. Human Rhinoviruses Enter and Induce Proliferation of B Lymphocytes. 2016 May 11. doi: 10.1111/all.12931. [Epub ahead of print]
  16. Edwards MR, Facchinetti F, Civelli M, Villetti G, Johnston SL. Anti-inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus-inducible cytokines. Pharmacol Res Perspect. 2016 Jan 15;4(1):e00202. doi: 10.1002/prp2.202. eCollection 2016 Feb.
  17. Stokes CA, Kaur R, Edwards MR, Mondhe M, Robinson D, Prestwich EC, Hume RD, Marshall CA, Perrie Y, O’Donnell VB, Harwood JL, Sabroe I, Parker LC. Human rhinovirus-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes. Mucosal Immunol. 2016 Feb 24. doi: 10.1038/mi.2015.137. [Epub ahead of print]
  18. Schögler A, Stokes AB, Casaulta C, Regamey N, Edwards MR, Johnston SL, Jung A, Moeller A, Geiser T, Alves MP. Interferon response of the cystic fibrosis bronchial epithelium to major and minor group rhinovirus infection. J Cyst Fibros. 2015 Nov 21. pii: S1569-1993(15)00257-X. doi: 10.1016/j.jcf.2015.10.013.
  19. Contoli M, Ito K, Padovani A, Poletti D, Marku B, Edwards MR, Stanciu LA, Gnesini G, Pastore A, Spanevello A, Morelli P, Johnston SL, Caramori G, Papi A. Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy. 2015 Aug;70(8):910-20. doi: 10.1111/all.12627. Epub 2015 Apr 24.
  20. Jackson DJ, Trujillo-Torralbo MB, del-Rosario J, Bartlett NW, Edwards MR, Mallia P, Walton RP, Johnston SL. The influence of asthma control on the severity of virus-induced asthma exacerbations. J Allergy Clin Immunol. 2015 Aug;136(2):497-500.e3. doi: 10.1016/j.jaci.2015.01.028.
  21. Jackson DJ, Glanville N, Trujillo-Torralbo MB, Shamji BW, Del-Rosario J, Mallia P, Edwards MJ, Walton RP, Edwards MR, Johnston SL. Interleukin-18 is associated with protection against rhinovirus-induced colds and asthma exacerbations. Clin Infect Dis. 2015 May 15;60(10):1528-31. doi: 10.1093/cid/civ062. Epub 2015 Feb 2.
  22. Gielen V, Sykes A, Zhu J, Chan B, Macintyre J, Regamey N, Kieninger E, Gupta A, Shoemark A, Bossley C, Davies J, Saglani S, Walker P, Nicholson SE, Dalpke AH, Kon OM, Bush A, Johnston SL, Edwards MR. Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons. J Allergy Clin Immunol. 2015 Jul;136(1):177-188.e11. doi: 10.1016/j.jaci.2014.11.039. Epub 2015 Jan 25.
  23. Schögler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, Kieninger E, Jung A, Moeller A, Geiser T, Regamey N, Alves MP. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J. 2015 Feb;45(2):428-39. doi: 10.1183/09031936.00102014. Epub 2014 Oct 30.
  24. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, Jerico Del-Rosario, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL. IL-33-dependent type  2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82.
  25. Beale J, Jayaraman A, Jackson DJ, Macintyre JD, Edwards MR, Walton RP, Zhu J, Ching YM, Shamji B, Edwards M, Westwick J, Cousins DJ, Hwang YY, McKenzie A, Johnston SL, Bartlett NW. Rhinovirus-induced IL-25 in asthma exacerbation drives  type 2 immunity and allergic pulmonary inflammation. Sci Transl Med. 2014 Oct 1;6(256):256ra134. doi: 10.1126/scitranslmed.3009124.
  26. Reed DM, Foldes G, Gatheral T, Paschalaki KE, Lendvai Z, Bagyura Z, Nemeth T, Skopal J, Merkely B, Telcian AG, Gogsadze L, Edwards MR, Gough PJ, Bertin J, Johnston SL, Harding SE, Mitchell JA. Pathogen sensing pathways in human embryonic stem cell derived-endothelial cells: role of NOD1 receptors. PLoS One. 2014 Apr 1;9(4).
  27. Rohde G, Message SD, Haas JJ, Kebadze T, Parker H, Laza-Stanca V, Khaitov MR, Kon OM, Stanciu LA, Mallia P, Edwards MR, Johnston SL. Cxc-Chemokines And Antimicrobial Peptides In Rhinovirus-Induced Experimental Asthma Exacerbations. Clin Exp Allergy. 2014 Mar 26.
  28. Sykes A, Macintyre J, Edwards MR, Del Rosario A, Haas J, Gielen V, Kon OM, McHale M, Johnston SL. Rhinovirus-induced interferon production is not deficient in well controlled asthma. 2014 Mar;69(3):240-6.
  29. Sykes A, Edwards MR, Macintyre J, Del Rosario A, Gielen V, Haas J, Kon OM, McHale M, Johnston SL. TLR3, TLR4 and TLRs7-9 Induced Interferons Are Not Impaired in Airway and Blood Cells in Well Controlled Asthma. PLoS One. 2013 Jun 18;8(6):e65921.
  30. Edwards, N. Regamey, E. Kieninger, M. Vareille A. Gupta, A. Shoemark A. Sykes J. MacIntyre C. Bossley, J. Davies, J. MacIntyre, A. Bush, SL. Johnston Impaired interferon expression in bronchial epithelial cells from severe asthmatic children. Muc Immunol 2013 Jul;6(4):797-806.
  31. Bartlett, L. Slater, N. Glanville, JJ. Haas, G. Caramori, P. Casolari, DL. Clarke, SD. Message, J. Anisenko, T. Kebadze, P. Mallia, Joseph P. Mizgerd, M. Belvisi, A. Papi, SV. Kotenko, SL. Johnston and MR. Edwards. Critical distinct roles for NF-kB p65 and Type I interferon signalling in the innate immune response to rhinovirus infection. EMBO Mol Med 2012 Dec;4(12):1244-60.
  32. George PM, Badiger R, Shao D, Edwards MR, Wort SJ, Paul-Clark MJ, Mitchell JA Viral Toll Like Receptor activation of pulmonary vascular smooth muscle cells results in endothelin-1 generation; relevance to pathogenesis of pulmonary arterial hypertension. Biochem Biophys Res Commun. 2012 Oct 5;426(4):486-91.
  33. Sykes A, Edwards MR, Macintyre J, Del Rosario A, Bakhsoliani E, Trujillo-Torralbo MB, Kon OM, Mallia P, McHale M, Johnston SL. Rhinovirus 16-induced IFN-α and IFN-β are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol. 2012 Jun;129(6):1506-1514.e6.
  34. Zdrenghea MT, Telcian AG, Laza-Stanca V, Bellettato CM, Edwards MR, Nikonova A, Khaitov MR, Azimi N, Groh V, Mallia P, Johnston SL, Stanciu LA. RSV infection modulates IL-15 production and MICA levels in respiratory epithelial cells. Eur Respir J. 2011 Aug 18. [Epub ahead of print]
  35. Kieninger E, Vareille M, Kopf BS, Blank F, Alves MP, Gisler FM, Latzin P, Casaulta C, Geiser T, Johnston SL, Edwards MR, Regamey N. Lack of an exaggerated inflammatory response upon virus infection in cystic fibrosis. Eur Respir J. 2011 Jun 30.
  36. Vareille, E. Kieninger, MP. Alves, BS. Kopf, A. Möller, T. Geiser, SL. Johnston, MR. Edwards and N. Regamey. Impaired type I and III interferon induction and rhinovirus control in human cystic fibrosis airway epithelial cells. Thorax 2012 Jun;67(6):517-25.
  37. Laza-Stanca V, Message SD, Edwards MR, Parker HL, Zdrenghea MT, et al. The Role of IL-15 Deficiency in the Pathogenesis of Virus-Induced Asthma Exacerbations. PLoS Pathog (2011) 7(7): e1002114. doi:10.1371/1002114.
  38. Ouda R, Onomoto K, Takahasi K, Edwards MR, Kato H, Yoneyama M, Fujita T. RIG-I-inducible miR-23b inhibits infections by minor group rhinoviruses through down-regulation of the receptor VLDLR. J Biol Chem. 2011 Jun 3. [Epub ahead of print].
  39. Stokes CA, Ismail S, Dick EP, Bennett JA, Johnston SL, Edwards MR, Sabroe I, Parker LC. J The role of IL-1 and MyD88-dependent signaling in rhinoviral infection. J Virol. 2011 May 18. [Epub ahead of print].
  40. Telcian AG, Stanca, VL Edwards MR, Harker, JA Wang H, Bartlett, NW, Mallia, P, Zdrenghea, MT, Kebadze, T, Coyle, AJ, Openshaw, PJM, Stanciu, LA,  Johnston, SL. RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell non-specific anti-viral activity. J Infect Dis. 2010 203(1):85-94.
  41. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T, Aniscenko J, Laza-Stanca V, Edwards MR, Slater L, Papi A, Stanciu LA, Kon OM, Johnson M, Johnston SL. Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbation. Am J Respir Crit Care Med. 2011 Mar 15;183(6):734-42.
  42. Slater, L, Bartlett, NW,  Haas, JJ, Zhu, J Message, SD Walton, RP,  Sykes, A, Dahdaleh, S, Clarke,  DL, Belvisi, M, Kon, OM, Fujita, T,  Jeffery, PK, Johnston SL and Edwards, MR. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathogens 2010 4;6(11):e1001178.
  43. Hewson CA, Haas JJ, Bartlett NW, Message SD, Laza-Stanca V, Kebadze T, Caramori G, Zhu J, Edbrooke MR, Stanciu LA, Kon OM, Papi A, Jeffery PK, Edwards MR, Johnston SL. Rhinovirus induces MUC5AC in a human infection model, & in vitro via NF-{kappa}B & EGFR pathways. Eur Respir J. 2010 36(6):1425-35.
  44. Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3): 646-654.
  1. Khaitov, MR., Laza-Stanca, V., Edwards, MR., Walton, RP., Rohde, G, Contoli, M, Papi, A, Stanciu, LA, Kotenko, SV., and Johnston, SL. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 2009; 64(3): 375-386.
  2. Papi A, Contoli M, Gasparini P, Bristot L, Edwards MR, Chicca M, Leis M, Ciaccia A, Caramori G, Johnston SL, Pinamonti S. Role of xanthine-oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells. J Biol Chem. 2008; 283(42):28595-606.
  3. NW. Bartlett, RP. Walton, MR. Edwards, J. Aniscenko, G. Caramori, J. Zhu, N. Glanville, KJ. Choy, P. Jourdan, J. Burnet, TJ. Tuthill, MS. Pedrick, MJ. Hurle, C. Plumpton, NA. Sharp, JN. Bussell, DM. Swallow, J. Schwarze, , B. Guy, JW. Almond, PK. Jeffery, CM. Lloyd A. Papi, RA. Killington,  DJ. Rowlands, ED. Blair, NJ. Clarke, and SL. Johnston. Mechanisms of rhinovirus-induced disease & exacerbation of allergic airway inflammation in novel mouse models of rhinovirus infection, Nat Med 2008; 14(2):199-204.
  1. Edwards MR Hewson CA Laza-Stanca V, Lau HH, Mukaida N,. Hershenson MB, and Johnston SL. Protein kinase R, IkB kinase-b and NF-kB are required for human rhinovirus induced pro-inflammatory cytokine production in bronchial epithelial cells. Mol Immunol. 2007; 44(7):1587-97.
  2. Edwards MR, Haas, J, Panettieri RA, Johnson M, Johnston SL. Corticosteroids and beta 2 agonists differentially regulate rhinovirus induced IL-6 via distinct cis-acting elements. J Biol Chem 2007:282(21) 15366-15375.
  1. Contoli, M, Message, SD, Laza-Stanca, V, Edwards, MR, Wark, PA, Bartlett, NW .Kebadze, T, Mallia, P, Stanciu, LA, Parker, HL, Slater, L, Lewis-Antes, A, Kon, OM, Holgate, ST, Davies, DE, .Kotenko, SV, Papi, A, Johnston, SL. Role of deficient type III interferon-l production in asthma exacerbations. Nat Med. 2006; 12 1023-26.
  2. Laza-Stanca V, Stanciu LA, Message SD, Edwards MR, Gern JE, Johnston SL. Rhinovirus replication in human macrophages induces NF-kappaB-dependent tumor necrosis factor alpha production. J Virol. 2006; 80(16):8248-58.
  1. Edwards MR, Johnson MW, and Johnston SL. Combination therapy: Synergistic suppression of virus induced chemokines. Am J Res Mol Cell Biol. 2006; 34(5):616-24.
  1. Hewson CA, Jardine A, Edwards MR, Laza-Stanca V, Johnston SL. Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. J Virol. 2005; 79(19):12273-9.
  1. Edwards MR, Mukaida N, Johnson MW, Johnston S.L. IL-1beta induces IL-8 in bronchial cells via NF-kappaB and NF-IL6 transcription factors and can be suppressed by glucocorticoids. Pulm Pharmacol Ther. 2005;18(5):337-45.
  1. Yip YL, Novotny J, Edwards M, Ward RL. Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling. Int J Cancer. 2003;104(3):303-9.
  1. Edwards MR, Brouwer W, Choi, CH, Ruhno J, Ward RL, Collins AM. Analysis of IgE antibodies from a patient with atopic dermatitis: biased V gene usage and evidence for polyreactive IgE heavy chain complementarity-determining region 3. J Immunol. 2002:168(12):6305-13.
  1. Philips JR, Brouwer W, Edwards M, Mahler S, Ruhno J, Collins AM. The effectiveness of different rat IgG subclasses as IgE-blocking antibodies in the rat basophil leukaemia cell model. Immunol Cell Biol. 1999; 77(2):121-6.

Research: Publications-Reviews & Editorials

  1. Edwards MR, Saglani S, Schwarze J, Skevaki C, Smith JA, Ainsworth B, Almond M, Andreakos E, Belvisi MG, Chung KF, Cookson W, Cullinan P, Hawrylowicz C, Lommatzsch M, Jackson D, Lutter R, Marsland B, Moffatt M, Thomas M, Virchow JC, Xanthou G, Edwards J, Walker S, Johnston SL; members of the EARIP WP2 working group. Addressing unmet needs in understanding asthma mechanisms: From the European Asthma Research and Innovation Partnership (EARIP) Work Package (WP)2 collaborators. Eur Respir J. 2017 May 1;49(5).
  2. Edwards MR, Walton RP, Jackson DJ, Feleszko W, Skevaki C, Jartti T, Makrinoti H, Nikonova A, Shilovskiy IP, Schwarze J, Johnston SL, Khaitov MR; EAACI Anti-infectives in Asthma and Asthma Exacerbations Task Force. The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations. Allergy. 2017 Jul 19. doi: 10.1111/all.13257. [Epub ahead of print].
  3. Ritchie AI, Jackson DJ, Edwards MR, Johnston SL. Airway Epithelial Orchestration of Innate Immune Function in Response to Virus Infection. A Focus on Asthma. Ann Am Thorac Soc. 2016 Mar;13 Suppl 1:S55-63. doi: 10.1513/AnnalsATS.201507-421MG.
  4. Wong EHC, Porter JD, Edwards MR, Johnston SL. The role of macrolides in asthma: current evidence and future directions. Lancet Respiratory Medicine. 2014. Accepted for publication.
  5. Dhariwal J, Edwards MR, Johnston SL. Anti-viral agents: potential utility in exacerbations of asthma. Curr Opin Pharmacol. 2013 Jun;13(3):331-6. doi: 10.1016/j.coph.2013.04.010.
  6. Almond MH, Edwards MR, Barclay WS, Johnston SL. Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax. 2013 Jul;68(7):684-6. doi: 10.1136/thoraxjnl-2012-203009.
  7. Edwards, NW. Bartlett, T. Hussell, P. Openshaw and SL Johnston. The Microbiology of Asthma. Nat Reviews Microbiol 2012 10(7):459-71.
  8. Edwards MR, Johnston SL. Interferon-lambda as a new approach for treatment of allergic asthma? EMBO Mol Med. 2011 Jun;3(6):306-8.
  9. Varielle, M, Kieninger, E, Edwards MR and Regamey N. The airway epithelium: soldier in the fight against respiratory viruses. Clin Micr Rev 2010 24(1):210-29.
  10. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, & Johnston SL. Targetting the NF-kB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther. 2009, 121:1-13.
  11. Johnston SL, Edwards MR. Mechanisms of adverse effects of b2-agonists in asthma. Editorial Thorax 2009: 739-41.
  12. Edwards MR & Johnston SL Deficient interferon in virus-induced asthma exacerbations. Editorial Clin Exp Allergy. 2008; 38(9):1416-8.
  13. Edwards MR, Slater L and Johnston SL. Signalling pathways mediating type I interferon gene expression Microbes Infect. 2007 9(11):1245-51.
  14. Edwards MR, Kebadze T, Johnson MW, Johnston S.L. New treatment regimes for virus-induced exacerbations of asthma. Pulm Pharmacol Ther. 2005; 19: 320-334.
  15. Collins AM, Sewell WA, Edwards MR. Immunoglobulin gene rearrangement, repertoire diversity, and the allergic response. Pharmacol Ther. 2003; 100(2):157-70.
  16. Edwards MR, Collins AM and Ward RL. The application of phage display in allergy research: characterization of IgE, identification of allergens and development of novel therapeutics. Curr Pharm Biotechnol. 2001; 2(3):225-40.
  17. Mitchell AJ, Edwards MR, Collins AM. Valency or wahlency: is the epitope diversity of the B-cell response regulated or chemically determined? Immunol Cell Biol. 2001; 79(5):507-11.

Research: Invited Seminars

  • New treatment regimes for virus-induced asthma exacerbation. Georgian Respiratory Society, Tbilisi, Georgia, June 2007.
  • Recognition of viral RNA by RNA helicases and its importance in virus-induced exacerbations of asthma. British Society for Allergy & Clincal Immunology (BSACI), Loughborough University, UK, July 2007.
  • Viral infections, immune modulation and acute exacerbations of asthma. The Asthma Burden, London, UK, March 2008.
  • Virus induced asthma exacerbations: The why, when where and how? XV Vilnius International Paediatric Pulmonology & Allergology Conference, Vilnius, Lithuania April, 2009.
  • What are the properties of an effective treatment for paediatric asthma exacerbations? XV Vilnius International Paediatric Pulmonology & Allergology Conference, Vilnius, Lithuania April, 2009.
  • Mechanisms of virus induced pro-inflammatory cytokine and interferon production. II World Asthma & COPD Forum Saint Petersburg, Russia, April, 2009.
  • Mechanisms of susceptibility to virus induced wheeze in asthma British Society for Allergy & Clinical Immunology (BSACI), Nottingham UK, July 2009.
  • Overview of human rhinovirus infection and asthma exacerbations 4th World Equine Airway Symposium, Berne Switzerland, August 2009.
  • Virus induced asthma exacerbations Pfizer Ltd, Sandwich UK, September 2009.
  • Epithelial cells in virus induced asthma exacerbations EAACI Clinical impact and mechanisms of infections in Allergy. Allergy School, Edinburgh, September, 2011
  • RLHs in virus induced asthma exacerbations The three Rs of innate immune recognition: Toll like receptors (TLRs), RIG-like receptors (RLRs) and Nod-like receptors (NLRs) Euroscicon Symposium, London September 2011.
  • Signalling pathways in rhinovirus infection MRC Center for Inflammation, Edinburgh, 2012
  • American Academy of Allergy & Asthma(AAAAI) January, Orlando, 2012
  • Anti-viral approaches in exacerbations EAACI Allergy School, Asthma Exacerbations: Risk Factors & Management Tallin, August, 2012
  • New viruses and asthma exacerbations in childhood EAACI Allergy School, Asthma Exacerbations: Risk Factors & Management Tallin, August, 2012.
  • Role played by the epithelial barrier in the defence against pulmonary viral infections ERS, Munich Germany 2014
  • Effects of Th2 inflammation on the anti-viral response in rhinovirus infection BSI, Brighton UK 2014
  • Dysfunction in innate immunity in asthma; new mechanisms and potential for therapeutic implications Controversias Y Novedades en Alergis Madrid, Spain, 2015
  • New targets for virus-induced asthma exacerbations: from bedside to bench. ELRIGG Drug Discovery Telford, UK 2015
  • Innate immune responses to rhinovirus in bronchial epithelium SFB Mini-symposium on Respiratory Viruses Marburg, Germany 2015.

Research: Academic National & International Standing

  • Associate Editor for Pharmacology & Therapeutics, Elsevier.
  • Associate Editor of BMC Pulmonary Medicine, BioMedCentral.
  • Acted as peer reviewer for the following journals; Thorax, European Respiratory Journal, American Journal of Respiratory Cell & Molecular Biology, Respiratory Medicine, Microbes & Infection, Pulmonary Pharmacology & Therapeutics, Respiratory Research, Clinical and Experimental Allergy, American Journal of Respiratory and Critical Care Medicine, Journal of Biological Chemistry, British Journal of Pharmacology, Immunology, European Cytokine Network, American Journal of Lung Physiology, Mucosal Immunology, Cytokine, Journal of Biotechnology, Journal of Infection, Journal of General Virology; Paediatric Pulmonology; Journal of Immunology; PLoS Pathogens; PLoS One; Journal of Infectious Disease; American Journal of Physiology-Lung Cellular and Molecular Physiology.
  • Peer reviewer for Telethon International (2007, 2008, 2011), Alberta Heritage Foundation for Medical Research (2007), Dr Hadwen Trust for Humane Research (2008), Action Medical Trust (2008), and The National Medical Research Council, Singapore (2008-present), Asthma UK (2009, 2010), MRC Project Grant (2009, 2017), National Medical Research Council, Singapore (2011-2018), Singapore call for H1N1 Proposals (2009), European Research Council’s Seventh Research Framework Programme (FP7, 2009); National Health & Medical Research Council Australia (2013); French National Research Agency (2010); the Netherlands Asthma Foundation (2010), Wellcome Trust UK (2016); Hong Kong Research Grants Council (2014-2018); National Science Centre Poland (2014-2016).

Undergraduate and Postgraduate Teaching

  • Graduated from Imperial College London with a Certificate of Advanced Study in Learning and Teaching (CASLAT), March 2011.
  • Act as a Postgraduate tutor and sit on the NHLI’s Higher Degrees Committee board. (2008-present)
  • Currently act as Module Leader for the 3rd Module of the Respiratory BSc Undergraduate Medicine Program at Imperial, November 2007-present. Duties involve performing lectures, tutorials, course design, organisation and setting of and marking of examinations and in course assessment of 4th year medical students.
  • Have supervised or co-supervised 9 PhD students (2 clinical), and 5 MSc students within the Department of Respiratory Medicine, Imperial College London (2004-present). All PhD students submitted within 4 years. I am currently supervising 1 PhD student, whom is in there 3rd
  • Have taught 7 4th year undergraduate medical students at Imperial College London during their BSc year within the College’s Immunobiology & Pathology, and Respiratory Medicine Program. The students performed a 3 month Research Project designed by myself, executed under my supervision.
  • In 2006, Mr Samer Dahdaleh, a BSc medical student received the Best Project Prize on the BSc Immunobiology & Pathology pathway, and has been nominated for the Evelyn de Rothschild Prize for Best BSc Project
  • Have acted as a relief tutor for the 1st Medical Program at Imperial, giving tutorials in the Cells, Molecules & Disease Program, 2006.
  • Acted as an adjunct lecturer in the School of Microbiology and Immunology, UNSW (1999-2000), performing two lectures per year on the Immunogenetics of Immunoglobulins.
  • Acted as tutor and demonstrator for laboratory classes within the School of Microbiology and Immunology, UNSW. Duties included the design and execution of tutorials and practical sessions for undergraduate 3rd year Immunology students.

                                                      CURRICULUM VITAE

 

Name                          Musa R. Khaitov                               Date of birth 31th August 1979

https://orcid.org/0000-0003-4961-9640

Scopus author ID: 7801543864

H-index 13

 

Address                      NRC Institute of Immunology FMBA Russia

Kashirskoe shosse 24/2,

Moscow, 115522, RUSSIA

Tel: +7 (499) 617 1027

Fax: +7 (499) 612 8151

e-mail: mr.khaitov@nrcii.ru

 

Education                  

1996 – 2002                Russian State Medical University (RSMU)

2007 – 2008                 The Academy of National Economy under the Government

of the Russian Federation (ANE)

 

Qualifications             2003    PhD

2008    DSc

2013    Professor of Immunology

2016   RAS Corresponding-member

Present Post

Jul 2014-                     Director

NRC Institute of Immunology FMBA Russia

 

Previous Appointments

Oct 2004 – Feb 2006 Fellow Researcher, Department of Respiratory Medicine

National Heart and Lung Institute and

Wright Fleming Institute of Infection & Immunity

Imperial College of Science, Technology & Medicine

Norfolk Place, London W2 1PG

 

Sept 2007 –                 Head of Nano- and Biotechnologies Laboratory

NRC Institute of Immunology FMBA Russia

Apr 2010 –                  Head of Nanobiomedical Technologies Departament

NRC Institute of Immunology FMBA Russia

 

 

Awards

2001                             Sechenov gold medal II Conference of Young Russian Scientists “Basic Sciences and Progress of Clinical Medicines”

2007                            Russian Federation State award for young scientists in the field of science and technology

2008                           Alferov fund award for the best work in the field of Bionanotechnology

2013                           Gold Medal of  Russian Scientific Society of Immunology

2014                           Silver Cross Federal Medico-biological Agency Russia

 

 

 

 

Memberships of Scientific Societies

 

1998-

Present time                           Member of Russian Association of Allergy and Clinical Immunology (RAACI)

2013-

Present time                           RAACI Vice –President

1999-

Present time                           Member of European Academy of Allergy and Clinical Immunology (EAACI)

2013

Present time                           EAACI Executive committee member

2017

Present time                            EAACI Exam Committee Chair

 

Expert activity

2014 –

Present time                           Expert of Russian Scientific Foundation

 

2014 –

Present time                           Expert of “Platinum Ounce” Award

 

2015 –

Present time                           Expert of Russian Foundation for Basic Research

 

2016                                                   Expert of Foundation “Skolkovo”

 

2016                                                   Expert of Russian Academy of Sciences

 

2019                                                   Expert of the Scientific Council on Biotechnology in OBN RAS

 

Editorial board memberships

Editorial board           Immunology (in Russian)

Editorial board           Russian Allergology Journal

Editorial board           Allergology and Immunology

Editorial board           Medicine of Extreme Situations

 

Social activity

2016                                                   Member of the Board for problems of drug abuse prevention at the Federation Council

 

2016                                                   Member of the Scientific Council of the Russian Federation President’s Advisor Klimenko G.S. on the implementation of methodological and organizational activities of creation and application intelligent decision support systems, medical solutions and justify the basic directions of development of the Russian Internet segment

 

2016                                                   Member of the Advisory Board “Vaccines and Immunoprophylaxis” JSC “National immunobiological Company”

 

2017                                                   Member of the Expert Council on improving the health organization of the Russian Federation State Duma Committee on Health

Research Areas         Immunology, Allergology, Virology, Molecular Biology

 

 

Major Publications

  1. Khaitov MR, Shilovskiy IP, Nikonova AA, Shershakova NN, Kamyshnikov OY, Babakhin AA, Zverev VV, Johnston SL, Khaitov RM. siRNA’s targeted to IL-4 and RSV reduce airway inflammation in a mouse model of virus-induced asthma exacerbation //Hum Gene Ther. 2014 Jul;25(7):642-50. doi: 10.1089/hum.2013.142.
  2. Jackson, H Makrinioti, Batika M.J., MB Trujillo-Torralbo, J Footitt, J del-Rosario, AG. Telcian, A Nikonova, Jie Zhu, J Aniscenko, L Gogsadze, E Bakhsoliani, S Traub, J Dhariwal, J Porter, D Hunt, T Hunt, LA. Stanciu, MR Khaitov, NW. Bartlett, MR. Edwards, OM Kon, Patrick Mallia, NG. Papadopoulos, CA. Akdis, J Westwick, MJ. Edwards, DJ. Cousins, RP. Walton, aSL. Johnston. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82. doi: 10.1164/rccm.201406-1039OC
  3. Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M,Papi A, Stanciu LA, Kotenko SV, Johnston S. L. Respiratory Virus Induction of Alpha- Beta- and Lambda- interferons in Bronchial Epithelial Cells and Peripheral Blood Mononuclear Cells. Allergy 2009;64:375-86. Epub 2009 Jan 28.
  4. Khaitov MR., Trofimov D.U., Petrova T.V., Yakovleva K.P.,. Boldyrevaa M.N, Yartseva M.N., Ilinaa N.I, DuBuske L.M., Alexeeva L.P. Mechanisms of viral impact on asthma exacerbations Journal of Allergy and Clinical Immunology. Volume 113, Issue 2, 2004, Pages 264–265.
  5. Stephanie Traub, Alexandra Nikonova, Alan Carruthers, Rebecca Dunmore, Katharine Vousden, Leila Gogsadze, Weidong Hao, Qing Zhu, Jie Zhu, Michael Dymond, Gary R McLean, Ross P Walton, Nicholas Glanville, Alison Humbles, Musa Khaitov, Ted Wells, Roland Kolbeck, Andrew J Leishman, Matthew A Sleeman, Nathan W Bartlett and Sebastian L Johnston. An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation. PLOS Pathogens. 2013, V 9. – Issue.8. – e1003520.
  6. Zdrenghea MT, Telcian AG, Laza-Stanca V, Bellettato CM, Edwards MR, Nikonova A, Khaitov MR, Azimi N, Groh V, Mallia P, Johnston SL, Stanciu LA. RSV infection modulates IL-15 production and MICA levels in respiratory epithelial cells. Eur Respir J. 2012 Mar;39(3):712-20.
  7. Rohde G, Message S, Haas J, Kebadze T, Parker, Hayley; Laza-Stanca V, Khaitov M, Kon O, Stanciu L, Mallia P, Edwards M, Johnston S. CXC-chemokines and antimicrobial peptides in rhinovirus–induced experimental asthma exacerbations. Clinical & Experimental Allergy, 2014Clin Exp Allergy. 2014 Jul;44(7):930-9. doi: 10.1111/cea.12313.
  8. Baca-Estrada M., Carter D., Coleman G, Feavers I., Griffiths E., Gruber M., Iguchi M., Ishii K., Dahlan J., Khaitov M.R. et al. – Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines/World Health Organization, 2013.—56p. Электронный ресурс:

http://www.who.int/biologicals/areas/vaccines/ADJUVANTS_Post_ECBS_edited_clean_Guidelines_NCE_Adjuvant_Final_17122013_WEB.pdf

  1. Khaitov MR. Biosafety and RNA interference. Post-genomic processes immunonanotehnology, new principles of creation and use of medicines. Monograph. Мoscow, 2012 – 320 p.
  2. Calderon MA, Cox L, Casale TB, Mösges R, Pfaar O, Malling HJ, Sastre J, Khaitov MR, Demoly P. The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey. Allergy, Asthma & Clinical Immunology. 2015, Vol. 11. doi:10.1186/s13223-015-0083-z
  3. Ansley L., Bonini M., Delgado L., Del Giacco S., Du Toit G., Khaitov M., Kurowski M., Hull J H, Moreira A., Robson A. P. Pathophysiological mechanisms of exercise-induced anaphylaxis: an EAACI position statement. Allergy. 2015, Vol. 70, 1212-1221.  DOI: 1111/all.12677
  4. Shershakova N, Bashkatova E, Babakhin A, Andreev S, Nikonova A, Shilovsky I, Kamyshnikov O, Buzuk A, Elisyutina O, Fedenko E, Khaitov M. Allergen-Specific Immunotherapy with Monomeric Allergoid in a Mouse Model of Atopic Dermatitis. PLoS One. 2015 Aug 14;10(8):e0135070. doi: 10.1371/journal.pone.0135070. eCollection 2015.
  5. Shershakova N., Baraboshkina E., Andreev S., Purgina D., Struchkova I., Kamyshnikov O., Nikonova A., Khaitov M. Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis. Journal of Nanobiotechnology. 2016; 14:8; 1483-1493. DOI 10.1186/s12951-016-0159-z
  6. Fedenko E., Elisyutina O., Shtyrbul O., Pampura A., Valenta R., Lupinek C., Khaitov M. Microarray-based IgE-serology improves management of severe atopic dermatitis in two children. Pediatric Allergy and Immunology. DOI:  10.1111/pai.12572.
  7. Koloskova OO, Nikonova AA, Budanova UA, Shilovskiy IP, Kofiadi IA, Ivanov AV, Smirnova OA, Zverev VV, Sebaykin YL, Andreev SM, Khaitov MR. Synthesis and evaluation of novel lipopeptide as a vehicle for efficient gene delivery and gene silencing.Eur J Pharm Biopharm. 2016 May;102:159-67. doi: 10.1016/j.ejpb.2016.03.014. Epub 2016 Mar 15.
  8. Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A, Bergmann KC, Bosnic-Anticevich S, Brozek J, Calderon M, Canonica GW,Casale TB, Chavannes NH, Cox L, Chrystyn H, Cruz AA, Dahl R, De Carlo G, Demoly P, Devillier P, Dray G, Fletcher M, Fokkens WJ, Fonseca J, Gonzalez-Diaz SN, Grouse L, Keil T, Kuna P, Larenas-Linnemann D, Lodrup Carlsen KC, Meltzer EO, Mullol J, Muraro A, Naclerio RN, Palkonen S, Papadopoulos NG, Passalacqua G, Price D, Ryan D, Samolinski B, Scadding GK, Sheikh A, Valiulis A, Valovirta E, Walker S, Wickman M, Yorgancioglu A, Zuberbier T; Khaitov M, Kalayci O, Kalyoncu F, Keith P, Khaltaev N, Kleine-Tebbe J, Kolek V, Koppelman GH, Kowalski M, Kull I, Kvedariene V, Lambrecht B, Lau S, Laune D, Le Thi Tuyet L, Li J, Lieberman P,Lipworth BJ, Renaud L, Magard Y, Magnan A, Mahboub B, Majer I. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology – 2016 – Available online 23 April 2016 – doi:10.1016/j.jaci.2016.03.025
  9. Michael R. Edwards ,  James D. Porter ,  Musa Khaitov ,  Sergei Moshkovski ,  Lyn Jones , PhD 4 , Lee Roberts ,  Kalesh K.N. Anandamma ,  Iain Kilty ,  Ed Tate ,  Sebastian L. Johnston. Azithromycin Augments RV-Induced Type I And Type III Interferon Production Via Interaction With MAVS – 2016 – ATSJournals. Doi: 1164/ajrccm-conference.2016.193.1_MeetingAbstracts.A6421
  10. Bousquet,  J. Farrell, G. Crooks, P. Hellings, E. H. Bel, M. Bewick, N. H. Chavannes, J. Correia de Sousa, A. A. Cruz, T. Haahtela, G. Joos, N. Khaltaev, J. Malva, A. Muraro, M. Nogues, S. Palkonen, S. Pedersen, C. Robalo-Cordeiro, B. Samolinski, T. Strandberg, A. Valiulis, A. Yorgancioglu, T. Zuberbier, A. Bedbrook, W. Aberer, M. Adachi. Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5) –July,  2016 – Clinical and Translational Allergy, 6:29. Doi: 10.1186/s13601-016-0116-9
  11. Jean Bousquet, M. Bewick, A. Cano, P. Eklund, G. Fico, N. Goswami, N. A. Guldemond, D. Henderson, M. J. Hinkema, G. Liotta, A. Mair, W. Molloy, A. Monaco, I. Monsonis-Paya, A. Nizinska, H. Papadopoulos, A. Pavlickova, S. Pecorelli, A. Prados-Torres, R. E. Roller-Wirnsberger, D. Somekh, C. Vera-Muñoz, F. Visser, J. Farrell, J. Malva, M.R. Khaitov. Building bridges for innovation in ageing: Synergies between Action Groups of the EIP on AHA – 2016 – The Journal of nutrition, health & aging. Doi:10.1007/s12603-016-0803-1
  12. Campana R,  Dzoro S,  Mittermann I,  Fedenko E,  Elisyutina O,  Khaitov M,  Karaulov A,  Valenta R.  Molecular aspects of allergens in atopic dermatitis.  // Curr Opin Allergy  Clin Immunol . 2017 Aug;17(4):269-277
  13. Valenta R,  Karaulov A,  Niederberger V,  Gattinger P, van  Hage M, Flicker S,  Linhart B,  Campana R,  Focke-Tejkl M,  Curin M,  Eckl-Dorna J,  Lupinek C, Resch-Marat Y,  Vrtala S,  Mittermann I,  Garib V,  Khaitov M,  Valent P,  Pickl WF.  Molecular Aspects of Allergens and Allergy.  // Adv Immunol . 2018; 138:195-256
  14. Curin M,  Khaitov M,  Karaulov A,  Namazova -Baranova L,  Campana R,  Garib V,  Valenta R.  Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches. // Сurr Allergy Asthma Rep. 2018 Jun 9;18(7):39.  doi : 10.1007/s11882-018-0790-x
  15. Valenta R,  Karaulov A,  Niederberger V,  Zhernov Y,  Elisyutina O,  Campana R,  Focke-Tejkl M,  Curin M,  Namazova -Baranova L, Wang JY,  Pawankar R,  Khaitov M. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?  // J Allergy  Clin Immunol Pract . 2018 Nov – Dec;6(6):1845-1855
  16. Garib V,  Rigler E,  Gastager F,  Campana R,  Dorofeeva Y,  Gattinger P,  Zhernov Y,  Khaitov M,  Valenta R.  Determination of  IgE and IgG reactivity to more than 170 allergen molecules in paper-dried blood spots.  // J Allergy  Clin Immunol . 2018 Oct 26.  pii : S0091-6749(18)31354-X.  doi : 10.1016/j.jaci.2018.08.04
  17. Campana R,  Marth K,  Zieglmayer P, Weber M,  Lupinek C,  Zhernov Y,  Elisyutina O,  Khaitov M,  Rigler E, MD,  Westritschnig K, Berger U,  Wolkersdorfer M,  Horak jr. F,  Horak F,  Valenta R.  Vaccination of non-allergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects and mechanisms.  // J Allergy  Clin Immunol . 2018
  18. Eckl-Dorna J,  Villazala -Merino S,  Linhart B,  Karaulov A,  Zhernov Y,  Khaitov M,  Niederberger-Leppin V,  Valenta R.  Allergen-specific antibodies regulate secondary allergen-specific immune responses. // Front  Immunol . 2018

 

 

Patents

  1. Patent for an invention № 2462474 Russian Federation, Method for preparing adducts of fullerene. Andreev SM, Bashkatova EN, Bashkatova YN, Khaitov MR, Petrukhina AO. Priority of invention 09.12.2010.
  2. Patent for an invention № 2499610 Russian Federation, Universal method for purifying air, fluids and surfaces using biocompatible microporous silicon for antiviral treatment in everyday life, in medicine and in industry. VY Timoshenko, Osminkina LA Kornilaeva GV Karamov EV, Khaitov MR, Shilovsky IP, Gaydarova AH, Dry GT, Batsev C . Priority of invention 28.12.2011.
  3. Patent for an invention № 2357960 Russian Federation, N, N-(Sulfonildi-1 ,4-phenylene) bis [(N, N-Dimethyl) Metiliminometan] 1, 2, 3, 4-Tetrahydro-6-methyl-2, 4-Dioxo-5-Pirimidinsulfonat possessing immunotropic Khaitov MR, Tsyvkina GI, SN Sedov, Gomzhin AM, Savelyev EA Khimich GN Khimich NN. Priority of invention 15.11.2007.
  4. Patent for an invention № 2264819 Russian Federation, Аntiherpethetical pharmaceutical composition and method for preparing a formulation based on it. Barinskiy IF, Lazarenko AA Musaeva AR, RV Petrov, RM Khaitov, MR Khaitov. Priority of invention 10.2003.
  5. Patent for an invention № 2548971 Russian Federation, Method for preparing water nanodispersions of fullerene. Andreev SM, Bashkatova EN, Khaitov MR, Purgina DD. Priority of invention 22.04.2013.
  6. Patent for an invention № 2549710 Russian Federation, Method of purifying recombinant protein interferon factor type III. Khaitov MR, Sidorovich IG, Shevalie AF, Gasanov VA, Shilovsky IP. Priority of invention 06.2012
  7. Patent for an invention № 2563989 Russian Federation, Composition for the suppression of the expression of cytokine gene IL-4. Khaitov MR, Smirnov VV, Andreev SM, Sergeev IV, Maerle AV, Lobanova SB, Kalinina EV, Shilovsky IP. Priority of invention 20.11.2014.
  8. Patent for an invention № 2572575 Russian Federation, Agent for intracellular delivery of nucleic acid into mammalian cells. Andreev SM, Chupina NA, Shilovsky IP, Khaitov MR. Priority of invention 31.10.2014.

 

 

Minor Publications

  1. Boldyreva, A.Zilov, D.Rakhimova, E.Groudakova, A.Boukina, I.Gouskova, D.Trofimov, R.Rouzybakiev, M.Khaitov, L.Alexeev. Distribution of the HLA DRB1, DQA1 and DQB1 gene specificities in Uzbek population //13th European Histocompatibility Conference, Abstracts, 13-17 April 1999 Crete, Greece. – P.32.
  2. Khaitov, D. Trofimov, T. Petrova, K. Yakovleva, L. Alexeev. Investigation of respiratory virus role in asthma development. Allergy, 2001, suppl.68, v.56, p. 158.
  3. Khaitov. Investigation of the role of respiratory syncitial virus in aetiology and pathogenesis of bronchial asthma. “Fundamental Science and Progress of Clinical Medicine”. Proceedings of Second Russian Conference of Young Scientists with International Participation (24-28 April, 2001, Moscow). 2001, v.1, p.179 (In Russian).
  4. Khaitov, L. Alexeev, D. Trofimov, M. Boldyreva, T. Petrova, K. Yakovleva. Molecular diagnostics of viral infections in bronchial asthma. Report №2. Respiratory viruses influence on outbreaks of bronchial asthma. Aspects of MHC-associated susceptibility to virus-induced bronchial asthma. Allergy, Asthma and Clinical Immunology J, 2002, v. 6, p.17-21 (In Russian).
  5. Khaitov M.R., Trofimov D.U., Petrova T.V., Yakovleva K.P., Alexeev L.P. Investigation of respiratory viruses role in asthma development. The Proceedings of EAACI 2002 Congress, Naples, 2002, chapter 58.
  6. Khaitov. Acute respiratory viral infections and bronchial asthma. Cellular and molecular aspects of the problem. Journal of Microbiology, Epidemiology and Immunobiology. 2002, v. 4, p. 84-93 (In Russian).
  7. Khaitov, L. Alexeev, D. Trofimov, M. Boldyreva, T. Petrova, K. Yakovleva. Development of new approaches to genetic prediction of virus-induced asthma. Proceedings of Fifth Congress “Modern Problems of Allergology, Immunology and Immunepharmacology” (12-14 November 2002, Moscow), v.2, p. 201 (In Russian).
  8. Khaitov M.R., Trofimov D.U., Petrova T.V. Investigation of the role of respiratory viruses in the development of asthma. Allergy, 2002, vol.57, suppl.73, р.296.
  9. Khaitov, D. Trofimov, T. Petrova, K. Yakovleva, M. Boldyreva, N. Ilina, M. Yartcev, L. Alexeev. Evaluation of respiratory virus role in aetiology and pathogenesis of bronchial asthma. Immunology (In Russian). 2003, v. 2, p. 96-100.
  10. Khaitov M.R., Trofimov D.U., Petrova T.V., Yakovleva K.P., Alexeev L.P. Virus-induced bronchial asthma and HLA markers of susceptibility, Allergy, 2003 vol.58, suppl.74, p.116.
  11. Khaitov M.R., Alexeev L.P.,Trofimov D.U., Boldyreva M.N., Petrova T.V., Yakovleva K.P. HLA-associated markers of susceptibility to virus-induced bronchial asthma. Immunol letters 2003, v.87, N.1-3, p.56.
  12. Khaitov M.R., Trofimov D.U., Petrova T.V., Yakovleva K.P., Alexeev L.P. Respiratory viruses and bronchial asthma, HLA-associated markers of susceptibility. Journal of World Allergy Organization, 2003, suppl.1, p.23.
  13. Khaitov MR, Tikhonova OV*, Zgoda VG*, Govorun VM*, Ulyanova LI, Toptygin AU, Alexeev LP, Archakov AI*, Khaitov RM. Proteomics Analysis of Human Immune Cells. Report 1. Proteomics Analysis of Stimulated Human T-lymphocytes. Immunologiya (In Russian). 2003, v.24, p. 276-281.
  14. Khaitov M.R., Trofimov D.U., Petrova T.V., Yakovleva K.P., Ilina N.I., Yartsev M.N., Boldyreva M.N., Alexeev L.P. Investigation of respiratory viruses role in asthma development. Clinical Immunology and Allergy in Medicine. JGC Editions, 2003, p. 403-409.
  15. Khaitov M.R. The role of respiratory viruses in pathogenesis of bronchial asthma. Immunologya(in Russian )2003, v.24, p.58-65.
  16. Kuznetsov M.R., Khaitov M.R., Turkin P.U., Moskalenko E.P., Ilinskaya A.N., Pinegin B.V. Evaluation of humoral and cellular immunity in patients with stenosis of vascular anastomosis after surgical interventions on pelvis and lower extremity arterias. Allergy, Asthma and Clinical Immunology, in Russian. 2003, №12, p.9-14
  17. Khaitov M.R., Alexeev L.P., Trofimov D.U., Boldyreva M.N., Petrova T.V., Yakovleva K.P., Yarcev M.N., Zverev V.V., Kiselev O.I., Gervazieva V.B., Semenov B.F. Development of PCR-diagnostic system for detection of respiratory syncitial virus. Physiology and Pathology of Immune System (in Russian). 2004, v. 2, p.85-91.
  18. Khaitov M.R., Trofimov D.U., Boldyreva M.N., Petrova T.V., Yakovleva K.P., Yartsev M.N., Ilina N.I.Хаитов М.Р., Трофимов Д.Ю., Петрова Т.В., Яковлева К.П., М.Н.Ярцев, Алексеев Л.П., Ильина Н.И. Rhinovirus infection in children with atopic asthma. Russian Journal of Allergology, 2004, №1, p.30-36.
  19. R. Khaitov, D. U. Trofimov, T. V. Petrova, K. P. Yakovleva, L. P. Alexeev. Evaluation of the role of rhinoviruses, adenoviruses, RS-viruses, PIV 1, PIV 2, PIV 3 and coronaviruses OC43 and 229E in exacerbations of asthma in children. Abstract Book XXIII EAACI Congress, 2004 Amsterdam, p. 37.
  20. Khaitov M.R. Recombinant allergens. Strategy of development of allegro vaccines of new generation. Russian jJournal of Allergology, 2004, №1,p.73-76.
  21. Khaitov M.R. Type 1 interferons in virus-induced asthma exacerbations. Allergology and Immunology in pediatrics(in Russian). 2005, № 6, p.166.
  22. Khaitov M.R., Akimov V.S. RNAi technology. siRNA in inhibition of replication of respiratory viruses the main ethiologic agents of bronchial asthma exacerbations. Immunology (in Russian), 2005, № 4, p. 249-255.
  23. Litvin L.S., Khaitov M.R. , Babakhin A.A. , Stetzenko O.N., Voronkova L.N., Ivanova A.S., Barsigjan G.G. Experimental model of murine asthma. Evaluation of various routs of immunization on experimental allergic response modeling. Russian Journal of Allergy. 2005,№1,p.35-42.
  24. Khaitov M.R., Litvin L.S., Babakhin A.A., Stesenko O.N., Voronova L.N., Ivanova A.S., Barsegiyan G.G. The evaluation of various shemes of ovalbumin administration in murine bronchial asthma modeling. J. World Allergy Organization, 2005, Suppl. 1, p. 80 (abstract).
  25. Litvin LS, Babakhin AA, Khaitov MR. Models of experimental atopic bronchial asthma. Patol Fiziol Eksp Ter. 2006 Jul-Sep;(3):26-8.
  26. Khaitov M., Laza-Stanca, V., Edwards, M., Contoli, M., Walton, R., Johnston SL. Type I and type III interferon expression in response to respiratory viruses. Abstract Book XXV EAACI Congress, 2006 Vienna, Austria, 10-14 June 2006 p.
  27. Litvin L.S., Khaitov M.R. , Babakhin A.A. , Stetzenko O.N.*, Voronkova L.N., Ivanova A.S. Asthma modeling using BALB/c and (CBAxC57BL/6)F1 mice. Abstract Book XXV EAACI Congress, 2006 Vienna, Austria, 10-14 June 2006 p.203.
  28. Khaitov MR, Laza-Stantca V, Edwards MR, Johnston SL. Production of alpha-, beta-, and lambda-interferons by epithelial and mononuclear cells during acute respiratory viral infection. Zh Mikrobiol Epidemiol Immunobiol. 2006, (7):63-9
  29. Akimov VS, Khaitov MR, Faizuloev EB, Nikonova AA, Trofimov DU, AlekseevLP, Sominina AA, Zverev VV. siRNA-mediated inhibition of respiratory syncytial virus replication. Vopr Virusol. 2007;52:8-12.
  30. Babakhin A.A., Litvin L.S, Andreev S.M., Stecenco O.N., Voronkova L.N., Ivanova A.S., Khaitov M.R., Barsegyan G.G., DuBuske I.V., DuBuske L.M. Allergen–specific immunotherapy using a highly modified allergen and the immunomodulator polyoxidonium in a murine model of allergic asthma. JACI 2007, v.119, №1, s.59.
  31. Babakhin A.A., Maximenko O.O., Vanchugova L.V., Shipulo E.V., Gelperina S.E., DuBuske I.V., DuBuske L.M. Immunogenicity of allergen adsorbed on polymeric nanoparticles. Annal Allergy, Asthma & Immunol, 2007, v. 98, N1, Suppl. 1, p. A76.
  32. Babakhin A.A., Litvin L.S, Stecenco O.N., Voronkova L.N., Borzova N.V., Ivanova A.S., Barsegyan G.G., DuBuske L.M., Khaitov M.R. Development and characterization of a short-term asthma model using BALB/c mice. J Allergy, 2007, v.62 (s.83), p.252.
  33. Babakhin A.A., Litvin L.S, Andreev S.M., Stecenco O.N., Voronkova L.N., Borzova N.V., Ivanova A.S., Khaitov M.R., Barsegyan G.G., DuBuske I.V., DuBuske L.M. Experimental desensitization using a modified allergen absorbed onto a synthetic Immunomodulator in a murine model of allergic asthma. J Allergy, 2007, v.62 (s.83), p.252-253.
  34. Babakhin A.A., Savchenko E.A., Andreev S.M., Shustova V.I., Khanferyan R.A., DuBuske L.M. Modulation of allergic responses by an immunomodulator-enhanced modified ragweed allergen. Abstract Book, Annual Scientific Meeting of American College of Allergy,Asthma & Immunology, 2007, Nov. 9-14, p. 40.
  35. Khaitov MR, Laza-Stanca, V., Edwards M., Walton, R., Contoli, M., Papi A., Johnston SL. Alpha-, beta-, lambda-interferon expression during rhinovirus infection. Abstract Book IX International Symposium on Respiratory Viral Infections, 2007 Hong Kong, p 15.
  36. Khaitov MR, Akimov VS, Faizuloev EB, Nikonova AA, Trofimov DU, Alekseev LP, Sominina AA, Zverev VV, DuBuske LM. Inhibition of respiratory syncytial virus replication by siRNA. JACI 2007, v.119, №1, p. 233. Khaitov MR, Akimov VS, Faizuloev EB, Nikonova AA, Trofimov DU, Alekseev LP, Sominina AA, Zverev VV, DuBuske LM. siRNA mediated inhibition of RSV replication. J Allergy, 2007, v.62 (s.83), p.127.
  37. Khaitov MR, Akimov VS, Faizuloev EB, Nikonova AA, Trofimov DU, Alekseev LP, Sominina AA, Zverev VV, DuBuske LM. Inhibition of RSV infection in vitro by small interfering RNAs. 2007 Annual Meeting ACAAI. November 8-14. p.33.
  38. Kryuchkov N.A., Babakhin A.A., Martinov A.I. Adjuvant-free mouse model of bronchial asthma on causally relevant G6 allergen. II International immunology congress “IMD”. Moscow, 2007., p. 33. ryuchkov N.A., Khaitov M.R., Alexeev L.P. Multimeric MHC-peptide complexes: biomedical application. II International immunology congress “IMD”. Moscow, 2007, p.33
  39. Petrov RV, Khaitov MR, Andreev SM, Benevolenskii SV, Smirnova OV. Immunogenic properties of recombinant and synthetic peptides of Humanpapillomavirus. Dokl Biochem Biophys. 2008 Jul-Aug;421:185-90.
  40. Khaitov M.R., Akimov, V; Trofimov, D; Alekseev, L; Faizuloev, E; Nikonova, A; Zverev, V; Du Buske. siRNA induced inhibition of RSV replication in vivo. Allergy, 2008, v.63(s.88.), p.59.
  41. Kryuchkov, N; Bashkatova, Y; Litvin, L. Khaitov M.R. IgE immune response in vivo to timothy grass allergen. Allergy, 2008, v.63(s.88.), p. 256.
  42. Bashkatova Yu.N., Petrukhina A.O., Andreev S.M., Kryuchkov N.A., Khaitov M.R. Abstract. An assay to detect IL-4d2.// Allergy, 2009, v.64, s. 90, p.45.
  43. Khaitov MR, Laza-Stanca V, Edwards MR, Walton RP, Rohde G, Contoli M, Papi A, Stanciu LA, Kotenko SV, Johnston S. L. Article. Respiratory Virus Induction of Alpha- Beta- and Lambda-interferons in Bronchial Epithelial Cells and Peripheral Blood Mononuclear Cells. Article.// Allergy, 2009, v.64(3), p.375-386.
  44. Khaitov M.R., Bashkatova Y.N., Andreev S.M. The developmtnt of interleikin-4 splicing from IL-4δ2 ELISA assay. Abstract.// Abstract book EAACI/GA2LEN Summer Allergy School, 2009, Norwich, United Kingdom, 23-25 July.p21.
  45. Khaitov M.R., Trofimov D.U., Alexseev L.P. Development of new nanobiotechnological tools for the diagnosis and treatment RSV. Abstract. //Allergy. 2009.v. 64,S. 90,p. 498.
  46. Kryuchkov N, Babakhin A, Bashkatova Y, Martynov A, Khaitov M. The novel acute adjuvant-free mutine model of bronchial asthma induced by timothy pollen allergen. Abstract. //Allergy. 2009.v. 64,S. 90,p. 310.
  47. Litvin L.S., Babakhin A.A, Barsejan G.G., Ivanova A.S., Khaitov M.R. Characterization of a short-term adjuvant-free asthma model in BALB/c mice. Abstract.// Allergy, 2009, v.64, S.90, p.310.
  48. Nikonova A., Lobodanov S., Oksanich A., Claas E. C.J., Zverev V., Faizuloev E. Use of a multiplex real-time PCR for differential diagnosis of respiratory viral infections. Abstract. // Abstract book of the Annual ERS congress, 2009, s.590.
  49. Андреев С.М., Башкатова Ю.Н., Петрухина А.О, Дубинкин И.В., Васильев А.М., Абрамов В.М., Куликова Н.Л., Хаитов М.Р. IL-4δ2 человека: структура и количественный анализ. // Иммунология,2009,№6, с.365-370.
  50. Долбин А.Г., Минина М.Г., Сергеев И.В., Кофиади И.А, Хаитов М.Р., Трофимов Д.Ю., Болдырева М.Н., Алексеев Л.П. Новые возможности поиска HLA-совместимых доноров для реципиентов листа ожидания почечного трансплантата. // ФИПИС,2009, №5, с.13-16.
  51. Хаитов М.Р., Акимов В.С., Файзулоев Е.Б., Никонова А.А., Трофимов Д.Ю., Алексеев Л.П., Карамов Э.В., Зверев В.В. Разработка новых нанобиотехнологических конструкций для профилактики излечения респираторно-синцитиальной вирусной инфекции. //Медицинская наука и практика,2009,№1, с.61-63.
  52. Хаитов М.Р. , Литвин Л.С. , Шиловский И.П., Башкатова Ю.Н., Мазуров Д.В., Файзулоев Е.Б. , Зверев В.В. Разработка и изучение наноструктур, обладающих РСВ-специфической противовирусной активностью invivo. Физиология и патология иммунной системы. том 13, №6 за 2009 год, стр. 3-7.
  53. Khaitov M.R., Shilovskiy I.P., Khaitov R.M. Type III interferons. Интерфероны третьего типа. Suc. Mod. Biol. 2010. v. 130, p. 147-153.
  54. Khaitov M.; Babakhin A.; Shilovsky I.; Kozmin L.; Andreev I.; Martynov A. Experimental specific I immunotherapy with Timpol decreases allergic sensitisation and airway inflammation in mice. Eur J Allergy Clin. Immunol. 2010 V. 65. P. 259.
  55. Shilovskiy I.; Babakhin A.; Zaitsev I.; Andreev I.; Kozmin L.; Martynov A.; Khaitov M. Development of experimental hyposensitisation with Timothy grass pollen extract in adjuvant-free IgE-mediated murine model of asthma. Eur J Allergy Clin Immunol. 2010. V. 65. P. 269.
  56. Musa Khaitov, Alexandr Babakhin, Igor Shilovsky, Igor Andreev, Leonid Koz’min, Alexandr Martynov. Experimental specific immunotherapy with timpol decreases allergic sensitization and airway inflammation in murine model of bronchial asthma. Eur Respir J 2010. V. 36. P. 5647.
  57. Kryuchkov NA, Bashkatova YN, Khaitov MR. Biological models of IgE-dependant bronchial asthma methodology and perspectives. Vestnik RAMS. 2010, №7, p. 22-28.
  58. Kryuchkov NA, Babakhin AA, Bashkatova YN, Martynov AI, Khaitov MR. New acute adjuvant-free murine model of bronchial asthma. Int Immunol 2010, volume 22, supp.number 1, iv.101.
  59. Aleksandra Nikonova, Stephanie Traub, Musa Khaitov, Luminita Stanciu, Sebastian Johnston. Suppressed rhinovirus (RV) induced type III interferon production in alternatively activated macrophages. Eur Respir J 2010. V. 36. P. 4344.
  60. Shilovskiy I.P., Mazurov D.V., Khaitov M.R. The Development of Vector Constructions for Respiratory Syncitial Virus (RSV) P-Gene Silencing. Path. Phiziol. Exp. Ther. 2010,v. 4, p. 11-1
  61. Bashkatova YN, Petrukhina AO, Kryuchkov NA, Khaitov MR, Andreev SM. Immune response to nanomaterials: fullerene C60. Allergy 2010. volume 65, supplement s92.
  62. Khaitov MR, Babakhin AA, Shilovsky IP, Andreev IV, Koz’min IP. Specific immunotherapy (SIT) with Timpol decreases allergic sensitization and airway inflammation in mice. Int Immunol 2010,volume 22, supplement 1, iv105.
  63. Шиловский И.П., Мазуров Д.В, Хаитов М.Р. Разработка векторных конструкций для сайленсинга Р-гена респираторного синцитиального вируса. Патологическая физиология и экспериментальная терапия, 2010, № 4 стр. 11-16.
  64. Шиловский И.П., Мазуров Д.В., Файзулоев Е.Б. , Хаитов М.Р. shRNA опосредованное ингибирование репликации РСВ. Сообщение №1: Создание векторных конструкций для сайленсинга гена P. Физиология и патология иммунной системы. Иммунофармакогеномика”, 2010 г., Т.14, №7, стр. 7-16.
  65. Хаитов М.Р., Литвин Л.С., Шиловский И.П., Башкатова Ю.Н., Файзулоев Е.Б., Зверев В.В. Интерференция РНК. Новые подходы к разработке противовирусных препаратов. Иммунология, 2010, № 2, том 31, стр. 69-76.
  66. Хаитов М.Р., Шиловский И.П., Хаитов Р.М. Интерфероны третьего типа // Успехи совр. биологии. Т 130. № 2. С. 147-153.
  67. Крючков Н. А., Башкатова Ю. Н., Хаитов М. Р. Биологические моделиIgE-зависимой бронхиальной астмы: методологические особенности и перспективы применения . Вестник РАМН, 2010,7,стр 22-28.
  68. Бабахин А.А., Шиловский И.П., Литвин Л.С., Андреев И.В., Козмин Л.Д., Мартынов А.И., Хаитов М.Р. Экспериментальная аллерген-специфическая иммунотерапия аллерготропином «Тимпол» на модели IgE-зависимой бронхиальной астмы // Российский аллергологический журнал. 2010. № 5. В.1. С. 16-17.
  69. Царев С.В, Хаитов М.Р. Респираторные вирусы у больных микоаллергозами. Материалы Национальной конференции «Аллергология и клиническая иммунология – практическому здравоохранению». Российский аллергологический журнал, 2010, №1, выпуск 1, с. 193-194.
  70. Khaitov M., Shilovski I., Mazurov D., Faizuloev E. Short hairpin RNA mediated inhibition of respiratory syncitial virus replication in vitro // Allergy. 2011. V. 66, Suppl. 94. P. 13.
  71. Shilovskiy I., Babakhin A., Andreev I., Kozmin L., Khaitov M., Martynov A. Allergen-specific modulation of allergic immune responses with low doses of timpol preparations in an experimental IgE-med iatedmurine model of asthma // Allergy. 2011. V. 66, Suppl. 94. P. 445.
  72. Nikonova, S. Traub, E.B. Faizuloev, S. L. Johnston, M. Khaitov, L. A. Stanciu. M2 macrophages produce less type I and III IFNs upon human rhinovirus (HRV) infection and have a higher viral load than M1 macrophages. European Respiratory Society Annual Congress 24-28 September 2011. Abstract book.
  73. Bashkatova E., Shilovski I., Bashkatova Yu., Khaitov M., Andreev S. Adducts of fullerene with basic amino acids as delivery vectors. Joint International conference. Abstract book “Advanced Carbon Nanostructures” (ACN’2011) St.Petersburg, Russia, July 4-8, 2011. Abstract book, P.248.
  74. Шиловский И.П., Мазуров Д.В., Шершакова Н.Н., Хаитов М.Р. Экспериментальное подавление экспрессии провоспалительного интерлейкина-13 invitro синтетическими siRNA. Российский аллергологический журнал, Труды Межрегионального форума, Казань, 2012, №5, вып.1, с.295.
  75. Musa R. Khaitov, Ilya A. Kofiadi, Dmitrii V. Mazurov, Alexandra Nikonova, Igor P. Shilovskii. “Inhibition of Hepatitis C virus RNA replication by siRNAs”. Abstract book of the 19th International Symposium on Hepatitis C Virus and Related Viruses.2012, p.298.
  76. Андреев С.М., Башкатова Е. Н., Бабахин А.А., Хаитов М.Р. Молекулярные мишени для аллергоспецифической иммунотерапии. Синтетические пептиды, моделирующие В- и Т-клеточные эпитопы мажорного аллергена пыльцы березы Bet v 1. // Российский аллергологический журнал, Труды Межрегионального форума, Казань, 2012, №5, вып.1, с. 12-13.
  77. В.Г. Кукес, Д. А Сычев, В.В. Смирнов, М.Р. Хаитов, Р.М. Хаитов, Р.В.Петров. Персонализированная медицина в клинической фармакологии: от мифа к реальной клинической практике. //Физиология и патология иммунной системы. Иммунофармакогеномика- 2013.- Т.16. -№1. с.3 – 13.
  78. Babakhin A., Shershakova N., Shilovskiy I., Kozmin L., Tarasov S., Sekirina M., Gorbunov E, Epstein O., Khaitov M. Efficacy of a mixture of release-active rabbit polyclonal antibodies to histamine, bradykinin and morphin in the treatment of mouse model of allergic asthma. // Allergy – 2013. – V.68.- s.97. – P.27.
  79. Shilovskiy I., Shershakova N., Nikonova A, Dmitrieva O., Babakhin A., Khaitov M. Synthetic siRNAs decrease allergic inflammation, airway hyperresponsiveness and respiratory syncytial virusload in a murine model of respiratory syncytial virus-exacerbated // Allergy – 2013. – V.68.- s.97. – P. 56.
  80. Shershakova N., Babakhin A., Bashkatova E, Shilovskiy I., Khaitov M. Preventive allergen-specific immunization reduces the symptoms in a murine model of atopic dermatitis // Allergy – 2013. – V.68.- s.97. – P.158.
  81. И.П. Шиловский, А.А. Никонова, И.А. Кофиади, М.Р. Хаитов Применение антисмысловых технологий для разработки препаратов, подавляющих активность вируса гепатита С. //Химическая и биологическая безопасность. Специальный выпуск.- 2013.-с.-157-162.
  82. Кoloskova O., Shilovskiy I.,. Andreev S, Khaitov M. Design of gene delivery system based on lipopeptides //Allergy 2013.-V.68.- s.97.- P.343.
  83. Khaitov M., Nikonova A., Jackson D., Traub S., Trujillo-Torralbo M.B., del Rosario A., Mallia P., Stanciu L.A., Johnston S.L. The role of M1 and M2 macrophages during rhinovirus-induced asthma exacerbation. Allergy, 2013. – V.68.- s.97. – P.56.

 

 

Management of scientific grants and projects:

№ Title of works Cost of work (million rubles) Source of funding Period
1 “Development of new approaches, diagnosis and treatment of viral infections” 0,3 Grant of  President of  the Russian Federation for state support of young Russian scientists (MK-1555.2008.7)

 

2008-2009

 

2 “Development and testing of nanostructures possessing antiviral properties against socially significant respiratory viral infections” 2 Grant of the President of the Russian Federation for state support of young Russian scientists – doctors

(МД-2284.2009.7)

2009-2010
3 “Development of the drug, which has antiviral properties against hepatitis C virus, acting on the basis of the mechanism of RNA interference” 5 Federal Target Programme

State contract

№ 22.063.11.6

from 31.05.2011

2011
4 “Development of means for targeted delivery of therapeutic and prophylactic drugs, working on the basis of the mechanism of RNA interference” 2 Grant of the President of the Russian Federation for state support of young Russian scientists – doctors (МД-774.2011.7) 2011-2012
5 “Development of  the  tools working on the basis of the mechanism of RNA interference whit  antiviral and anti-inflammatory effects for the asthma treatment and complicating its viral infections” 6,0

 

Federal Target Programme

State contract

№ 16.512.11.2257

from 10.08.2011

2011-2012
6 “Development of biomolecular complexes for targeted delivery of the drug into the cell, acting on the basis of the mechanism of RNA interference and has antiviral properties against hepatitis C virus” 13,78

 

Federal Target Programme

State contract

№ 22.071.12.6 from 04.05.2012

2012-2014
7 “Preclinical studies of a medication for combined therapy of hepatitis C, based on natural and synthetic regulators of the immune response” 44 Federal Target Programme

State contract

№ 16.N08.12.1003 from 17.08.2011

2011-2013
8 “Preclinical studies of the drug on the basis of the mechanism of RNA interference for the treatment of bronchial asthma” 44 Federal Target Programme

State contract

№14N08.12.0015

from 08.08. 2013

 

2013-2015
9 “Synthesis based  on hapten nicotine alkaloids and their use in the preparation of conjugated antigens” 0,35 Project included to the program of the Presidium of RAS “Fundamental science-for medicine”

Contract №30

from 01.09.2012

2012
10 “Optimization of haptens by the directed synthesis on the basis of nicotine alkaloids and receiving conjugated antigens with pronounced immunogenicity” 0,35 Project included to the program of the Presidium of RAS “Fundamental science-for medicine”

Contract №30  from 01.07.2013

2013
11 “Development of experimental drug based on water-soluble form fullerene therapy of atopic dermatitis”

 

 

26 Federal Target Program

“Research and development on priority directions of scientific-technological complex of Russia for 2014 – 2020 years”

Contract # 14.604.21.0059 from 27 June 2014

2014 – 2016
12 “Design of heterovalent allergoids based on synthetic T and B cell mimotopes of major birch pollen allergen Bet v1 and evaluation of its desensitizing activity in an animal model” 0,7 Russian Foundation for Basic Research

Contract # HK 15-04-07635/15 from 04 February 2015

2015
13 “Preclinical studies of a medicament for the treatment of hepatitis C viral RNA-based interference” 44 Federal Target Programme

State contract

№14.N08.12.0035

from 11.06.2015

 

2015 – 2017
14 “Studying the role of IL-33 with virus-induced exacerbations of asthma” 15 Grant “Russian Science Foundation”
Contract # 14-15-00894
from 16.06.2014
2014 – 2016

 

 

Editorial board member

Kofiadi Ilya Andreevich, PhD, DSc, Professor of Russian Academy of Sciences

https://orcid.org/0000-0001-9280-8282

H-index: 8

Kofiadi I.A. is a specialist in the field of genetics of immune response, cell physiology, molecular immunology, as well as the author of more than 60 scientific papers, 2 monographs, 2 patents for inventions and utility models.

The main scientific results of Kofiadi I.A. were obtained by studying the mechanisms of genetic control of immune response in normal and pathological conditions. He investigated the immunogenetic basis of individual human reaction to negative environmental factors; established the population distribution of clinically significant markers of cancer, infectious and autoimmune diseases; created more than 50 test-systems to characterize the activity of immune response genes, diagnose primary immunodeficiency, determine risk factors for diseases, monitor viral infections in persons with immune response disorders caused by immunosuppression, as well as the impact of immuno- and genotoxic factors.

Kofiadi I.A. is a developer of a hardware-diagnostic complex for the evaluation of genetic and functional indicators of health, as well as the technology of detection of underrepresented copies of DNA, used in the early diagnosis of the graft rejection and the detection of somatic mutations, associated with the development of tumors. The results of scientific and practical research carried out with the participation and under the guidance of Mr. I.A. Kofiadi were awarded by the Government of the Russian Federation in the field of science and technology for 2017.

Under the leadership of I.A. Kofiadi, two PhD projects were defended. He is an active teacher, is the author of a course of lectures within the framework of the program of training of postgraduate students of the Federal State Budgetary Institution “National Research Center Institute of Immunology” of the Federal Medical and Biological Agency of Russia, is a co-author of the textbook “PCR in real time”, a participant of translation of the IX edition of the textbook “Genes” by Benjamin Lewin.

Kofiadi I.A. is a member of the Scientific and Dissertation Councils of the Federal State Budgetary Institution “NRC Institute of Immunology” FMBA of Russia, a member of the European Federation of Immunogenetics and the Russian Scientific Society of Immunologists.

Editor-in-chief Ilyina Natalia Ivanovna, MD, PhD, professor

https://orcid.org/0000-0002-3556-969X

Scopus author ID: 6701421071 

h-index 28

Ilina Natalia graduated from the Moscow Medical Dental Institute in 1973, from 1974 to 1980 she worked as a therapist in outpatient department in Moscow. In 1980-1982 she studied in clinical residency at the Institute of Immunology of the Ministry of Public Health, Moscow, Russia.

Since 1982 she works as the doctor allergist–immunologist, Deputy chief doctor,  at  present time – Chief doctor and Deputy Director for clinical work at the National Research Center “Institute of Immunology” Federal Medical Biological Agency, Moscow, Russia.

In 1997 she completed her PhD study “Allergopathology in different regions of Russia according to the results of clinical and epidemiological studies”, and in 2002 has become professor of medicine.

Ilina Natalia is a Vice-President of Russian Association of Allergologists and Clinical Immunologists (RAACI) and  member of  European Academy of Allergy and Clinical Immunology (EAACI),  as well as of scientific and practical Council of Ministry of Public Health of Russian Federation.

She  is member of Scientific and Dissertation councils of the Institute of Immunology, professor of Immunology Department of Russian State Medical University.

Under the leadership of N. Ilina the clinic has become a leading institution in the country on the problems of allergy and immunology.

  1. Ilina is an author of more than 250 scientific articles published in Russian periodicals and authoritative scientific journals. Under her leadership four doctoral and seven master’s dissertation have been defenced .
Главный редактор Ильина Наталья Ивановна, доктор медицинских наук, профессор

https://orcid.org/0000-0002-3556-969X
Scopus author ID: 6701421071
Индекс Хирша 28

Ильина Наталья Ивановна окончила Московский стоматологический медицинский институт в 1973 г. С 1974 г. по 1980 г. работала терапевтом в поликлинике № 101 г. Москвы. В 1980-1982 гг. обучалась в клинической ординатуре на базе ГНЦ “Институт иммунологии” МЗ СССР.

С 1982 года работает в ГНЦ “Институт иммунологии” МЗ СССР: с 1982 по 1989 гг. врачом аллергологом-иммунологом научно-консультативного отделения клиники; с 1989 по 1997 гг. – заместителем главного врача клиники, с 1997г. – по настоящее время работает заместителем директора по клинической работе – главным врачом ФГБУ “ГНЦ “Институт иммунологии” ФМБА России.

В 1992 г. защитила диссертацию на соискание ученой степени кандидата медицинских наук, а в 1997 г. защитила диссертацию на соискание ученой степени доктора медицинских наук, в 2002 г. получила звание профессора по специальности аллергология и иммунология. Под руководством Н.И. Ильиной защищено 4 докторских и 7 кандидатских диссертаций.

Н. И. Ильина – является членом Российской Ассоциации Аллергологов и Клинических Иммунологов – РААКИ, Европейской Академии Аллергологии и Клинической Иммунологии – EAACI, а также научно-практического совета Министерства здравоохранения РФ,  входит в состав Ученого и Диссертационного советов Института иммунологии.

Н. И. Ильина – профессор кафедры иммунологии Российского Государственного медицинского университета, вице-президент Российской ассоциации аллергологов и клинических иммунологов. В 2003 году ей присвоено почетное звание «Заслуженный врач РФ».

Под руководством Н.И. Ильиной клиника Института иммунологии стала ведущим учреждением страны по проблемам аллергологии и иммунологии, проводником эффективной работы по апробации и внедрению в практическую медицину созданных в Институте новых диагностических и лечебных средств, новых методов лечения иммунозависимых и аллергических заболеваний.

Ильина Н.И. является автором более 250 статей по актуальным проблемам клинической иммунологии и аллергологии.

Vice-editor- in chief Fedenko Elena, MD, PhD, professor

https://orcid.org/0000-0003-3358-5087

Scopus author ID: 6603386923

H-index 12

Elena Fedenko graduated from the  First Moscow Medical University named after I. M. Sechenov in 1980,   completed her clinical scientist fellowship training in clinical allergology and immunology at the Institute of Immunology in Moscow, Russia, in 1987. She completed her PhD study “Differential approach to immunotherapy of atopic dermatitis” at the National Research Center “Institute of Immunology” Federal Medical Biological Agency in Moscow, Russia, in 2000 and in 2005 has become professor of medicine.

Since 2005 up to now E. Fedenko is the Head of Skin Allergy Department in the same Center.

Professor E. Fedenko has a specific interest in allergic diseases, especially in atopic dermatitis, urticaria, allergic contact dermatitis, as well as respiratory allergies – bronchial asthma, allergic rhinitis.

Elena Fedenko is a member of Russian Association of Allergologists and Immunologists (RAACI) and  European Academy of Allergy and Clinical Immunology (EAACI), trainer of International network of medical Universities and departments of postgraduate medical education in the field of Molecular Allergology and Immunology (INUNIMAI) . She has been invited to speak at plenary, keynote, symposia and expert discussion sessions, workshops and industry sponsored meetings at the, as well as workshops  at the  . She is an author of more than 180 scientific articles published in Russian periodicals and authoritative scientific journals such as Allergy, Pediatric Allergology and Immunology, PLoS ONE, Self/Nonself: Immune Recognition and Signaling. International Immunopharmacology,  Clinical and Experimental Allergy.

She is a vice-editor- in chief of the Russian Allergological Journal.

Заместитель главного редактора Феденко Елена Сергеевна, доктор медицинских наук, профессор

https://orcid.org/0000-0003-3358-5087

Scopus author ID: 6603386923

Индекс Хирша 12

Феденко Елена Сергеевна, окончила  1 Московский медицинский институт им. И.М. Сеченова в 1980г. и поступила в клиническую ординатуру, а потом и в очную аспирантуру  по аллергологии и иммунологии в Институт иммунологии. В 1987г. защитила кандидатскую диссертацию «Клинико-иммунологическая характеристика тяжелого атопического синдрома и экстракорпоральные методы лечения» а в 2000г.  –  докторскую диссертацию на тему «Дифференцированный подход к иммунотропной терапии атопического дерматита». В 2005 г. получила звание профессора. С 2005 года по настоящее время заведует отделением аллергии и иммунопатологии кожи ФГБУ «ГНЦ Институт иммунологии» ФМБА России.

Является лауреатом премии «Ленинского комсомола» 1987г., имеет  серебряную медаль ВДНХ за научную работу. Является автором  более 180 научных трудов, в том числе 9 монографий, по различным аспектам клинической аллергологии и иммунологии, опубликованных как в России,  так и за рубежом, имеет 2 авторских свидетельства на изобретения (в соавторстве) «Способ лечения гнойной кожной инфекции при атопическом дерматите» и «Способ лечения глюкокортикостероидзависимых атопических заболеваний» и один патент на изобретение.

Область научных интересов: аллергические и иммуноопосредованные  заболевания –атопический дерматит, аллергический контактный дерматит, пиодермии, крапивница, а также респираторные аллергические заболевания – аллергический ринит, бронхиальная астма и другие.

Феденко Е.С. является членом Российской Ассоциации Аллергологов и Клинических Иммунологов – РААКИ, Европейской Академии Аллергологии и Клинической Иммунологии – EAACI, тренером Международной платформы университетов по молекулярной аллергологии и иммунологии INUNIMAI, Вена, Австрия, регулярно принимает участие в качестве лектора и эксперта по проблеме аллергических заболеваний, в частности, аллергодерматозов, в работе научных конференций, конгрессов, съездов по аллергологии и иммунологии, как в России, так и за рубежом. Являлась координатором и ответственным исполнителем по созданию Российского национального консенсуса по атопическому дерматиту (2002г.), а также координатором, научным редактором и автором Национального согласительного документа по крапивнице (2008г.). Под руководством Феденко Е.С. защищено 9 кандидатских и 2 докторских диссертации  по специальности 14.03.09 клиническая иммунология,  аллергология.

С момента основания является заместителем главного редактора Российского аллергологического журнала.

Член редакционного совета

Царев Сергей Владимирович,

доктор медицинских наук

https://orcid.org/0000-0003-3358-5087

Scopus author ID: 57201616650

Индекс Хирша 7

Царев Сергей Владимирович, окончил  Московский медицинский стоматологический институт им. Семашко в 1985 г. В 1992 г закончил Клиническую ординатуру при Главном управлении медико-биологических и экстремальных проблем по специальности аллерголог-иммунолог. В 1997 г. защитил кандидатскую диссертацию «Особенности транспорта ионов кальция в лимфоцитах больных бронхиальной астмой», а в 2010 г.  –  докторскую диссертацию на тему «Роль микромицетов в аллергопатологии. Современные подходы к диагностике и терапии».

С 1992 г работает в Институте иммунологии. С 2004 г – старший научный сотрудник, а с 2010 года по настоящее время – ведущий научный сотрудник ФГБУ «ГНЦ Институт иммунологии» ФМБА России.            С 2005 по 2017 г – доцент кафедры Клинической аллергологии и иммунологии лечебного факультета Московского государственного медико-стоматологического университета.

Является автором  более 100 научных трудов по различным аспектам клинической аллергологии и иммунологии, опубликованных как в России,  так и за рубежом,  методических рекомендаций ФМБА «Диагностика, мониторинг и коррекция иммунодефицитных состояний у высококвалифицированных спортсменов», «Диагностика, лечение и профилактика сенсибилизации к грибам у больных аллергическими заболеваниями». В 2008 году получен патент на изобретение «Способ лечения полипозного риносинусита».

Область научных интересов: аллергические и иммуноопосредованные  заболевания – аллергический ринит, бронхиальная астма, микоаллергозы, атопический дерматит, пиодермии, крапивница и другие.

Царев С.В регулярно принимает участие в качестве лектора и эксперта по проблеме аллергических заболеваний, в работе научных конференций, конгрессов, съездов по аллергологии и иммунологии, как в России, так и за рубежом.

Индекс Хирша – 16.

Лусс Людмила Васильевна, 06 июня 1941 г.р.

Докт.мед.наук, профессор, академик РАЕН (Российская Академия Естественных наук),

Лауреат Премии Правительства Российской Федерации в области науки и техники

Окончила с отличием 2 МОЛГМИ (второй Московский ордена Ленина государственный медицинский институт) им. Н.И.Пирогова.

С 1968 – по 1971 – аспирантура на кафедре патологической физиологии (зав. кафедрой – академик А.Д. Адо)

1971 г. защитила кандидатскую диссертацию по теме: «Вопросы аллергии к коровьему молоку у детей». После защиты диссертации работала ассистентом на кафедре патфизиологии 2 МОЛГМИ им. Н.И.Пирогова. (зав. кафедрой – академик А.Д. Адо)

С 1981 по настоящее время работает в ФГБУ «ГНЦ Институт иммунологии» ФМБА России. Зав. каучно-консультативным отделением ФГБУ «ГНЦ Институт иммунологии» ФМБА России ).

В 1993 году защитила докторскую диссертацию по теме Аллергия и псевдоаллергия в клинике по специальности 14.03.09 клиническая иммунология,  аллергология.

В 1996 году присвоено ученое звание профессора по специальности аллергология и иммунология.

В 2011 году присуждена Премия Правительства Российской Федерации в области науки и техники

Опубликовано свыше 500 публикаций в виде монографий (12), методических и клинических рекомендаций, пособий для врачей, статей и тезисов по проблемам клинической аллергологии и иммунологии, посвященные вопросам диагностики и терапии лекарственной и пищевой аллергии, влиянию экологических факторов и климата на формирование, особенности фенотипических вариантов и прогноз аллергических (аллергический ринит, БА) и других иммуно-зависимых заболеваний,  проблем перекрестной и скрытой аллергии, вторичным иммунодефицитным состояниям и др.

Лусс Л.В. является членом Российской Ассоциации Аллергологов и Клинических Иммунологов – РААКИ, Европейской Академии Аллергологии и Клинической Иммунологии – EAACI, регулярно принимает участие в качестве лектора по проблемам аллергических заболеваний, в частности, эпидемиология аллергических заболеваний, пищевой аллергии,  принимает участие в работе научных конференций, конгрессов, съездов по аллергологии и иммунологии в России.

Под руководством Л.В. Лусс защищены 7 докторских и 24 кандидатских диссертаций по специальности 14.03.09 клиническая иммунология,  аллергология.

Членство в редколлегиях научных журналов:

1. Член редколлегии научно-практического медицинского рецензируемого журнала Российский Аллергологический журнал,

2. Главный редактор журнала «Доктор.Ру». Аллергология Дерматология.

3. Член редколлегии журнала Физиология и патология иммунной системы. Иммунофармакогеномика,

4. Главный редактор журнала Эвффекивная Фармакотерапия.

5. Член редколлегии научно-практического медицинского рецензируемого журнала Аллергология и иммунология в педиатрии.

Имеет 4 авторских свидетельства на изобретения (в соавторстве) «Способ лечения гнойной кожной инфекции при атопическом дерматите»

«Способ лечения полипозного риносинусита» , «Комплект средств для диагностики аллергии»  «Способ дифференциальной диагностики гиперчувствительности к яду пчелы (apis mellifera)»

Дополнительная информация: Профессор кафедры клинической аллергологии и иммунологии ФПДО МГМСУ им А.И. Владимирова с 2005 года, профессор кафедры персонализированной иммунологии и иммунодиагностики  ФГБОУ ДПО ИПК ФМБА.

публикаций 173, цитирование 1908, Хирши 13

Латышева Татьяна Васильевна 1951 года рождения, окончила 2 МОЛГМИ им. Н.И. Пирогова в 1975 году.  С 1975 г по 1980 г работала терапевтом.  В 1980-1982 гг. обучалась в  клинической ординатуре по анестезиологии-реаниматологии ЦОЛИУВ на базе ГКБ им. С.П. Боткина. С 1984 года работает в клинике Института Иммунологии РФ В 1990 году Латышева Т.В. защитила диссертацию на соискание ученой степени на кандидата медицинских наук  на тему «Острые токсико- аллергические реакции на медикаменты»,  в 1997 году защитила диссертацию на соискание ученой степени доктора медицинских наук  на тему «Тактика иммунокоррекции в интенсивной терапии аллергических и иммунопатологических состояний».  сначала в должности врача анестезиолога-реаниматолога. С 1984 года – заведующей отделением интенсивной терапии, с 1998 года является заведующей отделением иммунопатологии взрослых и отделением интенсивной терапии  ГНЦ Института иммунологии ФМБА России.

В  2003 г. получила звание профессора по специальности аллергология и иммунология. Имеет авторское свидетельство на «Способ лечения гнойной инфекции при атопическом дерматите». В 2009 г. присвоено почетное звание «Заслуженный врач»,  в 2012 г. – получила диплом лауреата премии правительства РФ в области науки и техники за создание, организацию и внедрение системы иммунологического и аллергологического мониторинга для профилактики и лечения иммунозависимых социально значимых заболеваний

Т.В.Латышева является автором более 280 научных трудов по различным аспектам  клинической аллергологии и иммунологии и реаниматологии тяжелых аллергических состояний, опубликованных как в России, так и за рубежом.

Область научных интересов: аллергичекие и иммуноопосредованные заболевания: диагностика лекарственной аллергия, диагностика и лечение больных иммунодефицитами как первичными, так и вторичными, ургентные ситуации в аллергологии,  респираторные проявления аллергии: аллергический ринит, бронхиальная астма, атопический дерматит, пиодермии.

Латышева Т.В.  регулярно принимает  участие в качестве лектора и эксперта по проблемам аллергических и иммуноопосредованных заболеваний на конференциях и съездах как по клинической аллергологии и иммунологии, так и по реаниматологии. Участвовала в сессиях общего собрания Российской академии медицинских наук, принимала участие в международных конференциях и конгрессах. Принимает участие в комиссии по судебно-медицинской экспертизе смертных случаев, связанных с острыми аллергическими состояниями.

Т.В.Латышева является членом правления  Межрегиональной общественной организации инвалидов «Общество пациентов с первичным иммунодефицитом».

Под руководством Латышевой Т.В. защищено 14 кандидатских  и 1 докторская диссертация по специальности 14.03.09 клиническая иммунология, аллергология.

С момента основания журнала является членом редколлегии.

Member of the Editorial Board of Russian Journal of Allergy

Beltyukov Evgeny, MD, DSc, Professor of Department of Faculty Therapy, Endocrinology, Allergology and Immunology of Ural State Medical University

https://orcid.org/0000-0003-2485–2243

Beltyukov Evgeny Kronidovich graduated from Sverdlovsk State Medical Institute in 1977, completed internship in therapy at the Sverdlovsk Regional Clinical Hospital No. 1 (SOKB No. 1) in 1978. He specialized in clinical allergology at the Central Order of Lenin Institute for Advanced Medical Studies in 1978, then worked as an allergist at the allergology department of the Clinical Hospital No. 1, and the head of the pulmonology department of the City Clinical Hospital No. 6 in Ekaterinburg. He passed his PhD defense on bronchial asthma in 1994. He headed the Department of Allergology and Immunology GBUZ SO SOKB №1 from 2001 to 2006. He defended his doctoral thesis “Medical and economic effectiveness of modern technologies for the diagnosis and treatment of bronchial asthma at the regional and local level” at the National Research Center “Institute of Immunology” Federal Medical Biological Agency in Moscow, Russia, in 2004.

Research interests: allergic rhinitis, bronchial asthma, atopic dermatitis, urticaria, epidemiology and pharmacoeconomics of allergic and bronchopulmonary diseases.

Beltyukov E.K. was the initiator and developer of regional and local programs to combat bronchial asthma (BA) in the Sverdlovsk region. He introduced assistance programs for patients with asthma in closed administrative-territorial units of Lesnoy and Novouralsk, which led to a decrease in mortality from asthma and was accompanied by a significant economic effect. He has been conducting population-based studies on the prevalence of bronchial asthma and allergic rhinitis in the Sverdlovsk region from 2000 to the present.

He has been working as a professor at the Department of Faculty Therapy, Endocrinology, Allergology and Immunology of Ural State Medical University since 2007, overseing advanced training courses and professional retraining in allergology and immunology, clinical pharmacology. He has been the chief external expert of allergy and immunology at the Ministry of Health of the Sverdlovsk Region since 2013; he has been a chief external expert of allergy and immunology at the Ministry of Health of the Russian Federation in the Urals Federal District since 2016. He is the head of the Sverdlovsk regional branch of RAACI and a member of EAACI.

Evgeny Beltyukov conducts an active scientific and pedagogical activity. He is the author of 228 scientific publications, two inventions; participates in clinical trials; makes presentations at regional, national and international conferences and congresses. 7 PhD thesis were defended under the leadership of Beltyukov E.K.

Член редакционного совета РАЖ Бельтюков Евгений Кронидович

доктор медицинских наук, профессор кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России

https://orcid.org/0000-0003-2485–2243

Бельтюков Евгений Кронидович в 1977 г. окончил Свердловский Государственный медицинский институт, в 1978 г. – интернатуру по терапии на базе Свердловской областной клинической больницы №1 (СОКБ №1); в 1979 г. специализировался по клинической аллергологии в Центральном ордена Ленина институте усовершенствования врачей, затем работал врачом аллергологом в аллергологическом отделении СОКБ №1, заведующим пульмонологическим отделением ГКБ №6 г. Екатеринбурга.  В 1994 г. защитил кандидатскую диссертацию по бронхиальной астме. С 2001 по 2006 гг. руководил отделением аллергологии и иммунологии ГБУЗ СО СОКБ №1. В 2004 г. в ГНЦ Институте иммунологии ФМБА России защитил докторскую диссертацию на тему «Медико-экономическая эффективность современных технологий диагностики и лечения бронхиальной астмы на региональном и локальном уровне».                                                     Область научных интересов: аллергический ринит, бронхиальная астма, атопический дерматит, крапивница, эпидемиология и фармакоэкономика аллергических и бронхолегочных заболеваний.

Бельтюков Е.К. являлся инициатором и разработчиком региональной и локальных программ по борьбе с бронхиальной астмой (БА) в Свердловской области. Внедрил программы помощи больным БА в закрытых административно-территориальных образованиях Лесной и Новоуральск, что привело к снижению смертности от астмы и сопровождалось значительным экономическим эффектом. С 2000 г. по настоящее время проводит популяционные исследования распространенности бронхиальной астмы и аллергического ринита в Свердловской области.

С 2007 г. работает профессором кафедры факультетской терапии, эндокринологии, аллергологии и иммунологии ФГБОУ ВО УГМУ Минздрава России, курирует циклы повышения квалификации и профессиональной переподготовки по аллергологии и иммунологии, клинической фармакологии. С 2013 г. является главным внештатным  специалистом аллергологом-иммунологом Министерства здравоохранения Свердловской области, с 2016 г. – главным внештатным специалистом аллергологом-иммунологом МЗ РФ в Уральском федеральном округе. Является руководителем Свердловского областного отделения РААКИ и членом EAACI.

Ведет активную научно-педагогическую деятельность; является автором 228 научных публикаций, двух изобретений; участвует в клинических исследованиях; выступает с докладами на региональных, национальных и международных конференциях и конгрессах. Под руководством Бельтюкова Е.К. защищено 7 кандидатских диссертаций, в том числе по специальности 14.03.09 – клиническая иммунология, аллергология.

Director of the Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan

Tamarakhon Aripova,

PhD, professor, academician of the Academy of Sciences of Uzbekistan.

 Tamarakhon Aripova, in 1976 she graduated with honors from the medical faculty of the Tashkent State Medical Institute. In 1979, in Moscow, she successfully defended her PhD dissertation on “The effect of methylcholanthrene and carcinogenesis induced by him on the individual stages of immunogenesis”, and in 1992, she successfully defended her doctoral dissertation in Moscow on the subject: “Cellular mechanisms and correction of immunodeficiency in cell growth”. In 2007, she was awarded the academic title of professor and in 2017 received the title of academician of the Academy of Sciences of the Republic of Uzbekistan. From 2003 to the present, he heads the Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan.

Aripova T. published over 370 scientific works, including 10 monographs, 5 patents, 2 international copyright certificates, 45 methodological recommendations.

She prepared 7 doctors and 13 candidates of sciences in the specialties “Allergology and Immunology”. Since 2013, Aripova T. Head of the Scientific Council – code 16.07.2013.Tib.16.01 on the defense of dissertations in the following specialties: Medical genetics-14.00.20; Allergology and immunology-14.00.36; Molecular biology. Molecular Genetics. Molecular Biotechnology-03.00.03.

Research interests: primary and secondary immunodeficiencies, allergic and autoimmune immuno-mediated diseases, cell technology, regenerative medicine, immunogenetics.

In 2011, under her leadership, for the first time in Central Asia, an international global grant was received for the 7th EU framework program on the topic “Genetic studies of preeclampsia in Central Asian and European populations” totaling more than $ 5 million.

In 2012, Aripova T. becomes the leader on the part of Uzbekistan of the collabarative international project “An open cross-sectional study of the association of the mutational load of the human mitochondrial genome with carotid atherosclerosis (2012-2013)” of the Foundation for the federal target program “Scientific and scientific-pedagogical personnel of Russia”, through the Research Institute of General Pathology and Pathophysiology RAMS and Institute of Atherosclerosis, Skolkovo (Moscow, Russia).

Aripova T. from 2011 to 2017 was the chairman of the Association of Women Scientists “Olima” in Tashkent and a member of the Republican Association for the fight against breast cancer.

Under the leadership of Aripova T. joint research is being carried out with leading scientific centers of the Russian Federation: Moscow, St. Petersburg (Federal State Budget Scientific Institution Research Institute of Automotive Research named after DO Otto, Federal State Unitary Enterprise State Research Institute of Occupational Safety and Health, FMBA of Russia), Ivanovo, Novosibirsk.

She was awarded a commemorative medal dedicated to the 20th anniversary and 25th anniversary of Independence of the Republic of Uzbekistan; the Golden Medal and the Di Merito Diploma of the European Scientific and Industrial Chamber for exemplary professional work and great contribution to medicine; the Golden Medal of the Society of immunologists of countries CIS; diplomas of the Federation of Trade Unions of the Republic of Uzbekistan. In 2019, Aripova Tamara was awarded the Order of Labor Glory for outstanding labor achievements that contribute to raising the economy and culture, increasing the well-being of the people, maintaining peace and stability in Uzbekistan.

Директор Института иммунологии и геномики человека АН РУз
Арипова Тамарахон Уктамовна,
доктор медицинских наук, профессор, академик АН РУз.

Арипова Тамарахон Уктамовна, в 1976 году с отличием окончила лечебный факультет Ташкентского государственного медицинского института. В 1979 году в г. Москве успешно защитила кандидатскую диссертацию на тему «Влияние метилхолантрена и индуцированного им канцерогенеза на отдельные этапы иммуногенеза» а в 1992 году с успехом защитила докторскую диссертацию в г. Москве на тему: «Клеточные механизмы и коррекция иммунодефицита при клеточном росте». В 2007 году ей присвоено ученое звание профессора и в 2017 году получила звания академика АН РУз. С 2003 года по настоящее время возглавляет Институт иммунологии и геномики человека АН РУз.
Ариповой Т.У. опубликовано свыше 370 научных работ, в том числе 10 монографий, 5 па-тента, 2 международных авторских свидетельства, 45 методических рекомендаций.
Она подготовила 7 докторов и 13 кандидатов наук по специальностям «Аллергология и иммунология». С 2013 г. Арипова Т.У. возглавляет научный совет – шифр 16.07.2013.Tib.16.01 по защите диссертаций по следующим специальностям: Медицинская генетика-14.00.20; Аллергология и иммунология-14.00.36; Молекулярная биология. Молекулярная генетика. Молекулярная биотехнология-03.00.03.
Область научных интересов: первичные и вторичные иммунодефициты, аллергические и аутоиммунные иммуноопосредованные заболевания, клеточные технологии, регенеративная ме-дицина, иммуногенетика.
В 2011 году под ее руководством впервые в Центральной Азии был получен международ-ный глобальный грант 7 рамочной программы Евросоюза на тему «Генетические исследования преэклампсии в центрально-азиатских и европейских популяциях» на общую сумму более 5 млн. долларов США.
В 2012 Арипова Т.У. становится руководителем со стороны Узбекистана совместного меж-дународного проекта «Открытое кросс-секционное исследование ассоциации мутационной нагрузки митохондриального генома человека с каротидным атеросклерозом (2012-2013)» Фон-да федеральной целевой программы «Научные и научно-педагогические кадры России» через НИИ Общей патологии и патофизиологии РАМН И Институт атеросклероза, Сколково (Москва, Россия).
Арипова Т.У. с 2011 по 2017 гг. являлась председателем Ассоциации женщин-ученых «Олима» г.Ташкента и членом Республиканской ассоциации по борьбе с раком молочной желе-зы.
Под руководством Ариповой Т.У. проводятся совместные исследования с ведущими науч-ными центрами Российской Федерации: г. Москва, г. Санкт-Петербург (ФГБНУ НИИ АГиР им. Д.О. Отто, ФГУП “Гос.НИИ ОЧБ” ФМБА России), г.Иваново, г.Новосибирск.
Награждена памятной медалью, посвященной 20-летию и 25-летию Независимости Респуб-лики Узбекистан, «Золотой медалью» и Дипломом «Di Merito» Европейской Научно-промышленной палаты за образцовую профессиональную деятельность и большой вклад в меди-цину, “Золотой медалью” общества иммунологов стран СНГ, дипломами Федерации профсоюзов РУз. В 2019 году Арипова Тамара Уктамовна за выдающиеся трудовые заслуги, способствующие подъему экономики и культуры, росту благосостояния народа, сохранению мира и стабильности в Узбекистане награждена орденом «Трудовая слава».

C u r r i c u l u m V i t a e

PERSONAL INFORMATION


First Name/ Family Surname Irina Zakharova, MD, PhD
Address Barrikadnaya str., 2/1, Moscow, Russia
E-mail zakharova-rmapo@yandex.ru
Citizenship Russian
Date of birth January 25, 1956
Gender Female
Hirsch index 29
AuthorID 633259
SPIN 4357-3897
ORCID https://orcid.org/0000-0003-4200-4598

CURRENT POSITIONS


• The Honored Doctor of Russia
• Head of the Speransky Department of Pediatrics of Russian Medical Academy of Continuous Professional Education
• Honored Professor of the National Scientific and Practical Center of Children’s Health
• Chairman of the Thesis Council Д 208. 071.01 Pediatrics and Child Surgery
• Member of the Executive Committee of the Union of Pediatricians of Russia
• Full Member of ESPGHAN, EAACI, ERS
• Editor-in-Chief of the “Concillium Medicum Pediatrics” and “Medical Council Pediatrics”
• Chairman of the Association of Doctors on Assistance in Training of Pediatricians of Russia
• Chairman of the Association of Doctors on Vitamin D Research

EDUCATION


1973–1979 Medical University named by D.I.Ulyanov, Kuibyshev, USSR
1988–1989 Russian Medical Academy of Postgraduate Education, Moscow Pediatric department PhD thesis “Dynamic DMSA in diagnostics of tubulointerstitial kidney diseases in children», defended in 1994 MD thesis “Clinic and diagnostics aspects of tubulointerstitial kidney diseases in children” defended in 2000

WORK EXPERIENCE


1979–1987 Pediatrician in outpatient department
1989–1997 Assistant of Department of Pediatrics, Russian Medical Academy of Postgraduate Education
1997–2002 Docent of Department of Pediatrics, Russian Medical Academy of Postgraduate Education
2002–2008 Professor of Department of Pediatrics, Russian Medical Academy of Postgraduate Education
from September 2008 till now Head of Department of Pediatrics, Russian Medical Academy of Postgraduate Education from 1997 till now Regular consultant in pediatrics in Clinic of the Presidential Administration of the Russian Federation and in many private clinics from December 2010 Honored Doctor of the Russian Federation, reward by the Ministry of Health of Russia
from 2008 Chairperson of the Thesis Council for Pediatrics and Child Surgery
from 2013 Member of EAACI
from 2014 Full member of ESPGHAN

MAIN SCIENTIFIC INTERESTS


Gastroenterology (probiotics, functional GI disorders, malabsorption, IBD), nutrition, pathology of children of early age.

BIOGRAPHY


Prof. Irina Zakharova graduated from D.I. Ulyanov Medical University in Kuibyshev, USSR, in 1979. After that she worked as a pediatrician in different regions in the USSR and other countries. In 1989 she completed her residency in pediatrics in the Russian Medical Academy of Continuous Professional Education, Moscow. She defended there a candidate thesis in 1994 and a doctoral thesis in 2000 (“Clinic and diagnostics aspects of tubulointerstitial kidney diseases in children”). In 2001-2008 she worked as a professor of department of pediatrics, since 2008 – as a head of this department. Prof. Irina Zakharova currently is also the Chairman of the Association of Doctors on Assistance in Training of Pediatricians of Russia, the Chairman of the Association of Doctors on Vitamin D Research, editor-in-chief of the “Concillium Medicum Pediatrics” and “Medical Council Pediatrics”.

Latysheva Tatiana born in 1951, graduated from 2 MOLGMI N. I. Pirogova in 1975. From 1975 to 1980 worked as a general practitioner. 1980-1982 clinical residency on anesthesiology and intensive care  S.P. Botkin Hospital. Since 1984 had been working in the clinic of the Institute of Immunology FMBA Russia.  1990 PhD  “Acute toxic-allergic reactions to drugs”, in 1997 MD “Tactics of immunocorrection of allergic and immunopathological conditions in intensive care unit “.

A chief of intensive care unit since 1984, since 1998 is the head of the Immunopathology Department with  intensive care unit in NRC Institute of immunology FMBA Russia.

From 2003 – received a title of Professor in the specialty Allergology and clinical immunology.

In 2009 was awarded the honorary title of “Honored doctor of  Russian Federation”, in 2012-received a diploma of the laureate of the RF government prize in science and technology for the creation, organization and implementation of the system of immunological and allergological monitoring for the prevention and treatment of immune-dependent socially significant diseases

T. V. Latysheva is the author of more than 280 scientific works on various aspects of Allergology and clinical immunology and resuscitation of severe allergic conditions, published both in Russia and abroad.

Research interests: allergic and immuno-mediated diseases: diagnosis of drug Allergy, diagnosis and treatment of patients with immunodeficiency both primary and secondary, urgent situations in Allergy, respiratory manifestations of Allergy: allergic rhinitis, bronchial asthma, atopic dermatitis, urticarial and angioedema.

T. V. Latysheva regularly takes part as a lecturer and expert meetings on the problems of allergic and immuno-mediated diseases at conferences and congresses both in clinical Allergology and immunology, and in resuscitation. She participated in the sessions of the General meeting of the Russian Academy of medical Sciences, took part in international conferences and congresses. Takes part in the Commission on forensic medical examination of deaths associated with acute allergic conditions. Take part in creation of National Guidelines.

T. V. Latysheva is a member of the Board of the Interregional public organization of disabled people “Society of patients with primary immunodeficiency”.

Under the leadership of T. V. Latysheva 14 PhD and 1 MD were defended on specialty 14.03.09 clinical immunology, allergology.

Since the founding of the journal is a member of the editorial Board.

Член редколлегии

Реброва Ольга Юрьевна,

доктор медицинских наук

ORCID: 0000-0002-6733-0958

Scopus AuthorID: 6601986825

Индекс Хирша Scopus: 5

Индекс Хирша РИНЦ: 17

Реброва Ольга Юрьевна окончила 2 МОЛГМИ (н.вр. РНИМУ) им. Н.И. Пирогова в 1986 г. и поступила на работу в лабораторию биохимии НИИ неврологии РАМН, с 1996 г. по 2010 г. работала там же руководителем лаборатории медицинской информатики. В 1993 г. защитила кандидатскую диссертацию «Информативность и диагностическая ценность лабораторных тестов при цереброваскулярных заболеваниях»,  а в 2003 г.  –  докторскую диссертацию на тему «Математические алгоритмы и экспертные системы в дифференциальной диагностике инсультов». С 2010 г. работает профессором кафедры медицинской кибернетики и информатики РНИМУ им. Н.И. Пирогова.

Является автором более 280 научных трудов, в том числе неоднократно переиздававшейся монографии «Статистический анализ медицинских данных».

Область научных интересов: статистический анализ медицинских данных, клиническая эпидемиология, доказательная медицина, искусственный интеллект.

О.Ю. Реброва регулярно принимает участие в качестве лектора в работе научных конференций и конгрессов. Является экспертом Фонда «Сколково», конкурса мега-грантов Правительства РФ, членом диссертационного совета Д 208.072.09, статистическим рецензентом нескольких российских и зарубежных научных медицинских журналов, членом Правления МОО «Общество специалистов доказательной медицины».

Под руководством О.Ю. Ребровой подготовлены 3 кандидатские диссертации, при ее консультировании защищена 1 докторская диссертация.

Member of Editorial Board
Olga Yu. Rebrova, PhD, DHab

ORCID: 0000-0002-6733-0958
Scopus AuthorID: 6601986825
H-index Scopus: 5
H-index RSCI: 17

Olga Yu. Rebrova graduated from 2 MOLGMI (now RNRMU) named after N.I. Pirogov in 1986 and started her academic career at the biochemistry laboratory of the Research Institute of Neurology of the Russian Academy of Medical Sciences. From 1996 to 2010 she worked as the head of the laboratory of medical informatics ate this Institute. In 1993, she received PhD for the dissertation “Informativity and diagnostic value of laboratory tests for cerebrovascular diseases”, and in 2003 DHab was awarded for dissertation “Mathematical algorithms and expert systems in the differential diagnosis of strokes”. Since 2010, he has been working as a professor at the Department of Medical Cybernetics and Informatics at Pirogov Russian National Research Medical University.
She is the author of more than 280 scientific papers, including the monograph “Statistical Analysis of Medical Data”. Research interests include statistical analysis of medical data, clinical epidemiology, evidence-based medicine, artificial intelligence.
O.Yu. Rebrova takes part as a lecturer in scientific conferences and congresses. She is an expert at the Skolkovo Foundation, a mega-grant competition of the Government of the Russian Federation, a member of the dissertation council D 208.072.09, a statistical reviewer of several Russian and foreign scientific medical journals, and a member of the Board of the Russian Society of Evidence-Based Medicine. O.Yu. Rebrova supervised 4 dissertations.

Индекс Хирша 29

AuthorID 633259

SPIN: 4357-3897

ORCID: https://orcid.org/0000-0003-4200-4598

 Ирина Николаевна Захарова – доктор медицинских наук, профессор, заслуженный врач России, заведующая  кафедрой педиатрии с курсом поликлинической педиатрии ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России, Почетный профессор Научного центра здоровья детей МЗ РФ.

После  окончания в 1979 году с отличием Куйбышевского государственного медицинского института им. Д.И. Ульянова в течение 9 лет работала участковым врачом–педиатром в различных регионах СССР и за рубежом. В 1988 году  поступила в клиническую ординатуру на кафедру педиатрии Центрального института усовершенствования врачей (ныне – ФГБОУ ДПО РМАНПО Минздрава РФ, с которой неразрывно связана по настоящее время. И.Н. Захарова прошла путь – от ординатора, врача старшего лаборанта, ассистента, доцента, профессора до заведующей кафедрой. В 1994 году защитила кандидатскую диссертацию на тему «Значение динамической нефросцинтиграфии в диагностике тубулоинтерстициальных заболеваний почек у детей», в 2001 году – докторскую диссертацию «Клинические и патогенетические аспекты тубулоинтерстициальных заболеваний почек у детей». С  2001 года Захарова работала профессором кафедры, с 2008 года – заведующей  кафедрой педиатрии. Кафедра педиатрии РМАНПО создана в 1932 году академиком РАН, проф., д.м.н. Георгием Нестеровичем Сперанским. На кафедре ежемесячно проходят обучение врачи-педиатры по педиатрии, детской гастроэнтерологии, нефрологии, кардиологии. С 2008 года И.Н. Захарова является Председателем Диссертационного Совета по педиатрии и детской хирургии. С 1997 года – Консультант по педиатрии поликлиник Управления Делами Президента Российской Федерации, многих частных центров.

Главный редактор журналов  «Медицинский Совет» Педиатрия, «Консилиум медикум (Педиатрия), член редколлегии многих журналов.

В 2010 году стала Почетным Профессором Научного центра здоровья детей РАМН.

В декабре 2010 года получила звание Заслуженный Врач РФ.

В феврале 2012 года награждена Грамотой Минздрава России.

С мая 2012 года по декабрь 2017 года  главный внештатный педиатр Центрального федерального округа России.

C 2013 года член Европейской ассоциации иммунологов и аллергологов.

В мае 2014 года избрана  полным членом ESPGHAN.

Член Исполкома Союза педиатров России (2012-2016, 2017-2021)

Заведующая кафедрой педиатрии с курсом поликлинической педиатрии им. Г.Н.Сперанского с сентября 2008 года.

Индекс Хирша 29

Член редакционной коллегии

Федоскова Татьяна Германовна  

доктор медицинских наук

https://orcid.org/0000-0003-1456-3923

Reseacher ID WoS:  Р–1278-2015

Scopus author ID: 12765658700

Author ID РИНЦ:   190990

Индекс Хирша 10

Федоскова Татьяна Германовна, окончила  II Московский Ордена Ленина Государственный медицинский институт имени Н.И. Пирогова. С 1996 года по 2016 год работала в Научно-консультативном отделении ФГБУ «ГНЦ Институт иммунологии» ФМБА России, в должности ведущего научного сотрудника. С 2016 г. по настоящее время работает там же в должности заведующего лабораторией Молекулярных механизмов аллергии.

В 2008 году защитила докторскую диссертацию на тему «Аллергия к “нежалящим” насекомым (распространенность, клиническая характеристика, диагностика и аллерген-специфическая иммунотерапия)».

Федоскова Т.Г. имеет награды: ведомственный знак отличия в труде Ветеран атомной промышленности, Почетная грамота ФМБА. Является автором более 150 печатных работ, в том числе 11 монографий и  6 руководств для практикующих врачей (в соавторстве)  по различным аспектам клинической аллергологии и иммунологии, опубликованных как в России, так и за рубежом. Имеет 3 авторских патента на изобретения (в соавторстве) «Аллергоид из яда пчел для аллерген-специфической иммунотерапии больных с аллергическими реакциями на ужаление пчелами и способ его получения», «Способ определения специфических IgE к стафилококку в сыворотке крови больного аллергическими заболеваниями, имеющего гиперчувствительность к аллергенам стафилококка, с применением тест-системы для определения специфических IgE  к стафилококку и выделенной из стафилококка активной аллергенной субстанции», «Способ дифференциальной диагностики гиперчувствительности к яду пчелы Apis mellifera» и 1 индивидуальный патент на изобретение «Средство и способ специфической иммунотерапии больных аллергическими заболеваниями, имеющих сенсибилизацию к укусам комаров». Активно совмещает научную и лечебно-консультативную работу, а также преподавательскую деятельность в должности профессора кафедры иммунологии Российского национального исследовательского медицинского университета имени Н. И. Пирогова и профессора кафедры клинической иммунологии и аллергологии Федерального государственного образовательного учреждения “Институт повышения квалификации ФМБА России”.

Область научных интересов – механизмы развития, клинические особенности течения и диагностика инсектной, бактериальной, лекарственной аллергии, разработка новых методов лечения инсектной аллергии, иммунотерапия, фармакотерапия иммуноопосредованных состояний, аллерген-специфическая иммунотерапия, влияние на организм сочетанного воздействия климатических и производственных факторов и другие.

Федоскова Т.Г. регулярно принимает участие в качестве лектора по проблеме аллергических заболеваний и иных иммуноопосредованных состояний  в работе научных конференций, конгрессов, съездов по аллергологии и иммунологии, как в России, так и за рубежом. Является членом экспертного совета РАН, членом двух диссертационных советов по защите докторских и кандидатских диссертаций. С 2013 года –  Член-корреспондент Российской академии естественных наук.

С момента основания до 2011 года состояла в должности ответственного секретаря, далее по настоящее время является членом редакционной коллегии Российского аллергологического журнала.

Garib Victoria, MD, PhD, professor

Scopus author ID: 57192071033

h-index: 5

 Окончила с отличием первый лечебный факультет Ташкенского государственного медицинского института (1990) клиническую ординатуру (1993) и аспирантуру (1996)  по специальностям иммунология и аллерглогия/ терапия, тренинг в Тель-Авивском медицинском университете, Израиль (1996), занималась начной работой в университете Виттен/Хердеке, Германия (2000-2003), получила признание диплома PhD в Германии в 2002 году. Виктория Гариб имеет звание профессора в области иммунологии и аллергологии с 2005 года. Она заведовала Центральной научно-исследовательской лабораторией, с 2005 года – кафедрой медицинской иммунологии с Центром молекулярной медицины. Одновременно с этим, с 2006 по 2013 годы проф. Гариб  Виктория работала на должности проректора по международным связям Ташкентского института усовершенствования врачей, была экспертом и ученым секретарем медико-биологической секции ВАК. С 2014 года по настоящее время работает в департаменте  патофизиологии и исследований аллергии Венского медицинского университета, Австрия. С 2018 года также является международным консультантом Министерства инновационного развития Республики Узбекистан. C 2013 года является организатором и Вице-Президентом Международной платформы университетов по молекулярной аллергологии и иммунологии INUNIMAI, Вена, Австрия. В 2018 году по ее инициативе и консультациях при министерстве инновационного развития Республики Узбекистан был создан первый в мире Международный Центр Молекулярной Аллергологии.

Виктория Гариб удостоена наград и грантов DAAD, Германия (2000), DGAI,Германия (2001), медалью Отличник здравоохранения, Узбекистан (2012), медалью «Рабочая Слава» 2 степени в номинации «За значительный вклад в развитие аллергологии и иммунологии в Украине» (2016), глобальной  наградой по Аллергологии и иммунологии, Австрия (2018).

Автор 130 научных публикаций, монографий, учебников, образовательных программ. Организатор более 60 национальных и международных конференций, школ, симпозиумов. Член Европейской Академии Аллергологов и клинических иммунологов (EAACI), Австрийского общества аллергологов и иммунологов (ÖGAI ) .

Область научных интересов:  Картирование молекулярных профилей сенсибилизации и формирование шкалы приоритетов по внедрению аллерговакцин;   разработка и адаптация методов стандартизации аллергенов;  разработка и внедрение молекулярного паспорта аллергической сенсибилизации;  определение факторов риска развития аллергии; разработка новых форм диагностики, профилактики  и лечения аллергии, иммунодефицитных состояний  и инфекций.

Член Редколлегии Российского Аллергологического Журнала

Ревякина Вера Афанасьевна

Доктор медицинских наук, профессор

https://orcid.org/0000-0002-1149-7927

Scopus author ID: 571999999310

Индекс Хирша 26

Ревякина Вера Афанасьевна, окончила  2 Московский медицинский институт им. И.М. Пирогова в 1976г. и поступила в клиническую ординатуру, а затем  в очную аспирантуру  по педиатрии в Институт педиатрии. В 1982г. защитила кандидатскую диссертацию «Клинико-иммунологические проявления пищевой аллергии у детей»,  а в 1993 г.  –  докторскую диссертацию на тему «Атопический дерматит у детей. В 2002 г. получила звание профессора. С 2009 года по настоящее время заведует отделением ФГБУН «ФИЦ питания и биотехнологии».

Является лауреатом премии им М.С Маслова» 1983г., имеет  золотую медаль  ВДНХ за научную работу. Является автором  более 400 научных трудов, в том числе 5 монографий, по различным аспектам педиатрии, клинической аллергологии и иммунологии, опубликованных как в России,  так и за рубежом, имеет 6 авторских свидетельства на изобретения (в соавторстве).

Область научных интересов: аллергические и иммуноопосредованные  заболевания –атопический дерматит, аллергический контактный дерматит, крапивница, а также респираторные аллергические заболевания – аллергический ринит, бронхиальная астма и другие.

Ревякина В.А. регулярно принимает участие в качестве лектора и эксперта по проблеме аллергических заболеваний, в работе научных конференций, конгрессов, съездов по аллергологии и иммунологии, как в России, так и за рубежом. Под руководством Ревякиной В.А.  защищено  18 кандидатских и 1 докторская  диссертации  по специальности 14.01.08 педиатрия и 14.03.09 клиническая иммунология,  аллергология.

Является  членом  редколлегии  Российского аллергологического журнала.

Editorial board member

Revyakina Vera, MD, PhD, professor

https://orcid.org/0000-0002-1149-7927

Scopus author ID: 571999999310

H-index 12

Revyakina Vera graduated from the  2  Moscow Medical University named after N.I. Pirogov in 1976.  She completed clinical scientist fellowship training in pediatrics at the Institute of Pediatrics in Moscow, Russia. In completed her MD study “Clinical and immunological manifestations of food allergies in children” and in 1993 – PhD study “Atopic dermatitis in children” in the Institute of Pediatrics in Moscow, Russia. In 2002  has become professor of medicine.

Since 2009 up to now V. Revyakina  is  the Head of  Allergy Department in the Federal Research Centre  of Nutrition and Biotechnology.

Professor V. Revyakina  has a specific interest in allergic diseases, especially in atopic dermatitis, urticaria, allergic contact dermatitis, as well as respiratory allergies–bronchial asthma, allergic rhinitis.

Vera  Revyakina V.A. been invited to speak at plenary, keynote, symposia and expert discussion sessions, workshops and industry sponsored meetings at the Russian Association of Allergologists and Immunologists (RAACI), as well as workshops  at the European Academy Allergy and Clinical Immunology (EAACI). She is an author of more than 400 scientific articles published in Russian periodicals and authoritative scientific journals such as Allergy, Pediatric Allergology and Immunology.,.

He is a member of the editorial board of the Russian Allergological Journal.

Член редакционной коллегии

Кофиади Илья Андреевич, доктор биологических наук, профессор РАН

https://orcid.org/0000-0001-9280-8282

Индекс Хирша: 8

Кофиади И.А. является специалистом в области генетики иммунного ответа, физиологии клетки, молекулярной иммунологии, а также автором более 60 научных работ, 2 монографий, 2 патентов на изобретения и полезные модели.

Основные научные результаты Кофиади И.А. получены при изучении механизмов генетического контроля иммунного ответа в норме и при патологии. Им исследованы иммуногенетические основы индивидуальной реакции человека на действие негативных факторов окружающей среды; установлено популяционное распределение клинически значимых маркеров онкологических, инфекционных и аутоиммунных заболеваний; создано более 50 тест-систем для характеристики активности генов иммунного ответа, диагностики первичных иммунодефицитов, определения факторов риска развития заболеваний, мониторинга вирусных инфекций у лиц с нарушениями иммунного ответа, вызванными иммуносупрессией, а также действием иммуно- и генотоксических факторов.

Кофиади И.А является разработчиком аппаратно-диагностического комплекса для оценки генетических и функциональных показателей состояния здоровья, а также технологии детекции низкопредставленных копий ДНК, применяемой при ранней диагностике развития криза отторжения трансплантата и обнаружении соматических мутаций, ассоциированных с развитием опухолей. Результаты научно-практических исследований, выполненных при участии и под руководством Кофиади И.А. отмечены премией Правительства РФ в области науки и техники за 2017 год.

Под руководством Кофиади И.А. защищено две кандидатских диссертации. Он ведет активную преподавательскую работу, является автором курса лекций в рамках программы подготовки аспирантов ФГБУ «ГНЦ Институт иммунологии» ФМБА России, является соавтором учебника «ПЦР в реальном времени», участником перевода IX издания учебника «Гены» Бенджамина Льюина.

Кофиади И.А. – член ученого и диссертационного советов ФГБУ «ГНЦ Институт иммунологии» ФМБА России, член Европейской федерации иммуногенетиков и Российского научного общества иммунологов.

Лопатин Андрей Станиславович

доктор медицинских наук, профессор

https://orcid.org/0000-0002-2662-3367

Индекс Хирша 21 (РИНЦ)

Индекс в базе Research Gate 27.44

Окончил Ярославский медицинский институт в 1980г. и поступил в клиническую ординатуру, а потом и в заочную аспирантуру по оториноларингологии. В 1989 г. защитил кандидатскую диссертацию, а в 1998 г. – докторскую диссертацию на тему «Минимально инвазивная эндоскопическая хирургия заболеваний полости носа, околоносовых пазух и носоглотки”.

С 1993 по 2006 гг. работал в ЛОР-отделении Центральной клинической больницы Медицинского центра Управления делами Президента Российской Федерации  сначала в должности старшего ординатора, с 1997 г. – заведующего отделением. С 2006 по 2013 гг. Руководил клиникой и кафедрой болезней уха, горла и носа Первого Московского медицинского университета им. И.М. Сеченова. С 2013 г. по настоящее время– научный руководитель по оториноларингологии ФГБУ «Поликлиника № 1» Управления делами Президента Российской Федерации; с 2016 г. – руководитель направления оториноларингология-отоневрология ООО «Первая Хирургия».

С 2005 г. –  президент Российского общества ринологов; с 1998-2008 гг. – представитель России в Европейском ринологическом обществе, с 2006 по 2009 – президент Международной консенсусной комиссии по полипозному риносинуситу. С 1995 г. – член-корреспондент Американского ринологического общества, почетный член Украинского общества отоларингологов и Итальянского ринологического общества; · член редакционных советов 10 медицинских научных журналов в России и Европе; автор 450 научных статей и 16 учебных пособий для врачей и педагогов высшей школы. Под руководством А.С.Лопатина защищено 7 докторских и 16 кандидатских диссертаций по специальности 14.01.03 – болезни уха, горла и носа.

Область научных интересов: диагностика и лечение хронического/полипозного риносинусита, эндоскопическая хирургия околоносовых пазух, носоглотки и основания черепа, риносептопластика.

Andrey Lopatin MD, PhD, professor

https://orcid.org/0000-0002-2662-3367

H-index 21

Research Gate profile 27.44

Andrey Lopatin graduated from the Yaroslavl Medical University in 1980, and completed his clinical and scientific fellowship training in otorhinolaryngology in 1986. Completed his PhD study «Minimally invasive endoscopic surgery of the nasal cavity, paranasal sinuses and nasopharynx» in 1998, and become professor of medicine in 2001.

From 1993 to 2006 – Vice chair and then Chair of the ENT department of the Central Clinical Hospital in Moscow. From 2006 till 2013 chaired ENT clinic of the Sechenov First Moscow Medical University. From 2013 till now – Senior ENT consultant and surgeon in the Policlinic №1 of the Business Administration of the President of Russian Federation.

Andrey Lopatin has a specific interest in medical and surgical treatment of chronic rhinosinusitis/nasal polyposis, endoscopic sinus and skull base surgery, rhinoseptoplasty and sleep apnea. He is a member of the Editorial Board of 7 national and 4 foreign scientific medical journals, honorary member of Ukrainian ENT society and Italian rhinologic society. From 2005 till now – President of the Russian rhinologic society, from1998 to 2008 – national delegate for Russia in the European rhinologic society (ERS), from 2006 to 2009 – Chairman of the International Consensus Committee on Nasal Polyposis. Since 1996 – a Faculty member and Invited speaker at numerous international ENT and rhinologic congresses (IRS, ISIAN, ERS, EUFOS et al). He is an author of 450 papers published in Russian and international peer-reviewed scientific journals such as «Laryngoscope», «Archives of Otolaryngology Head and Neck Surgery», «European Archives of Otorhinolaryngology», «Rhinology», |«American Journal of Rhinology and Allergy», «International Forum of Allergy and Rhinology», «International Journal of Audiology», «Acta otorhinolaryngologica Italica», «Clinical Experimental Allergy», «International Archives of Allergy and Immunology».